(19) World Intellectual Property Organization International Bureau

(43) International Publication Date 10 January 2008 (10.01.2008)



PCT

- (51) International Patent Classification:
- **C07K 16/00** (2006.01)
- (21) International Application Number: PCT/EP2007/006027
- (22) International Filing Date: 6 July 2007 (06.07.2007)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 06014166.0 7 July 2006 (07.07.2006) EP
- (71) Applicant (for all designated States except US): INTER-CELL AG [AT/AT]; Campus Vienna Biocenter 6, A-1030 Vienna (AT).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): MEINKE, Andreas [DE/AT]; Piettegasse 26/1, A-3013 Pressbaum (AT).
 NAGY, Eszter [HU/AT]; Klimschgasse 30/II/21, A-1030 Vienna (AT). VON GABAIN, Alexander [AT/AT]; Hockegasse 77, A-1180 Vienna (AT). BERGER, Manfred [AT/AT]; Francesco Solimena Weg 18, A-2700 Wr. Neustadt (AT). SENN, Beatrice [CH/AT]; Gumpendorfer Strasse 135/41, A-1060 Vienna (AT). SCHUNN, Michael [AT/AT]; Neuwaldeggerstrasse 4A/1/7, A-1170 Vienna (AT).
- (74) Agent: BÖSL, Raphael; Isenbruck Bösl Hörschler Wichmann Huhn, Prinzregentenstrasse 68, 81675 München (DE).

(10) International Publication Number WO 2008/003515 A1

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SMALL STREPTOCOCCUS PYOGENES ANTIGENS AND THEIR USE

(57) Abstract: The present invention relates to a peptide consisting of one antigen of *Streptococcus pyogenes* (*S. pyogenes*) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a *S. pyogenes* infection; a method for identifying a ligand capable of binding to said peptide; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.

Small Streptococcus pyogenes Antigens and their Use

- 5 The present invention relates to a peptide consisting of one antigen of *Streptococcus pyogenes (S. pyogenes)* of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically lo binding to the antigen; a hybridoma cell line which produces said antibody; a method for
- producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a *S. pyogenes* infection; a method for identifying a ligand capable of binding to
- 15 diagnosing a S. pyogenes infection; a method for identifying a ligand capable of binding to said peptide; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.
- Streptococcus pyogenes, also called group A streptococcus (GAS), is an important grampositive extracellular bacterial pathogen and commonly infects humans. GAS colonizes the
 throat or skin and is responsible for a number of suppurative infections and nonsuppurative sequelae. It is primarily a disease of children and causes a variety of infections
 including bacterial pharyngitis, scarlet fever, impetigo and sepsis in humans. Decades of
 epidemiological studies have led to the concept of distinct throat and skin strains, where
 certain serotypes are often associated with throat or skin infections, respectively
 (Cunningham, M. (2000). Clin Microbiol Rev 13: 470-511). GAS has been discovered
 responsible for streptococcal toxic shock syndrome associated necrotizing fasciitis which is
 recently resurgent in the USA (Cone, L., et al. (1987). New Engl J Med 317: 146-9;
 Stevens, D. (1992). Clin Infect Dis 14: 2-11) and has been described as the "flesh eating"
 bacterium which invades skin and soft tissues leading to tissue or limb destruction.

Several post-streptococcal sequelae may occur in humans subsequent to infection, such as acute rheumatic fever, acute glomerulonephritis and reactive arthritis. Acute rheumatic

fever and rheumatic heart disease are of these the most serious autoimmune sequelae and have led to disability and death of children worldwide. *S. pyogenes* can also causes severe acute diseases such as scarlet fever and necrotizing fasciitis and has been associated with Tourette's syndrome, tics and movement and attention disorders.

5

10

Group A streptococci are the most common bacterial cause of sore throat and pharyngitis and account for at least 16% of all office calls in a general medical practice, season dependent (Hope-Simpson, R. (1981). <u>J Hyg (Lond)</u> 87: 109-29). It primarily affects children in school-age between 5 to 15 years of age (Cunningham, supra). All ages are susceptible to spread of the organism under crowded conditions, for example in schools. GAS are not considered normal flora though, but pharyngeal carriage of group A streptococci can occur without clinical symptoms.

Group A streptococci can be distinguished by the Lancefield classification scheme of
serologic typing based on their carbohydrate or classified into M protein serotypes based
on a surface protein that can be extracted by boiling bacteria with hydrochloric acid. This
has led to the identification of more than 80 serotypes, which can also be typed by a
molecular approach (emm genes). Molecular typing has identified more than 150
individual emm types. Certain M protein serotypes of *S. pyogenes* are mainly associated
with pharyngitis and rheumatic fever, while others mainly seem to cause pyoderma and
acute glomerulonephritis (Cunningham, supra).

Also implicated in causing pharyngitis and occasionally toxic shock are group C and G streptococci, which must be distinguished after throat culture (Hope-Simpson, supra; Bisno, A., et al. (1987). Infect Immun 55: 753-7).

25 Bisno, A., et

30

Currently, streptococcal infections can only be treated by antibiotic therapy. However, 25-30% of those treated with antibiotics show recurrent disease and/or shed the organism in mucosal secretions. There is at present no preventive treatment (vaccine) available to avoid streptococcal infections.

Thus, there remains a need for an effective treatment to prevent or ameliorate streptococcal infections. A vaccine could not only prevent infections by streptococci, but more

specifically prevent or ameliorate colonization of host tissues, thereby reducing the incidence of pharyngitis and other suppurative infections. Elimination of non-suppurative sequelae such as rheumatic fever, acute glomerulonephritis, sepsis, toxic shock and necrotizing fasciitis would be a direct consequence of reducing the incidence of acute infection and carriage of the organism. Vaccines capable of showing cross-protection against other streptococci would also be useful to prevent or ameliorate infections caused by all other beta-hemolytic streptococcal species, namely groups A, B, C and G.

10

5

A vaccine can contain a whole variety of different antigens. Examples of antigens are whole-killed or attenuated organisms, subfractions of these organisms/tissues, proteins, or, in their most simple form, peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear 15 epitopes as short as 4-5 amino acids, as well as three-dimensional structures (conformational epitopes).

In some circumstances, adjuvants may be useful for sustaining antigen-specific immune responses. Primarily, adjuvants are acting, but are not restricted in their mode of action, on 20 so-called antigen presenting cells (APCs). These cells usually first encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a 25 chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

Approaches to develop a group A streptococcal vaccine have focused mainly on the cell surface M protein of S. pyogenes (Bessen, D., et al. (1988). Infect Immun 56: 2666-2672; 30 Bronze, M., et al. (1988). J. Immunol 141: 2767-2770). Since more than 80 different M serotypes of S. pyogenes exist and new serotypes continually arise (Fischetti, V. (1989). Clin Microbiol Rev 2: 285-314), inoculation with a limited number of serotype-specific M

10

15

protein or M protein derived peptides will not likely be effective in protecting against all other M serotypes. Furthermore, it has been shown that the conserved region of the M protein contains an amino acid sequence, which is immunologically cross-reactive with human heart tissue, which is thought to account for heart valve damage associated with rheumatic fever (Fenderson, P., et al. (1989). J Immunol 142: 2475-2481).

There are other proteins under consideration for vaccine development, such as the erythrogenic toxins, streptococcal pyrogenic exotoxin A and streptococcal pyrogenic exotoxin B (Lee, P. K. (1989). J Clin Microbiol 27: 1890-2). Immunity to these toxins could possibly prevent the deadly symptoms of streptococcal toxic shock, but it may not prevent colonization by group A streptococci.

The use of the above described proteins as antigens for a potential vaccine as well as a number of additional candidates (Ji, Y., et al. (1997). <u>Infect Immun</u> **65**: 2080-2087; Guzman, C., et al. (1999). <u>J Infect Dis</u> **179**: 901-6) resulted mainly from a selection based on easiness of identification or chance of availability. There is a demand to identify efficient and relevant antigens for *S. pyogenes*.

WO 2004/078907 describes a method for identification, isolation and production of
hyperimmune serum reactive antigens from *Streptococcus pyogenes*.

The antigens described herein focus on regions shown in the present application to be protective. A suitable antigen size to obtain protection varies based on different factors such as the type of protective epitope (e.g., conformational versus linear) and the number of protective epitopes providing a level of protection. Large antigens containing regions not providing useful protection may be disadvantageous in the context of immunization. First, providing of smaller antigens eases production of the protein in recombinant form. It is generally accepted that it is more difficult to produce larger proteins. Smaller proteins may be produced in a more economic manner, thus saving costs, particularly in the health care system. Second, reducing the size of antigenic proteins used for vaccination may lead to safer products. Eliminating extra sequences in antigenic proteins is desirable, since this reduces the probability of inducing antibodies which can cause cross-reactions with human tissues. Third, proteins used for vaccination may contain more than one antigen, the

antigens directed either against the same disease or against different diseases, in order to obtain a more effective vaccination or vaccination against several diseases. However, if the single antigens are too large a combination into one protein is not feasible.

- 5 Accordingly, one problem underlying the present invention was to provide alternative means for the development of medicaments such as vaccines against *S. pyogenes* infection, particularly smaller proteins.
- Surprisingly, the object has been solved by a peptide consisting of one antigen of S. *pyogenes* of the SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7 or a functional active variant of one antigen of S. *pyogenes* of the SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7. These peptides are referred to as antigenic peptides.

15

The sequences of SEQ ID NOS: 1 to 7 are characterized in table 1 of the present specification. The underlying amino acid sequences are disclosed in the attached sequence data. The peptides of SEQ ID NOS: 1 to 7 have been shown to induce an immune response and/or to show protection against *S. pyogenes* in a sepsis and/or lethality model (see Example 1). Functional active variants are obtained by changing the sequence of the antigen as defined below and are characterized by having a biological activity similar to that displayed by the antigen of any of the sequences of SEQ ID NO: 1 to 7 from which it is derived, including the ability to induce immune responses and/or to show protection against *S. pyogenes* e.g. in a sepsis and/or lethality model.

25

In some embodiments of the invention the peptide of the invention consists of one antigen of *S. pyogenes* of the SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7 or a functional active variant of one antigen of *S. pyogenes* of the SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7; and

- 30
- a) 1 to 350 additional amino acid residue(s), preferably 1 to 200, more preferably 1 to 150, even more preferably at most 1 to 100, still more preferably at most 1 to 50,

most preferably 1, 2, 3, 4, 5, 10, 15, 20 or 25 additional amino acids residue(s) if the antigen is SEQ ID NO: 1; or

b) 1 to 200 additional amino acid residue(s), preferably 1 to 150, more preferably 1 to 100, even more preferably at most 1 to 50, still more preferably at most 1 to 25, most preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acids residue(s) if the antigen is SEQ ID NO: 2; or

6

- c) 1 to 100 additional amino acid residue(s), preferably 1 to 75, more preferably 1 to 50, even more preferably at most 1 to 25, still more preferably at most 1 to 10, most preferably 1, 2, 3, 4 or 5 additional amino acids residue(s) if the antigen is that of SEQ ID NO: 3; or
- d) 1 to 150 additional amino acid residue(s), preferably 1 to 100, more preferably 1 to 75, even more preferably at most 1 to 50, still more preferably at most 1 to 25, most preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acids residue(s) if the antigen is that of SEQ ID NO: 4; or
- e) 1 to 450 additional amino acid residue(s), preferably 1 to 300, more preferably 1 to 150, even more preferably at most 1 to 100, still more preferably at most 1 to 50, most preferably 1, 2, 3, 4, 5, 10, 20, 30 or 40 additional amino acids residue(s) if the antigen is SEQ ID NO: 5; or
 - f) 1 to 250 additional amino acid residue(s), preferably 1 to 200, more preferably 1 to 150, even more preferably at most 1 to 100, still more preferably at most 1 to 50, most preferably 1, 2, 3, 4, 5, 10, 15, 20 or 25 additional amino acids residue(s) if the antigen is SEQ ID NO: 6 or SEQ ID NO: 7.

The antigen of *S. pyogenes* can be any of the antigens as defined above, namely as defined in any of the SEQ ID NOS: 1, 2, 3, 4, 5, 6 or 7, or a functional active variant thereof, wherein the functional active variant is as defined below.

The antigen or the functional active variant thereof may have added at least one additional amino acid residue heterologous or homologous to the peptide. Homologous refers to any amino acid or amino acid sequence which is identical to the amino acid sequence of the *S*.

amino acid or amino acid sequence which is identical to the amino acid sequence of the S.
 pyogenes protein from which the antigen is derived, wherein the sequences of SEQ ID NO:
 1 to 7 are derived from the following proteins:

10

20

Sequence	derived from protein (as disclosed in e.g. WO 2004/078907 or in the attached sequence data)
SEQ ID NO: 1	Spy0269
SEQ ID NO: 2	Spy0292
SEQ ID NO: 3	Spy0292
SEQ ID NO: 4	Spy0416
SEQ ID NO: 5	Spy0416
SEQ ID NO: 6	Spy0416
SEQ ID NO: 7	Spy0872

In one embodiment the antigen or the functional active variant thereof having one or more additional amino acid residues (see above, particularly as defined in items (a) to (f)) further

- encompasses at least one amino acid residue heterologous to the antigen. The feature "heterologous amino acid" or "amino acid heterologous to the antigen or protein" refers to any amino acid which is different from that amino acid located adjacent to the antigen or protein in any naturally occurring protein of *S. pyogenes*, particularly from that of *S. pyogenes* SF370 (serotype M1). Therefore, the protein of the invention encompassing at least one heterologous amino acid refers to a protein which is different from any naturally occurring protein of *S. pyogenes* or fragment thereof, particularly which is different from that of *S. pyogenes* SF370 (serotype M1). The proteins from which the antigens of the invention are derived as well as a reference for their sequences are listed above.
- 15 In certain embodiments, the peptide consists of the antigen, optionally the at least one additional amino acid residue as defined above, and at least one additional heterologous amino acid sequence comprising a marker protein.
- The additional sequence or amino acid residue(s) as defined above consists of (an) amino acid residue(s), which may be any amino acid, which may be either an L-and/or a D-amino acid, naturally occurring and otherwise. Preferably the amino acid is any naturally occurring amino acid such as alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan or tyrosine.

However, the amino acid residue(s) may also be (a) modified or unusual amino acid(s). Examples of those are 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diaminobutyric

- 5 acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, Nethylasparagine, hydroxylysine, allo-hydroxylysine, 3-hydroxyproloine, 4hydroxyproloine, isodesmosine, allo-isoleucine, N-methylglycine, N-methylisoleucine, 6-N-Methyllysine, N-methylvaline, norvaline, norleucine or ornithine.
- 10 Additionally, the amino acid(s) may be subject to modifications such as posttranslational modifications. Examples of modifications include acetylation, amidation, blocking, formylation, γ-carboxyglutamic acid hydroxylation, glycosilation, methylation, phosphorylation and sulfatation.
- 15 If more than one additional or heterologous amino acid residue is present in the peptide, the amino acid residues may be the same or different from one another.

The antigenic peptide may be flanked by the amino acid residue(s) C-terminally, N-terminally, or C- and N-terminally.

20

In a further embodiment the peptide is as described above in the different embodiments, and contains a region that is essentially identical to any of the antigens of the SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7, but differs from the antigens of any of the of the SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7, in that is it derived from a homologous sequence of a different serotype of *S. pyogenes*, particularly wherein the serotype is M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118, especially *S. pyogenes* SF370.

30

25

Accordingly, the present invention also relates to antigens of different *S. pyogenes* isolates. Such homologues may easily be identified and isolated based on the nucleic acid and amino acid sequences disclosed herein. A homologous antigen of a different serotype may

be identified by e.g. sequence alignment. The homologous antigen sequence may vary from the antigen of any of the sequences of SEQ ID NO: 1 to 7 by one or more amino acid substitutions, deletions and/or additions. Preferably the homologous antigen sequence has the sequence of any of the homologous variants identified in the attached listing of amino

5 acid sequences.

Examples of homologous sequences of a different serotype are detailed in the attached sequence data. Particularly, sequences homologous to the respective peptide of the invention are those listed below:

10

Full length amino acid	Peptide of the invention	Homologous amino acid sequen-
sequence	(SEQ ID NO)	ces
(SEQ ID NO)		(SEQ ID NOS)
57	1	58 to 67
68	2	69 to78
68	3	79 to 88
89	4	90 to 99
89	5	100 to 109
89	6	110 to 119
120	7	121 to 130

There are more than 150 emm types distinguished to date and the typing is based on the variable region at the 5' end of the emm gene (see e.g. Vitali, L., et al. (2002) <u>J. Clin.</u> <u>Microbiol</u> **40**: 679-681). The presence of a homologous antigen can accordingly be determined for every emm type. In addition it is possible to determine the variability of a particular antigen in the various emm types as described for the *sic* gene (Hoe N., et al. (2001) <u>J. Inf. Dis.</u> **183**: 633-9). The influence of the various M serotypes on the kind of disease it causes is summarized in a recent review (Cunningham, supra). In particular, two groups of serotypes can be distinguished:

20

15

- 1) Those causing Pharyngitis and Scarlet fever (e.g. M types 1, 3, 5, 6, 14, 18, 19, 24)
- Those causing Pyoderma and Streptococcal skin infections (e.g. M types 2, 49, 57, 59, 60, 61)

This can serve as the basis to identify the relevance of an antigen for the use as a vaccine or in general as a drug targeting a specific disease.

- 5 The information e.g. from the homepage of the Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov/ncidod/biotech/strep/emmtypes.htm) gives a dendrogram showing the relatedness of various emm types. Further relevant references are Vitali et al., supra (molecular emm typing method), Enright et al., Infection and Immunity 69: 2416-2427. (2001) (alternative molecular typing method (MLST)), Hoe et al., supra (example for
- 10 the variation of one antigen (*sic*) in many different serotypes) and Cunningham, supra (review on GAS pathogenesis). All emm types are completely listed and are available at publicly available databases (e.g., through the CDC).

In another embodiment of the present invention the variant is a fragment. The fragment is characterized by being derived from the antigen as defined above by one or more amino 15 acid deletions. The deletion(s) may be C-terminally, N-terminally and/or internally. Preferably the fragment is obtained by at most 10, 20, 30, 40, 50, 60, 80, 100, 150 or 200, more preferably by at most 10, 20, 30, 40 or 50, even more preferably at most 5, 10 or 15, still more preferably at most 5 or 10, most preferably 1, 2, 3, 4 or 5 amino acid deletion(s). The functional active fragment of the invention is characterized by having a biological 20 activity similar to that displayed by the complete antigen, including the ability to induce immunization and/or to show protection against S. pyogenes e.g. in a sepsis and/or lethality model. The fragment of an antigen is functional active in the context of the present invention, if the activity of the fragment amounts to at least 10%, preferably at least 25%, more preferably at least 50%, even more preferably at least 70%, still more preferably at 25 least 80%, especially at least 90%, particularly at least 95%, most preferably at least 99% of the activity of the antigen without sequence alteration. These fragments may be designed or obtained in any desired length, including as small as about 50 to 80 amino acids in length.

30

The functional active fragment may be also characterized by other structural features. Accordingly, in one preferred embodiment of the invention the functional active fragments consists of at least 60%, preferably at least 70%, more preferably at least 80%, still more

preferably at least 90%, even more preferably at least 95%, most preferably 99% of the amino acids of the antigen of any of the SEQ ID NOS: 1 to 7. The functional active fragment as defined above may be derived from the peptide by one or more amino acid deletions. The deletions may be C-terminally, N-terminally and/or internally.

5

10

Another preferred embodiment of the invention relates to a peptide as defined above in the previous embodiments, wherein the antigen is a functional active variant of an antigen of any of the SEQ ID NOS: 1 to 7 and wherein the variant has at least 50% sequence identity to the antigen of any of the SEQ ID NOS: 1 to 7. In a more preferred embodiment the functional active variant has a sequence identity of at least 60%, preferably at least 70%, more preferably at least 80%, still more preferably at least 90%, even more preferably at least 95%, most preferably 99% to the antigen of any of the SEQ ID NOS: 1 to 7.

The percentage of sequence identity can be determined e.g. by sequence alignment.
Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms have been described e.g. in Smith and Waterman, Adv. Appl. Math. 2: 482, 1981 or Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85: 2444-2448, 1988.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 20 215: 403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. Variants of an antigen of any of the sequences of SEQ ID NOS: 1 to 7 are typically characterized using the NCBI Blast 2.0, gapped blastp set to default parameters. For 25 comparisons of amino acid sequences of at least 35 amino acids, the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around 35 amino acids), the alignment is performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension 30 gap 1 penalties). Methods for determining sequence identity over such short windows such as 15 amino acids or less are described at the website that is maintained by the National

Center for Biotechnology Information in Bethesda, Maryland (http://www.ncbi.nlm.nih.gov/BLAST/).

The functional active variant of an antigen is obtained by sequence alterations in the antigen, wherein the antigen with the sequence alterations retains a function of the 5 unaltered antigen, e.g. having a biological activity similar to that displayed by the complete antigen, including the ability to induce an immune response and/or to show protection against S. pyogenes e.g. in a sepsis and/or lethality model. Such sequence alterations can include, but are not limited to, conservative substitutions, deletions, mutations and insertions. These characteristics of the functional active variant can be assessed e.g. as 10 detailed in Example 1. In the context of the present invention a variant specifically has a biological activity similar to that displayed by the antigen without alteration, including the ability to induce an immune response and/or to show protection against S. pyogenes e.g. in a sepsis and/or lethality model if the activity of the variant amounts to at least 10%, preferably at least 25%, more preferably at least 50%, even more preferably at least 70%, 15 still more preferably at least 80%, especially at least 90%, particularly at least 95%, most preferably at least 99% of the activity of the antigen without sequence alterations.

- The term "functional active variant" includes naturally-occurring allelic variants, as well as mutants or any other non-naturally occurring variants. As is known in the art, an allelic variant is an alternate form of a (poly)peptide that is characterized as having a substitution, deletion, or addition of one or more amino acids that does essentially not alter the biological function of the polypeptide. By "biological function" is meant a function of the polypeptide in the cells in which it naturally occurs, even if the function is not necessary for the growth or survival of the cells. For example, the biological function of a porin is to allow the entry into cells of compounds present in the extracellular medium. The biological function is distinct from the antigenic function. A polypeptide can have more than one biological function.
- 30 Within any species of the living world, allelic variation is the rule. For example, any bacterial species, *e.g. S. pyogenes*, is usually represented by a variety of strains (characterized by clonal reproduction) that differ from each other by minor allelic variations. Indeed, a polypeptide that fulfils the same biological function in different

strains can have an amino acid sequence that is not identical in each of the strains. Such an allelic variation is equally reflected at the polynucleotide level.

Allelic variation is very common within the *S. pyogenes* species. Such allelic variation is
also the basis for the molecular typing of group A streptococcal strains by emm typing as described above (see, e.g. Facklam, R. et al. (1999) Emerg Infect Dis. 5: 247-53 or http://www.cdc.gov/ncidod/biotech/strep/emmtypes.htm). Further, genes such as *sic* are subject to allelic variation (Hoe N., et al. (2001) J. Inf. Dis. 183: 633-9). However, proteins with large allelic variation are in general not suitable candidates for a vaccine, as
immunization would not protect against infection with all strains, or alternative immunization would possibly induce the emergence of new allelic variants not covered by the vaccine.

In a preferred embodiment, the functional active variant or fragment derived from the antigen by amino acid exchanges, deletions or insertions may also conserve, or more 15 preferably improve, the activity (as defined above). Furthermore, these peptides may also cover epitopes, which trigger the same or preferably an improved T cell response. These epitope are referred to as "heteroclitic". They have a similar or preferably greater affinity to MHC/HLA molecules, and the ability to stimulate the T cell receptors (TCR) directed to the original epitope in a similar or preferably stronger manner. Heteroclitic epitopes can be 20 obtained by rational design i. e. taking into account the contribution of individual residues to binding to MHC/HLA as for instance described by (Rammensee, H. et al., 1999, Immunogenetics. 50: 213-219), combined with a systematic exchange of residues potentially interacting with the TCR and testing the resulting sequences with T cells directed against the original epitope. Such a design is possible for a skilled man in the art 25 without much experimentation.

In a still more preferred embodiment of the invention the functional active variant of an antigen of any of the SEQ ID NOS: 1 to 7 having at least 50% sequence identity to the antigen of any of the SEQ ID NOS: 1 to 7, especially at least 60%, preferably at least 70%, more preferably at least 80%, still more preferably at least 90%, even more preferably at least 95%, most preferably 99% to the antigen of any of the SEQ ID NOS: 1 to 7 is derived from the antigen of any of the sequences of SEQ ID NOS: 1 to 7 by conservative

substitutions. Conservative substitutions are those that take place within a family of amino acids that are related in their side chains and chemical properties. Examples of such families are amino acids with basic side chains, with acidic side chains, with non-polar aliphatic side chains, with non-polar aromatic side chains, with uncharged polar side

- 5 chains, with small side chains, with large side chains etc.. In one embodiment, one conservative substitution is included in the peptide. In another embodiment, two conservative substitutions or less are included in the peptide. In a further embodiment, three conservative substitutions or less are included in the peptide.
- 10 Examples of conservative amino acid substitutions include, but are not limited to, those listed below:

	Original Residue	Conservative Substitutions
	Ala	Ser
15	Arg	Lys
	Asn	Gln; His
	Asp	Glu
	Cys	Ser
	Gln	Asn
20	Glu	Asp
	His	Asn; Gln
	Ile	Leu, Val
	Leu	Ile; Val
	Lys	Arg; Gln; Asn
25	Met	Leu; Ile
	Phe	Met; Leu; Tyr
	Ser	Thr
	Thr	Ser
	Trp	Tyr
30	Tyr	Trp; Phe
	Val	Ile; Leu

Examples of suitable variants of the peptide of the invention obtained by one or more amino acid exchange(s), deletion(s) and/or insertion(s) may be derived from data provided in tables 5 to 7 and 9. Particularly, tables 5 to 7 and 9 list naturally occurring amino acid alterations (substitutions, insertions, deletions) at particular positions in comparison to S.

pyrogenes SF370. 5

10

20

30

With respect to a variant of a peptide having (i.e. consisting of or comprising as defined above, particularly as defined in the above items (a) to (f)) SEQ ID NO: 1, the variant of the invention may differ from the peptide having SEQ ID NO: 1 by one or more of the alterations identified in table 5.

With respect to a variant of a peptide having (i.e. consisting of or comprising as defined above, particularly as defined in the above items (a) to (f)) SEQ ID NO: 2, the variant of the invention may differ from the peptide having SEQ ID NO: 2 by one or more of the alterations identified in table 6.

15

With respect to a variant of a peptide having (i.e. consisting of or comprising as defined above, particularly as defined in the above items (a) to (f)) SEQ ID NO: 3, the variant of the invention may differ from the peptide having SEQ ID NO: 3 by one or more of the alterations identified in table 6.

With respect to a variant of a peptide having (i.e. consisting of or comprising as defined above, particularly as defined in the above items (a) to (f)) SEQ ID NO: 4, the variant of the invention may differ from the peptide having SEQ ID NO: 4 by one or more of the alterations identified in table 7.

25

With respect to a variant of a peptide having (i.e. consisting of or comprising as defined above, particularly as defined in the above items (a) to (f)) SEQ ID NO: 5, the variant of the invention may differ from the peptide having SEQ ID NO: 5 by one or more of the alterations identified in table 7.

With respect to a variant of a peptide having (i.e. consisting of or comprising as defined above, particularly as defined in the above items (a) to (f)) SEQ ID NO: 6, the variant of

the invention may differ from the peptide having SEQ ID NO: 6 by one or more of the alterations identified in table 7.

With respect to a variant of a peptide having (i.e. consisting of or comprising as defined above, particularly as defined in the above items (a) to (f)) SEQ ID NO: 7, the variant of the invention may differ from the peptide having SEQ ID NO: 7 by one or more of the alterations identified in table 9.

It should be understood that variants obtained from a peptide of the invention by one or more sequence alterations in accordance with tables 5 to 7 and 9 are preferred.

A further aspect of the present invention describes a peptide comprising an amino acid sequence with at least 95% sequence identity to at least one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7. In different embodiment the peptide comprises, consists, or consists essentially of a region of at least 95%, at least 97% or at least 99% identical to SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7, or differs by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid alteration(s). In one embodiment the term "consist" may be as defined in the above items (a) to (f)). Preferably, the peptide does not contain a full-length naturally occurring Spy0269, Spy0292, Spy0416A (amino acids 33-867), or Spy0872.

20

5

10

15

SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 provide core sequences useful for producing a protective immune response. SEQ ID NO: 1 provides an amino acid core from amino acids 37-488 of Spy0269. SEQ ID NO: 2 provides a core region of amino acids 23-184 of Spy0292. SEQ ID NO: 3 provides a core of amino acids 23-300 of Spy0292, which is a longer-length sequence containing the shorter-length core sequence of 23-184 of Spy0292 provided in SEQ ID NO: 2. Surprisingly, the shorter fragment Spy0292-1 (SEQ ID NO: 2) shows even greater protection in the mouse model compared to the longer fragment Spy0292-3 (SEQ ID NO: 3), as depicted in Figure 1. As described above, smaller peptides are in general advantageous over larger ones, since they may be produced in a more economic manner, they reduce the probability of inducing antibodies which can cause cross-reactions with human tissues, and they facilitate the preparation of combination vaccines comprising

more than one antigen. SEQ ID NO: 4, 5, and 6 provide different Spy0416A core sequences of varying activity. SEQ ID NO: 5 provides a common core of amino acids 148-

458 of Spy0416A and has the lowest activity. SEQ ID NO: 6 provides a core sequence containing amino acids 72-558 of Spy0416A with greater activity than the shorter core. SEQ ID NO: 4 provides an amino acid core containing amino acids 34-677 of Spy0416, also with activity greater than the 148-458 core.

5

10

15

Based on the guidance provided herein different peptides can be designed taking into account the core sequences provided in SEQ ID NOs: 1-7. Such guidance includes structurally related peptides containing (1) internal alterations; (2) additional amino acid groups at the amino and/or carboxyl terminus; and/or (3) additional modification(s) as described herein.

For structurally related peptides, each amino acid alteration is independently either an addition, substitution, or deletion. In a further embodiment, the amino terminus is methionine. The presence of methionine may be useful for recombinant expression. In some cases, the methionine may be initially present as a result of translation and subsequently cleaved. Additional examples and embodiments, including broader embodiments and some further descriptions applicable for structurally related peptides such as functional variants are provided above, particularly in the description of functional active variants.

20

25

30

In another subject of the invention the peptide as described above comprises or consists of at least 2, preferably at least 3, more preferably at least 4 antigens as defined above. If two ore more peptides derived from the same full length sequence (e.g Spy0292 or Spy0416) are combined into one peptide, these sequences do preferably not overlap. In one embodiment the term "consist" may be as defined in the above items (a) to (f)).

In another embodiment of the invention the peptide as defined above may be modified by one or more of a variety of chemical techniques to produce derivatives having essentially the same activity (as defined above for fragments and variants) as the modified peptides, and optionally having other desirable properties. For example, carboxylic acid groups of

the protein, whether C-terminal or side chain, may be provided in the form of a salt of a pharmaceutically-acceptable cation or esterified to form an ester, or converted to an amide. Amino groups of the peptide, whether amino-terminal or side chain, may be in the form of

a pharmaceutically-acceptable acid addition salt, such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric and other organic salts, or may be converted to an amide. Hydroxyl groups of the peptide side chains may be converted to alkoxy or to an ester using well recognized techniques. Phenyl and phenolic rings of the peptide side chains may be substituted with one or more halogen atoms, such as fluorine, chlorine, bromine or iodine,

- 5 substituted with one or more halogen atoms, such as fluorine, chlorine, bromine or iodine, or with alkyl, alkoxy, carboxylic acids and esters thereof, or amides of such carboxylic acids. Thiols can be protected with any one of a number of well recognized protecting
- 10 Peptides of this invention may be in combination with outer surface proteins or other proteins or antigens of other proteins. In such combination, the antigen may be in the form of a fusion protein. The antigen of the invention may be optionally fused to a selected peptide or protein derived from other microorganisms. For example, an antigen or polypeptide of this invention may be fused at its N-terminus or C-terminus to a polypeptide

15 from another pathogen or to more than one polypeptide in sequence. Peptides which may be useful for this purpose include polypeptides identified by the prior art.

In an embodiment of the invention the peptide of the invention is fused to an epitope tag which provides an epitope to which an anti-tag substance can selectively bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of the peptide but may be incorporated as an internal insertion or substitution as the biological activity permits. The presence of such epitope-tagged forms of a peptide can be detected using a substance such as an antibody against the tagged peptide. Also, provision of the epitope tag enables the peptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his), poly-histidine-glycine (poly-his-gly) tags, the HA tag polypeptide, the c-myc tag, the Strep

tag and the FLAG tag.

groups, such as acetamide groups.

30 Fusions also may include the peptides or antigens of this invention fused or coupled to moieties other than amino acids, including lipids and carbohydrates. Further, antigens of this invention may be employed in combination with other vaccinal agents described by the prior art, as well as with other species of vaccinal agents derived from other

microorganisms. Such proteins are useful in the prevention, treatment and diagnosis of diseases caused by a wide spectrum of Streptococcus isolates.

These fusion proteins are constructed for use in the methods and compositions of this invention. These fusion proteins or multimeric proteins may be produced recombinantly, or may be synthesized chemically.

The peptides of the invention may be prepared by any of a number of conventional techniques. Desired peptides may be chemically synthesized. An alternative approach involves generating the fragments of known peptides by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes, expressing the digested DNA and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired peptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed as the 5' and 3' primers in the PCR. Techniques for

making mutations, such as deletions, insertions and substitutions, at predetermined sites in DNA, and therefore in proteins, having a known sequence are well known. One of skill in the art using conventional techniques, such as PCR, may readily use the antigens and
peptides provided herein to identify and isolate other similar proteins. Such methods are routine and not considered to require undue experimentation, given the information provided herein. For example, variations can be made using oligonucleotide-mediated site-directed mutagenesis (Carter et al., Nucl. Acids Res., 13: 4431 (1985); Zoller et al., Nucl. Acids Res. 10: 6487 (1987)), cassette mutagenesis (Wells et al., Gene, 34: 315 (1985)),
restriction selection mutagenesis (Wells et al., Philos. Trans. R. Soc. London SerA, 317: 415 (1986)), PCR mutagenesis, or other known techniques can be performed on the cloned DNA to produce the peptide of the invention.

Another subject of the present invention relates to a nucleic acid encoding a peptide of the invention, i.e. any peptide as defined above, or a nucleic acid complementary thereto. Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA or cRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA e.g. obtained by cloning or produced by chemical synthetic techniques or by a

combination thereof. The DNA may be double- stranded or single-stranded. Singlestranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand. Nucleic acid molecule as used herein also refers to, among other, single- and double- stranded DNA, DNA that is a mixture of single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions hybrid molecules comprising DNA and RNA that may be single-

- 5 mixture of single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be singlestranded or, more typically, double-stranded, or a mixture of single- and double-stranded regions.
- The nucleic acid may be a fragment of a nucleic acid occurring naturally in *S. pyogenes*, especially in *S. pyogenes* serotype M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118, particularly *S. pyogenes* SF370. Preferably the nucleic acid has a sequence as defined in any of the sequences of SEQ ID NOS: 11 to 17 or of any of the homologous variants identified in the attached listing of nucleic acid sequence data. Examples of homologous sequences of a different serotype are those listed below:

Full length nucleic	Nucleic acid of the invention	Homologous nucleic acid
acid sequence	(SEQ ID NO)	sequences
(SEQ ID NO)		(SEQ ID NOS)
133	11	134 to 143
144	12	145 to 154
144	13	155 to 164
165	14	166 to 175
165	15	176 to 185
165	16	186 to 195
196	17	197 to 206

The nucleic acid also includes sequences that are a result of the degeneration of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all nucleotide sequences are included in the invention which result in the peptide as defined above.

10

15

Additionally, the nucleic acid may contain one or more modified bases. Such nucleic acids may also contain modifications e.g. in the ribose-phosphate backbone to increase stability and half life of such molecules in physiological environments. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "nucleic acid molecule" as that feature is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are nucleic acid molecule within the context of the present invention. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term nucleic acid molecule as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of nucleic acid molecule, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia. For example, nucleotide substitutions can be made which do not affect the polypeptide encoded by the nucleic acid, and thus any nucleic acid molecule which encodes an antigen or fragment or functional active variant thereof as defined above is encompassed by the present invention.

Furthermore, any of the nucleic acid molecules encoding an antigen of the invention or fragment or functional active variant thereof can be functionally linked, using standard
techniques such as standard cloning techniques, to any desired regulatory sequences, whether a *S. pyogenes* regulatory sequence or a heterologous regulatory sequence, heterologous leader sequence, heterologous marker sequence or a heterologous coding sequence to create a fusion protein.

- The nucleic acid of the invention may be originally formed *in vitro* or in a cell in culture, in general, by the manipulation of nucleic acids by endonucleases and/or exonucleases and/or polymerases and/or ligases and/or recombinases or other methods known to the skilled practitioner to produce the nucleic acids.
- 30 In one embodiment of the invention the nucleic acid is located in a vector. A vector may additionally include nucleic acid sequences that permit it to replicate in the host cell, such as an origin of replication, one or more desired genes and/or selectable marker genes and other genetic elements known in the art such as regulatory elements directing transcription,

10

30

translation and/or secretion of the encoded protein. The vector may be used to transduce, transform or infect a cell, thereby causing the cell to express inserted nucleic acids and/or proteins other than those native to the cell. The vector optionally includes materials to aid in achieving entry of the nucleic acid into the cell, such as a viral particle, liposome, protein coating or the like. Numerous types of appropriate expression vectors are known in the art for protein expression, by standard molecular biology techniques. Such vectors are selected from among conventional vector types including insects, e.g., baculovirus expression, or yeast, fungal, bacterial or viral expression systems. Other appropriate expression vectors, of which numerous types are known in the art, can also be used for this purpose. Methods for obtaining such expression vectors are well-known (see, e.g. Sambrook et al, Molecular Cloning. A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, New York (1989)). In one embodiment, the vector is a viral vector. Viral

Suitable host cells or cell lines for transfection by this method include bacterial cells. For example, the various strains of *E. coli* are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis, Pseudomonas, Streptomyces*, and other bacilli and the like may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the peptides of the present invention. Other fungal cells or insect cells such as *Spodoptera frugipedera* (Sf9) cells may also be employed as expression systems. Alternatively, mammalian cells, such as human 293 cells, Chinese hamster ovary cells (CHO), the monkey COS-1 cell line or murine 3T3 cells derived from Swiss, BALB/c or NIH mice may be used. Still other suitable host cells, as well as methods for transfection, culture, amplification, screening, production, and purification are known in the art.

vectors include, but are not limited to, retroviral and adenoviral vectors.

A peptide of the invention may be produced by expressing a nucleic acid of the invention in a suitable host cell. The host cells can be transfected, e.g. by conventional means such as electroporation with at least one expression vector containing a nucleic acid of the invention under the control of a transcriptional regulatory sequence. The transfected or transformed host cell is then cultured under conditions that allow expression of the protein. The expressed protein is recovered, isolated, and optionally purified from the cell (or from the culture medium, if expressed extracellularly) by appropriate means known to one of

skill in the art. For example, the proteins are isolated in soluble form following cell lysis, or extracted using known techniques, e.g. in guanidine chloride. If desired, the peptides or fragments of the invention are produced as a fusion protein. Such fusion proteins are those described above. Alternatively, for example, it may be desirable to produce fusion proteins

- to enhance expression of the protein in a selected host cell or to improve purification. The molecules comprising the peptides and antigens of this invention may be further purified using any of a variety of conventional methods including, but not limited to: liquid chromatography such as normal or reversed phase, using HPLC, FPLC and the like; affinity chromatography (such as with inorganic ligands or monoclonal antibodies); size
 exclusion chromatography; immobilized metal chelate chromatography; gel electro-
- phoresis; and the like. One of skill in the art may select the most appropriate isolation and purification techniques without departing from the scope of this invention. Such purification provides the antigen in a form substantially free from other proteinaceous and non-proteinaceous materials of the microorganism.

15

Another subject of the invention is a pharmaceutical composition, especially a vaccine, comprising

(i) at least one peptide according to the invention, and/or

(ii) at least one peptide comprising or consisting of the sequence of any of the SEQ ID

20

NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, or a functional active variant thereof, and

(iii) optionally a pharmaceutically acceptable carrier or excipient.

The variants of the peptides of (ii) are as defined and may be obtained as the peptides of (i) (see above description of the peptides of the invention). Preferred alterations of the sequences of SEQ ID NO: 8 or 10 are those listed in tables 8 and 9, respectively.

25

30

The peptides of (i) and (ii) are referred to as pharmaceutical peptides of the invention.

With respect to the peptide of (ii), these proteins have been shown for the first time to be capable to provide protection against lethal *S. pyogenes* challenge (see Example 1), particularly in a physiologically highly relevant intranasal challenge model. Especially protein Spy0895 (SEQ ID NO: 9) shows particular promise as a vaccine candidate, because it provided protection against group A streptococcal infection in all three models listed in Table 1.

A pharmaceutical peptide of the invention may be used for methods for immunizing or treating humans and/or animals with the disease caused by infection with S. pyogenes. Therefore, the pharmaceutical peptide may be used within a pharmaceutical composition. The pharmaceutical composition of the present invention may further encompass 5 pharmaceutically acceptable carriers and/or excipients. The pharmaceutically acceptable carriers and/or excipients useful in this invention are conventional and may include buffers, stabilizers, diluents, preservatives, and solubilizers. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the 10 (poly)peptides herein disclosed. In general, the nature of the carrier or excipients will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt 15 solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e. g. powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example

20

sodium acetate or sorbitan monolaurate.

In a preferred embodiment the pharmaceutical composition further comprises an

immunostimulatory substance such as an adjuvant. The adjuvant can be selected based on

- the method of administration and may include mineral oil-based adjuvants such as Freund's 25 complete and incomplete adjuvant, Montanide incomplete Seppic adjuvant such as ISA, oil in water emulsion adjuvants such as the Ribi adjuvant system, syntax adjuvant formulation containing muramyl dipeptide, IC31[™] (Intercell; a synthetic adjuvant comprising the peptide motif KLK [WO 02/32451] and an oligonucleotide [WO 01/93905]), or aluminum
- salt adjuvants. Preferably, the adjuvant is a mineral oil-based adjuvant, most preferably 30 ISA206 (SEPPIC, Paris, France).

In other embodiments the immunostimulatory substance is selected from the group comprising polycationic polymers, especially polycationic peptides such as polyarginine, immunostimulatory deoxynucleotides (ODNs), especially Oligo(dIdC)₁₃, peptides containing at least two LysLeuLys motifs, especially KLKLLLLKLK (SEQ ID NO: 55), neuroactive compounds, especially human growth hormone, alum, adjuvants or

- 5 combinations thereof. In further embodiments, the combination is either a polycationic polymer and immunostimulatory deoxynucleotides or of a peptide containing at least two LysLeuLys motifs and immunostimulatory deoxynucleotides. In a still another embodiment the polycationic polymer is a polycationic peptide.
- 10

15

The term "Oligo(dIdC)₁₃" as used in the present invention means a phosphodiester backboned single-stranded DNA molecule containing 13 deoxy (inosine-cytosine) motifs, defined sequence also by the term $[oligo-d(IC)_{13}].$ The exact is 5'-Oligo(dIdC)₁₃ can also be defined by the terms (oligo-dIC₂₆); oligo-dIC_{26-mer}; oligo-deoxy IC, 26-mer; or oligo-dIC, 26-mer, as specified for example in WO 01/93903 and WO 01/93905.

In an embodiment the immunostimulatory substance is at least one immunostimulatory nucleic acid. Immunostimulatory nucleic acids are e.g. neutral or artificial CpG containing nucleic acids, short stretches of nucleic acids derived from non-vertebrates or in form of 20 short oligonucleotides (ODNs) containing non-methylated cytosine-guanine dinucleotides (CpG) in a defined base context (e.g. as described in WO 96/02555). Alternatively, also nucleic acids based on inosine and cytidine as e.g. described in WO 01/93903, or deoxynucleic acids containing deoxy-inosine and/or deoxyuridine residues (described in WO 01/93905 and WO 02/095027) may preferably be used as immunostimulatory nucleic 25 acids in the present invention. Preferably, mixtures of different immunostimulatory nucleic acids are used in the present invention. Additionally, the aforementioned polycationic compounds may be combined with any of the immunostimulatory nucleic acids as aforementioned. Preferably, such combinations are according to the ones described in WO 01/93905, WO 02/32451, WO 01/54720, WO 01/93903, WO 02/13857, WO 02/095027 30 and WO 03/047602.

10

15

20

25

In addition or alternatively, such pharmaceutical or vaccine composition may comprise a neuroactive compound. Preferably, the neuroactive compound is human growth factor, e.g. described in WO 01/24822. Also preferably, the neuroactive compound is combined with any of the polycationic compounds and/or immunostimulatory nucleic acids as defined above.

The composition may be used e.g. for immunization or treatment of a subject. The pharmaceutical composition encompasses at least one pharmaceutical peptide of the invention; however, it may also contain a cocktail (i.e., a simple mixture) containing different pharmaceutical peptides (including fragments and other variants) of the invention, optionally mixed with different antigenic proteins or peptides of other pathogens. Such mixtures of these peptides, polypeptides, proteins or fragments or variants thereof are useful e.g. in the generation of desired antibodies to a wide spectrum of Streptococci isolates. The pharmaceutical peptide(s) of the present invention may also be used in the form of a pharmaceutically acceptable salt. Suitable acids and bases which are capable of forming salts with the peptides of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases.

Still another subject of the invention is a pharmaceutical composition containing a nucleic acid selected from the group consisting of:

- (i) a nucleic acid of the invention and/or a nucleic acid complementary thereto, and/or
- (ii) a nucleic acid coding for the peptide comprising or consisting of the sequence of any of the SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, particularly a DNA sequence of any of the SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20, or a functional active variant thereof or a nucleic acid complementary thereto or the corresponding RNA sequence, and
- (iii) optionally a pharmaceutically acceptable carrier or excipient.

The variants of the nucleic acids of (ii) are as defined and may be obtained as the nucleic acids of (i) (see above description of the nucleic acids of the invention). The nucleic acids of (i) and (ii) are referred to as pharmaceutical nucleic acids of the invention.

The pharmaceutical nucleic acid sequences, alone or in combination with other nucleic acid sequences encoding antigens or antibodies or directed to other pathogenic microorganisms, may further be used as components of a pharmaceutical composition. The composition may be used for immunizing or treating humans and/or animals being susceptible to or having a disease caused by infection with *S. pyogenes*, particularly *S. pyogenes* serotype M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118, especially *S. pyogenes* SF370. The pharmaceutically acceptable carrier or excipient may be as defined above.

10

5

In another embodiment, the pharmaceutical nucleic acids of this invention, alone or in combination with nucleic acid sequences encoding other antigens or antibodies from other pathogenic microorganisms, may further be used in compositions directed to actively induce a protective immune response in a subject to the pathogen. These components of the present invention are useful in methods for inducing a protective immune response in humans and/or animals against infection with *S. pyogenes*, particularly with *S. pyogenes* serotype M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118, especially *S. pyogenes* SF370.

20

15

For use in the preparation of the therapeutic or vaccine compositions, nucleic acid delivery compositions and methods are useful, which are known to those of skill in the art. The pharmaceutical nucleic acid of the invention may be employed in the methods of this invention or in the compositions described herein as DNA sequences, either administered as naked DNA, or associated with a pharmaceutically acceptable carrier and provide for *in vivo* expression of the antigen, peptide or polypeptide. So-called "naked DNA" may be used to express the antigen, peptide or polypeptide of the invention *in vivo* in a patient. (See, e.g., J. Cohen, Science, 259: 1691-1692, which describes similar uses of "naked DNA"). For example, "naked DNA" associated with regulatory sequences may be administered therapeutically or as part of the vaccine composition e.g., by injection.

Alternatively, a nucleic acid, especially a pharmaceutical nucleic acid according to the invention, encoding an antigen or peptide of the invention or a nucleic acid complementary

thereto may be used within a pharmaceutical composition, e.g. in order to express the antigen or (pharmaceutical) peptide of the invention in vivo, e.g., to induce antibodies.

A preferred embodiment of the invention relates to a pharmaceutical composition, wherein the pharmaceutical nucleic acid according to the invention is comprised in a vector and/or 5 a cell. Vectors and cells suitable in the context of the present invention are described above. Vectors are particularly employed for a DNA vaccine. An appropriate vector for delivery may be readily selected by one of skill in the art. Exemplary vectors for in vivo gene delivery are readily available from a variety of academic and commercial sources, and include, e.g., adeno-associated virus (International patent application No. 10 PCT/US91/03440), adenovirus vectors (M. Kay et al, Proc. Natl. Acad. Sci. USA, 91: 2353 (1994); S. Ishibashi et al, J. Clin. Invest., 92: 883 (1993)), or other viral vectors, e.g., various poxviruses, vaccinia, etc.. Recombinant viral vectors, such as retroviruses or adenoviruses, are preferred for integrating the exogenous DNA into the chromosome of the cell.

15

20

Another subject of the invention relates to an antibody or functional active fragment thereof which binds specifically to the antigen of the invention. The present invention includes, for example, monoclonal and polyclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of a Fab expression library.

While S. pyogenes infections are primarily a disease of children and cause non-severe diseases such as bacterial pharyngitis and impetigo, GAS are also responsible for streptococcal toxic shock syndrome associated necrotizing fasciitis (Cone, L., et al. (1987).

New Engl J Med 317: 146-9; Stevens, D. (1992). Clin Infect Dis 14: 2-11) and several 25 post-streptococcal sequelae such as acute rheumatic fever, acute glomerulonephritis and reactive arthritis. It would be very beneficial to provide monoclonal or polyclonal antibody therapies which target antigenic proteins of S. pyogenes and have the potential to support a therapy of an infection or eliminate the pathogen and the disease altogether.

30

In a preferred embodiment the antibody is a monoclonal, polyclonal, chimeric or humanized antibody or functional active variant thereof. In another preferred embodiment the functional active fragment comprises a Fab fragment.

25

30

Antibodies generated against the antigens, fragments or variants thereof of the present invention can be obtained by direct injection of the antigens, fragments or variants thereof into an animal or by administering the antigens, fragments or variants thereof to an animal,

5 preferably a non-human. The antibody so obtained will then bind the antigens, fragments or variants. Such antibodies can then be used to isolate reactive antigens, fragments or variants thereof from tissue expressing those.

For preparation of monoclonal antibodies, any technique known in the art, which provides
antibodies produced by continuous cell line cultures, e.g. a hybridoma cell line, can be used.

Techniques described for the production of single chain antibodies (U. S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to the antigens, fragments or variants thereof according to this invention. Also, transgenic mice or other organisms such as other mammals may be used to express humanized antibodies to antigens, fragments or variants thereof according to this invention.

Still another subject of the invention relates to a hybridoma cell line which produces the antibody of the invention.

Hybridoma cell lines expressing desirable monoclonal antibodies are generated by wellknown conventional techniques. The hybridoma cell can be generated by fusing a normalactivated, antibody-producing B cell with a myeloma cell. In the context of the present invention the hybridoma cell is able to produce an antibody specifically binding to the antigen of the invention.

Similarly, desirable high titre antibodies are generated by applying known recombinant techniques to the monoclonal or polyclonal antibodies developed to these antigens (see, e.g., PCT Patent Application No. PCT/GB85/00392; British Patent Application Publication No. GB2188638A; Amit et al., Science, 233: 747-753 (1986); Queen et al., Proc. Natl.

Acad. Sci. USA, 86: 10029-10033 (1989); PCT Patent Application No. WO90/07861;

Riechmann et al., Nature, 332: 323-327 (1988); Huse et al., Science, 246: 1275-1281 (1988)).

The present invention also provides a method for producing an antibody according to the invention, characterized by the following steps:

- (a) administering an effective amount of the peptide according to the invention to an animal; and
- (b) isolating the antibody produced by the animal in response to the administration of step (a) from the animal.
- 10

5

Another subject of the invention relates to a method for producing an antibody according to the invention, characterized by the following steps:

- (a) contacting a B cell with an effective amount of the peptide according to the invention;
- 15 (b) fusing the B cell of step (a) with a myeloma cell to obtain a hybridoma cell; and
 - (c) isolating the antibody produced by the cultivated hybridoma cell.

More particularly, the antibody may be produced by initiating an immune response in a non-human animal by administrating a peptide of the invention to an animal, removing an
antibody containing body fluid from said animal, and producing the antibody by subjecting said antibody containing body fluid to further purification steps. Alternatively, the antibody may be produced by initiating an immune response in a non-human animal by administrating an antigen, fragment or variant thereof, as defined in the present invention, to said animal, removing the spleen or spleen cells from said animal and/or producing hybridoma cells of said spleen or variant thereof and producing the antibody by cultivation of said cloned hybridoma cells.

In a preferred embodiment the antibody produced according to a method of the invention is additionally purified. Methods of purification are known to the skilled artisan.

The antibody may be used in methods for preventing or treating an infection. Accordingly, still another subject of the invention relates to a pharmaceutical composition, especially a

31

vaccine, comprising an antibody of the invention. The pharmaceutical composition may encompass further components as detailed above. The composition may further encompass substances increasing their capacity to stimulate T cells. These include T helper cell epitopes, lipids or liposomes or preferred modifications as described in WO01/78767. Another way to increase the T cell stimulating capacity of epitopes is their formulation with immune stimulating substances for instance cytokines or chemokines like interleukin-2, -7, -12, -18, class I and II interferons (IFN), especially IFN-gamma, GM-CSF, TNFalpha, flt3-ligand and others.

- A further subject of the invention relates to a pharmaceutical composition comprising the 10 pharmaceutical peptide of the invention or the pharmaceutical nucleic acid of the invention or an antibody of the invention or functional fragment thereof for the immunization of a subject against an infection or the treatment of a subject having an infection, wherein the infection is preferably a S. pyogenes infection. In another aspect of the invention a pharmaceutical peptide of the invention or a pharmaceutical nucleic acid of the invention 15 or an antibody of the invention or functional fragment thereof is used for the manufacture of a medicament for the immunization of a subject against an infection or the treatment of a subject having an infection, wherein the infection is preferably a S. pyogenes infection, more preferably an infection with S. pyogenes serotype M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, 20 M84, M87, M89 or M118, especially S. pyogenes SF370. Alternatively, a pharmaceutical peptide or a pharmaceutical nucleic acid of the invention or an antibody of the invention or functional fragment thereof is used in a method of immunizing or treating a subject in need
- thereof, wherein an effective amount of the pharmaceutical peptide or the pharmaceutical
 nucleic acid of the invention or an antibody of the invention or functional fragment thereof
 is administered to the subject. The subject may be immunized in order to prevent an
 infection, particularly a *S. pyogenes* infection, or may be treated to ameliorate or cure an
 infection, particularly a *S. pyogenes* infection. The determination of the effective amount to
 be administered is within the knowledge of the skilled practitioner. Exemplary amounts are
 mentioned below.

The pharmaceutical peptides or the pharmaceutical nucleic acids of the invention are generally useful for inducing an immune response in a subject. The vaccine used for

10

15

immunization may be administered to a subject susceptible to infection by S. pyogenes, preferably mammals, and still more preferably humans. Potential modes of administration include oral, intranasal, intramuscular, intra-lymph node, intradermal, intraperitoneal, subcutaneous, and combinations thereof, but most preferably intramuscular injection. The volume of the dose for intramuscular administration is preferably up to about 5 mL, for example, between 0.3 mL and 3 mL, between 1 mL and 3 mL, about 0.5 to 1 mL, or about 2 mL. The amount of protein comprising the antigen in each dose should be enough to confer effective immunity to decrease the risk of developing clinical signs, e.g. resulting from S. pyogenes infection. In different embodiments, the unit dose of protein should be up to about 5 μ g protein/kg body weight, between about 0.2 to 3 μ g, between about 0.3 to 1.5 μ g, between about 0.4 to 0.8 μ g, or about 0.6 μ g. In alternative embodiments unit doses of protein could be up to about 6 µg protein/kg body weight, between about 0.05 to 5 µg, or between about 0.1 to 4 µg. In different embodiments, the dose is administered 1 to 3 times, e.g. with an interval of 1 to 3 weeks. Representative amounts of protein per dose are from approximately 1 µg to approximately 1 mg, more preferably from approximately 5 µg to approximately 500 μ g, still more preferably from approximately 10 μ g to approximately 250 μ g and most preferably from approximately 25 μ g to approximately 100 μ g.

- In still another aspect of the invention the antibody of the invention or functional fragment
 thereof is used for the manufacture of a medicament for the treatment of an infection, preferably a *S. pyogenes* infection, more preferably an infection with *S. pyogenes* serotype
 M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118, especially *S. pyogenes* SF370. Alternatively, the antibody of the invention is used in a method of treating a subject
 in need thereof, wherein an effective amount of the antibody of the invention is administered to the subject. The subject may be treated to ameliorate or cure an infection, particularly a *S. pyogenes* infection. The determination of the effective amount to be administered is within the knowledge of the skilled practitioner.
- 30 The treatment involves administering an effective amount of an antibody of the invention to a subject, preferably a mammal, more preferably a human. Thus, antibodies against the antigens, fragments or variants thereof of the present invention may be employed to inhibit and/or treat infections, particularly bacterial infections and especially infections arising

from *S. pyogenes*, especially *S. pyogenes* serotype M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118, especially *S. pyogenes* SF370.

- 5 An "effective amount" of a pharmaceutical peptide, a pharmaceutical nucleic acid or an antibody of the invention may be calculated as that amount capable of exhibiting an *in vivo* effect, e.g. preventing or ameliorating a sign or symptom of infection, particularly *S. pyogenes* infection, especially of *S. pyogenes* serotype M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83,
- 10 M84, M87, M89 or M118, especially *S. pyogenes* SF370. Such amounts may be determined by one of skill in the art. Preferably, such a composition is administered parenterally, preferably intramuscularly or subcutaneously. However, it may also be formulated to be administered by any other suitable route, including orally or topically. The selection of the route of delivery and dosage of such therapeutic compositions is
- 15 within the skill of the art.

20

Treatment in the context of the present invention refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

Another subject of the invention relates to a method of diagnosing a *S. pyogenes* infection comprising the steps of:

- 25 (a) contacting a sample obtained from a subject with the peptide according to the invention; and
 - (b) detecting the presence of an antibody against S. pyogenes in the sample.

The peptides of the invention may be used for the detection of the *S. pyogenes*, particularly *S. pyogenes* serotype M1, M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25,
M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118, especially *S. pyogenes* SF370. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease, most preferably for the diagnosis of a *S. pyogenes* infection. The

peptides or polypeptides may be used to detect the presence of a *S. pyogenes*-specific antibody or fragment thereof e.g. in a sample obtained from a subject. The sample may be e.g. a blood sample. Alternatively, the presence of a *S. pyogenes*-specific antigen can be detected using an antibody of the invention.

5

15

20

Accordingly, an alternative method of diagnosing a *S. pyogenes* infection comprises the steps of:

(a) contacting a sample obtained from a subject with the antibody according to the invention; and

10 (b) detecting the presence of an antigen of S. pyogenes in the sample.

The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of the peptides or antibodies of the present invention in cells and tissues or body fluids, including determination of normal and abnormal levels. Assay techniques that can be used to determine levels of a peptide or an antibody, in a sample derived from a host are well known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Among these, ELISAs frequently are preferred. An ELISA assay initially comprises preparing an antibody specific to the peptide, particularly the antigen, preferably a monoclonal antibody. In addition, a reporter antibody generally is prepared which binds to the monoclonal antibody. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, such as horseradish peroxidase enzyme.

The peptides or antibodies of the present invention may also be used for the purpose of or in connection with an array. More particularly, at least one of the peptides or antibodies of the present invention may be immobilized on a support. Said support typically comprises a variety of antigens and fragments thereof whereby the variety may be created by using one or several of the peptides or antibodies of the present invention. The characterizing feature of such array as well as of any array in general is the fact that at a distinct or predefined region or position on said support or a surface thereof, a distinct polypeptide is immobilized. Because of this any activity at a distinct position or region of an array can be correlated with a specific polypeptide. The number of different peptides or antibodies of

the present invention immobilized on a support may range from as little as 10 to several 1000 different peptides or antibodies of the present invention.

The manufacture of such arrays is known to the one skilled in the art and, for example, described in US patent 5,744,309. The array preferably comprises a planar, porous or non-5 porous solid support having at least a first surface. Preferred support materials are, among others, glass or cellulose. It is also within the present invention that the array is used for any of the diagnostic applications described herein. Apart from the peptides or antibodies of the present invention also the nucleic acid molecules according to the present invention may be used for the generation of an array as described above. 10

Another aspect of the invention relates to a method for identifying a ligand capable of binding to a peptide according to the invention comprising:

- providing a test system comprising the peptide, (a)
- contacting the test system with a test compound, and 15 (b)
 - detecting a signal generated in response to the binding of the test compound to the (c) peptide.
- More particularly, the method may be carried out by contacting an isolated or immobilized peptide according to the invention with a candidate ligand under conditions to permit 20 binding of the candidate ligand to the peptide, wherein the test system comprises a component capable of providing a detectable signal in response to the binding of the candidate ligand to said peptide; and detecting the presence or absence of a signal generated in response to the binding of the ligand to the peptide. The ligand may be an agonist or an antagonist. 25

Test systems for detection binding of a ligand are known to the skilled artisan and include e.g. binding assays with labeled ligand such as radioligands, fluorescence-labeled ligands or enzyme-labeled ligands.

30

The test compound can be any test compound either naturally occurring or chemically synthesized. Naturally occurring test compounds include in particular antibodies, preferably those showing similarity to the antibodies of the invention. In one preferred embodiment of the invention the test compound is provided in the form of a chemical compound library. Chemical compound libraries include a plurality of chemical compounds and have been assembled from any of multiple sources, including chemically synthesized molecules and natural products, or have been generated by combinatorial

5 chemistry techniques. They are especially suitable for high throughput screening. They may be comprised of chemical compounds of a particular structure or compounds of a particular creature such as a plant.

The method for identifying a ligand may also include the following steps:

- 10 (a) providing a peptide according to the invention,
 - (b) providing an interaction partner to the peptide especially an antibody according to the invention,
 - (c) allowing interaction of the peptide to said interaction partner to form a interaction complex,
- 15 (d) providing a test compound,
 - (e) allowing a competition reaction to occur between the test compound and the interaction complex, and
 - (f) determining whether the test compound inhibits or reduces the interaction activities of the peptide with the interaction partner.
- 20

The ligands identified may be employed, for instance, to inhibit diseases arising from infection with Streptococcus, especially *S. pyogenes* and may therefore be formulated in a pharmaceutical composition.

- In a last aspect, the peptide according to the invention is used for the isolation and/or purification and/or identification of a ligand of the peptide, wherein the isolation and/or purification and/or identification of the ligand may be carried out as detailed above or as known to the person skilled in the art. In a preferred embodiment of the invention an affinity device may be used. The affinity device may comprise as least a support material
- 30 and any peptide according to the present invention, which is attached to the support material. Because of the specificity of the peptides according to the present invention for their target cells or target molecules or their interaction partners, the peptides allow a selective removal of their interaction partner(s) from any kind of sample applied to the

support material provided that the conditions for binding are met. The sample may be a biological or medical sample, including but not limited to, fermentation broth, cell debris, cell preparation, tissue preparation, organ preparation, blood, urine, lymph liquid, liquor and the like. The peptide may be attached to the matrix in a covalent or non-covalent manner. Suitable support material is known to the one skilled in the art and can be selected from the group comprising cellulose, silicon, glass, aluminium, paramagnetic beads, starch and dextrane.

The present invention is further illustrated by the following figures, examples and the sequence data, from which further features, embodiments and advantages may be taken. It is to be understood that the present examples are given by way of illustration only and not by way of limitation of the disclosure.

Figure 1 shows the protection achieved by active immunization with selected *S. pyogenes* antigens and sub-constructs in a mouse lethality model.

Figure 2 shows the protection achieved by active immunization with selected *S. pyogenes* antigens and sub-constructs in a mouse lethality model.

Figure 3 shows the protection achieved by active immunization with selected *S. pyogenes* antigens and sub-constructs in a mouse lethality model.

Figure 4 shows the protection achieved by active immunization with selected *S. pyogenes* antigens in a mouse lethality model.

25

15

5

Table 1 shows the recombinant proteins of *S. pyogenes* and fragments thereof assessed for protection in murine models of infection.

Table 2 shows the oligonucleotides used for the cloning of genes encoding antigenic30 proteins and fragments thereof of S. pyogenes.

Table 3 shows the S. pyogenes strains used for the gene conservation study.

Table 4 shows the oligonucleotides used for PCR and sequencing of the S. pyogenes genes.

Table 5 shows the variable amino acid positions of Spy0269 from S. pyogenes strains.

5

Table 6 shows the variable amino acid positions of Spy0292 from S. pyogenes strains.

Table 7 shows the variable amino acid positions of Spy0416 from S. pyogenes strains.

10 **Table 8** shows the variable amino acid positions of Spy0488 from *S. pyogenes* strains.

Table 9 shows the variable amino acid positions of Spy0872 from S. pyogenes strains.

Table 10 shows the variable amino acid positions of Spy0895 from S. pyogenes strains.

15

Table 11 shows the variable amino acid positions of Spy1536 from S. pyogenes strains.

Table 12 shows the variable amino acid positions of Spy1666 from S. pyogenes strains.

20

FIGURES

Figure 1: Protection achieved by active immunization with selected S. pyogenes antigens and sub-constructs in a mouse lethality model. CD-1 mice (10 mice per group)
were immunized subcutaneously with recombinant antigens cloned from an emm type 1 S. pyogenes strain (SF370) and challenged with the MA-A20 (emm type 23) strain. Survival was monitored for 14 days post-challenge. Mice were immunized subcutaneously with 50 µg recombinant protein adjuvanted with CFA/IFA. (A) Spy0292, and its sub-constructs Spy0292-1 and Spy0292-3; Spy0488; (B) Spy0872 and its sub-construct Spy0872-2.
Anesthetized mice were challenged intranasally with 10⁸ cfu S. pyogenes MA-A20. Adjuvant control mice were used as negative controls, while M1 (Spy2018) served as positive control. Numbers of surviving mice are plotted as percentage of total mice.

10

Figure 2: Protection achieved by active immunization with selected *S. pyogenes* antigens and sub-constructs in a mouse lethality model. CD-1 mice (10 mice per group) were immunized subcutaneously with recombinant antigens cloned from an emm type 1 *S. pyogenes* strain (SF370) and challenged with the MA-A20 (emm type 23) strain. Survival was monitored for 14 days post-challenge. Mice were immunized subcutaneously with 50 μ g recombinant protein adjuvanted with CFA/IFA. (A) Spy0269 and its sub-construct Spy0269-1; (B) Spy0416A and 3 sub-constructs (Spy0416A-1, Spy0416A-6 and Spy0416A-7) and Spy0416B. Anesthetized mice were challenged intranasally with 10⁸ cfu *S. pyogenes* MA-A20. Adjuvant control mice were used as negative controls, while M1 protein (Spy2018) served as positive control. Numbers of surviving mice are plotted as percentage of total mice.

Figure 3: Protection achieved by active immunization with selected S. pyogenes antigens or sub-constructs in a mouse lethality model. CD-1 mice (10 mice per group)
were immunized subcutaneously with recombinant antigens cloned from an emm type 1 S. pyogenes strain (SF370) and challenged with the MA-A20 (emm type 23) strain. Survival was monitored for 14 days post-challenge. Mice were immunized subcutaneously with 50 µg recombinant protein adjuvanted with aluminum hydroxide. (A) Spy1727, Spy0269-1, Spy0872-2, and Spy0416A-1; (B) Spy1666, Spy1536, Spy0895, and Spy0292-1.
Anesthetized mice were challenged intranasally with 10⁸ cfu S. pyogenes MA-A20. Adjuvant control mice were used as negative controls, while M1 protein (Spy2018) served as positive control. Numbers of surviving mice are plotted as percentage of total mice.

Figure 4: Protection achieved by active immunization with selected S. pyogenes antigens in a mouse lethality model. BALB/c mice (10 mice per group) were immunized intranasally with recombinant antigens cloned from an emm type 1 S. pyogenes strain (SF370) and challenged either with (A) MA-A20 (emm type 23) strain or with (B) MA-A147 (emm type 11/106) strain. Survival was monitored for 14 days post-challenge. Mice were immunized intranasally with 30-50 μg recombinant protein adjuvanted with IC31TM.

30 (A) Spy1536 and Spy0895; (B) Spy1727 and Spy1536. Anesthetized mice were challenged intranasally with 10⁶ cfu *S. pyogenes* MA-A20 or 10⁸ cfu *S. pyogenes* MA-A147. Adjuvant control mice were used as negative controls, while M1 protein (Spy2018) served as positive control. Numbers of surviving mice are plotted as percentage of total mice.

EXAMPLES

Example 1: Group A streptococcal antigens and fragments thereof inducing protective immune responses against lethal sepsis in intranasal challenge models.

5

15

20

Experimental procedures

Cloning and expression of recombinant pneumococcal proteins

10 Cloning of genes / DNA fragments:

The gene/DNA fragment of interest (see Table 1) was amplified from genomic DNA of *Streptococcus pyogenes* SF370 (serotype M1) by PCR using gene specific primers (see Table 2). Apart from the gene specific part, the primers had restriction sites that aided in a directional cloning of the amplified PCR product. The gene annealing (specific) part of the primer ranged between 15-30 bases in length. The PCR products obtained were digested with the appropriate restriction enzymes and cloned into the pET28b (+) vector (Novagen) for His-tagged proteins. The constructs including full length and fragments of the selected antigens are listed in Table 1. Once the recombinant plasmid was confirmed to contain the gene of interest, *E. coli* BL21 star[®] cells (Invitrogen) that served as expression host were transformed.

Expression and purification of proteins:

E coli BL21 star[®] cells harboring the recombinant plasmid were grown into log phase in the required culture volume. Once an OD_{600nm} of 0.6 was reached the culture was induced with 0.5 mM IPTG (isopropyl-beta-D-thiogalactopyranoside) at 37°C for 3 hours. The cells were harvested by centrifugation, lysed by a combination of the freeze-thaw method followed by disruption of cells with BugBuster[®] (Novagen). The lysate was separated by centrifugation into soluble (supernatant) and insoluble (pellet) fractions. Depending on the location of the protein different purification strategies were applied.

30

A) If the His-tagged protein was in the soluble fraction, protein purification was done by binding the supernatant to Ni-Sepharose beads (Ni-SepharoseTM 6 Fast Flow, GE Healthcare). Due to the presence of the hexa Histidine (6xHIS) at the C terminus of the

expressed protein, it bound to the Ni-Sepharose while the other contaminating proteins were washed from the column by wash buffer. The protein was eluted by 500 mM Imidazole in 20 mM NaH₂PO₄, 0.5 mM NaCl buffer at pH 7.4. The eluate was concentrated, assayed by Bradford for protein concentration and checked by SDS-PAGE and Western blot

5 and Western blot.

10

15

B) If the protein was present in the insoluble fraction the pellet was solubilized in suitable buffer containing 8 M urea and applied onto the Ni-NTA column under denaturing conditions (in buffer containing 8 M urea) using the same materials and procedure as mentioned above. Contaminating proteins were washed from the column by wash buffer without urea. Refolding of the His-tagged protein was performed while the protein was immobilized on the Ni-NTA matrix. After renaturation, proteins were eluted by the addition of 500 mM Imidazole. The eluate was dialyzed to remove traces of urea and concentrated if the volume was large, checked by SDS-PAGE and measured by the Bradford method.

Animal protection studies

<u>Animals:</u>

20 CD-1 or BALB/c female mice (6 - 8 weeks) were used.

Active immunization (subcutaneous route):

50 μg of recombinant proteins buffered in PBS were injected subcutaneously into CD-1 mice (volume 100 μL), adjuvanted with Complete Freund adjuvant (CFA, final concentration: 50%), aluminium hydroxide (ALUM, final concentration: 1%) or IC31TM (final concentration: 100 nmol L-KLKLLLLKLK (SEQ ID NO: 55), 4 nmol oligodexoynucleotide ODN1a (dIdC)₁₃ in PBS) (Intercell AG, Vienna, Austria). Animals were boosted twice with the same amount of protein and adjuvant (except for CFA where Incomplete Freund adjuvant (IFA) was used for the booster immunizations; final concentration: 50%), at days 14 and 28. The published (Dale et al., J. Immunol. 151: 2188 (1993)) protective M1 or M23 protein antigens were used as positive controls, while mice immunized with adjuvant only served as negative controls. Antibody titers were measured at day 35 by ELISA using the respective recombinant proteins.

Active immunization (intranasal route):

30 - 50 µg of recombinant proteins buffered in PBS were injected intranasally into BALB/c mice (volume 20 µL), adjuvanted with $IC31^{TM}$ (final concentration: 10 nmol L-KLKLLLLKLK (SEQ ID NO: 55), 0.4 nmol oligodexoynucleotide ODN1a (dIdC)₁₃ in PBS) (Intercell AG, Vienna, Austria). Animals were boosted three times with the same amount of protein and adjuvant at days 7, 14 and 28. The published protective M1 or M23 protein antigens were used as positive controls, while mice immunized with adjuvant only served as negative controls. Antibody titers were measured at day 35 by ELISA using the

10 respective recombinant proteins.

Bacterial challenge:

Freshly grown S. pyogenes strains MA-A20 or MA-A147 were used. 1 mL bacterial suspension from an o/n culture of the respective S. pyogenes strain was added to 50 mL

THY culture medium. Optical density was measured until the bacterial suspension reached an OD_{600nm} between 0.4 and 0.6. Bacterial counts were determined using an individually established growth curve. Bacterial cells were spun down and adjusted with PBS to obtain the desired cfu count. In order to determine the viable cell numbers present in the bacterial inoculum, cfus were determined via plating on blood agar plates. 10⁶ - 10⁸ cfus were applied intranasally (20 μL) into individually anesthetized mice. Protection by

immunization was measured by a bacteraemia / sepsis model where survival rates were followed for 2 to 3 weeks post-challenge and survival was expressed in percentage of the total number of animals (10 mice / group).

25 *Results*

30

Group A streptococcal antigens and/or their fragments were identified showing protection in an intranasal mouse sepsis/lethality model. As the target indication for a preventive vaccine in humans is pharyngitis, an intranasal challenge model for the evaluation of candidate antigens is believed to be physiologically more relevant than an intravenous or intraperitoneal model, which have been described previously (Guzman et al., J. Inf. Dis. 179: 901 (1999); Stalhammar-Carlemalm et al., Mol. Microbiol. 33: 208 (1999)). Therefore protection was assessed in three distinct models, all applying the bacterial

challenge via the intranasal route. Protection was observed for 9 distinct proteins in the intranasal challenge model, some of which were tested as a fragment of the full length recombinant protein.

- 5 Since protection against streptococcal challenge is mediated by antibodies, immunizations were first performed using CFA/IFA as adjuvant in order to obtain very high levels of antibodies. Subsequently, experiments were also performed with Alum and IC31TM as adjuvants, as these adjuvants are suited for use in humans and would be a preferred choice for a vaccine to prevent group A streptococcal infections in humans. As can be seen for the experiment depicted in Figure 1, fragment Spy0292-1 performed as well as full length
- Spy0292 protein for protection, while Spy0292-3 showed lower levels of protection. This clearly indicates that one region useful for protection lies within the sequence encompassing the Spy0292-1 protein.
- 15 Similar results were obtained for the proteins, Spy0269 (good protection also observed with Spy0269-1), Spy0416 (good protection also observed with Spy0416A-1, Spy0416A-6 and Spy0416A-7), and Spy0872 (good protection also observed with Spy0872-2).

For the proteins Spy0488, Spy0895, and Spy1727 full length recombinant proteins were used (Table 1), as these proteins have been shown for the first time to be capable to provide protection against lethal *S. pyogenes* challenge. Especially protein Spy0895 shows promise as a vaccine candidate, because it provided protection against group A streptococcal infection in all three models listed in Table 1.

Spy1536 and Spy1666 have been shown to provide protection in an intravenous challenge model before (WO 2004/078907), but importantly it could now be shown that they also provide protection in the physiologically more relevant intranasal challenge model. Spy1536 was most consistent in providing significant protection in all three models of GAS infection. Besides these two antigens, Spy0895 and Spy1536, several antigens showed protection in at least 2 models: Spy0269-1, Spy0292-1, Spy0416A-1, Spy0872-2, Spy1666 and Spy1727. Importantly, several antigens showed a level of protection that was as high as the level seen for the positive control protein M1 (e.g. Spy0416A-1, Spy0488, Spy0895; Table 1).

the full length recombinant protein.

These data clearly provide evidence, that the selected proteins are promising candidates for vaccine development. In addition, proteins Spy0269, Spy0292, Spy0416, and Spy0872 have been shown to possess amino acid sequences that are dispensable for protection, since sub-fragments were capable to provide the same or even superior levels of protection than

5

Table 1: Recombinant proteins of *S. pyogenes* and fragments thereof assessed for protection in murine models of infection.

10

ORF/ Protein	Length ¹ (aa)	Amino acids ¹ (from – to)	SEQ ID No	Calculated MW (kDa) ²	Vector	Base pairs ¹ (from – to)	Protection ³
Spy0269	837	36 - 873	57	92.34	pET28b	106-2619	10% (30%, 60%)^
Spy0269-1	452	37-488	1	50.85	pET28b	109-1464	50% (10%, 50%) ^{B,A,C}
Spy0292	388	23 - 410	68	44.91	pET28b	67-1233	60% (10%, 90%) ^{A,C}
Spy0292-1	162	23-184	2	19.41	pET28b	67-554	56% (10%, 90%) ^{A,B}
Spy0292-3	278	23-300	3	32.39	pET28b	67-900	30% (10%, 90%)^
Spy0416A	834	34 - 867	89	95.80	pET28b	100-2601	20% (10%, 63%) ^A
Spy0416A-1	644	34-677	4	74.70	pET28b	100-2031	80% (20%, 80%) ^{C,A}
Spy0416A-6	311	148-458	5	38.77	pET28b	442-1374	40% (10%, 63%) ^A
Spy0416A-7	487	72-558	6	57.68	pET28b	214-1674	63% (10%, 63%) ^A
Spy0416B	882	736 - 1617	56	103.08	pET28b	2206-4851	20% (10%, 63%)^
Spy0488	331	1-331	8	37.84	pET28b	1-993	90% (20%, 80) ^{C,A}
Spy0872	613	28 - 640	120	68.38	pET28b	82-1920	20% (0%, 60%) ^A
Spy0872-2	290	351-640	7	33.02	pET28b	1051-1920	60% (0%, 60%) ^{A,C,B}
Spy0895	261	2-262	9	32.15	pET28b	4-786	90% (20%, 80%) ^{C,A,B}
Spy1536	314	32-345	131	35.27	pET28b	94-1035	70% (20%, 80%) ^{C,A,B}
Spy1666	315	23-337	132	37.02	pET28b	67-1011	60% (20%, 80%) ^{C,B}
Spy1727	263	1-263	10	32.43	pET28b	1-789	70% (20%, 80%) ^{с,в}

¹ Length, amino acids and base pairs are calculated for the *S. pyogenes* gene specific sequence only.

² The calculated molecular weight includes amino acids derived from the vector and the His6-tag.

³ Protection is based on the animal model as indicated:

- A s.c. immunization using CFA/IFA as adjuvant, i.n. challenge with S. pyogenes A20
- B s.c. immunization using ALUM as adjuvant and i.n. challenge with S. pyogenes A20
 - C intranasal immunization using IC31[™] or a mucosal adjuvant and intranasal challenge with either S. pyogenes A20 or A147.

Brackets show protection in the respective model with the negative (PBS + adjuvant only) and positive control (M protein). If protection was seen in more than one model, the protection data of the model listed first are shown.

20

Table 2: Oligonucleotides used for the cloning of genes encoding antigenic prote	ins
and fragments thereof of S. pyogenes.	

ORF-protein	Plasmid name	Primer ¹	Name	Restriction enzyme
SPy0269	pET28b-SPy0269	TAGTAG <u>CCATGG</u> GCGATGATAGAGCCTCA GGA SEQ ID NO: 21	210-2129	Ncol
		TAGTAG <u>GCGGCCGC</u> CTTAGATTCCTTACG GAACCT SEQ ID NO: 22	210-2196	Notl
SPy0269-1	pET28b-SPy0269-1	TAGTAG <u>CCATGG</u> GCGATGATAGAGCCTCA GGA SEQ ID NO: 23	210-2129	Ncol
		TAGTAG <u>GCGGCCGC</u> AACAGGCGCATTAGG G SEQ ID NO: 24	210-2719	Notl
SPy0292	pET28b-SPy0292	TAGTAG <u>CCATGG</u> GC GAAGAGTATTCGGTA ACTGC SEQ ID NO: 25	210-2131	Ncol
		TAGTAG <u>GCGGCCGC</u> TAAAGAGGTATTGAC ATACCT SEQ ID NO: 26	210-2197	Notl
SPy0292-1	pET28b-SPy0292-1	TAGTAG <u>CCATGG</u> GCGAAGAGTATTCGGTA ACTGC SEQ ID NO: 27	210-2131	Ncol
		TAGTAG <u>GCGGCCGC</u> GCAAAAACAATTTTC ATCATC SEQ ID NO: 28	210-2954	Notl
SPy0292-3	pET28b-SPy0292-3	TAGTAG <u>CCATGG</u> GC GAAGAGTATTCGGTA ACTGC SEQ ID NO: 29	210-2131	Ncol
		TAGTAG <u>GCGGCCGC</u> TTCAATTAACTGGAC TTTTTG SEQ ID NO: 30	210-2956	Notl
SPy0416A	pET28b-SPy0416A	TAGTAG <u>GAATTC</u> G GCAGATGAGCTAAGCA CAATG SEQ ID NO: 31	210-2246	EcoRI
		TAGTAG <u>CTCGAG</u> CTCTGAACCAAGAGTGA CAAG SEQ ID NO: 32	210-2247	Xhol
SPy0416A-1	pET28b-SPy0416A-1	TAGTAGGAATTCGGCAGATGAGCTAAGCA CAATG SEQ ID NO: 33	210-2246	EcoRi
		TAGTAG <u>CTCGAG</u> TGCCCCTTGCTGACGCG GTG SEQ ID NO: 34	210-2663	Xhol
SPy0416A-6	pET28b-SPy0416A-6	TAGTAG <u>GAATTC</u> G GCAGTTATTGACACAGG G SEQ ID NO: 35	210-2715	EcoRI
		TAGTAG <u>CTCGAG</u> TAGGCTATCTTTTATGTC SEQ ID NO: 36	210-2717	Xhol
SPy0416A-7	pET28b-SPy0416A-7	TAGTAG <u>GAATTC</u> G TCACAAATCACTCTCAA G SEQ ID NO: 37	210-2716	EcoRI
		TAGTAG <u>CTCGAG</u> ACTTCCTGTACCATTGCC SEQ ID NO: 38	210-2718	Xhol
SPy0416B	pET28b-SPy0416B	TAGTAG <u>GAATTC</u> GCATGTAGACCCACAAA AGGGC SEQ ID NO: 39	210-2248	EcoRI
		TAGTAG <u>CTCGAG</u> CGTTGATGGTAGGGCTTT TGC SEQ ID NO: 40	210-2249	Xhol
SPy0488	pET28b-SPy0488	TAGTAG <u>CCATGG</u> GCTTGCGGCAGATTCAG TCCATT SEQ ID NO: 41	210-2139	Ncol
		TAGTAG <u>GCGGCCGC</u> ACTTTTTAACCTGTCC TCAGC SEQ ID NO: 42	210-2199	Notl
SPy0872	pET28b-SPy0872	TAGTAGCCATGGGCCGATCAAGTTGATGTG CAATTC SEQ ID NO: 43	210-2143	Ncol
		TAGTAG <u>GCGGCCGC</u> TGTTATTGGAAGAGT GGAACT SEQ ID NO: 44	210-2144	Notl
SPy0872-2	pET28b-SPy0872-2	TAGTAG <u>CCATGG</u> GCGCTATAATAAATCATG CT SEQ ID NO: 45	210-2962	Ncol
		TAGTAG <u>GCGGCCGC</u> TGTTATTGGAAGAGT GGAACT SEQ ID NO: 46	210-2144	Notl
SPy0895	pET28b-SPy0895	TAGTAG <u>CCATGG</u> GCACTAATAATCAAACA	210-2145	Ncol

ORF-protein	Plasmid name	Primer ¹	Name	Restriction enzyme
		CTA SEQ ID NO: 47		
		TAGTAG <u>GCGGCCGC</u> GACAATAGATTGTCT CCAAAG SEQ ID NO: 48	210-2201	Notl
SPy1536	pET28b-SPy1536	TAGTAG <u>CCATGG</u> GCATTGAAATGCCTGGA GGCG SEQ ID NO: 49	210-2161	Ncol
		TAGTAG <u>GCGGCCGC</u> TTTGCGAAGATAAAC CAGTGC SEQ ID NO: 50	210-2207	Notl
SPy1666	pET28b-SPy1666	TAGTAG <u>CCATGG</u> GCACAAAAGAATTTCATC ACGTG SEQ ID NO: 51	210-2165	Ncol
		TAGTAG <u>GCGGCCGC</u> TTTCCGAATTTTTTTG GCAAC SEQ ID NO: 52	210-2209	Notl
SPy1727	pET28b-SPy1727	TAGTAG <u>CCATGG</u> GC GTGACAACGACGGAA CAAG SEQ ID NO: 53	210-2167	Ncol
		TAGTAG <u>GCGGCCGC</u> TTTCTTTCTAAATATT TCTCT SEQ ID NO: 54	210-2210	Notl

Primer, letters in bold indicate gene-specific sequences, letters underlined indicate the restriction enzyme sites, letters in normal font indicate sequences necessary for cloning, but not present in the final plasmid construct used for expression. The first primer always refers to the sense and the second primer to the anti-sense oligonucleotide in relation to the encoded gene used for amplification.

5

Example 2: Group A streptococcal antigens and variants thereof.

10 Experimental procedures

Preparation of streptococcal genomic DNA

5 mL Todd-Hewitt Broth medium were inoculated with the respective strain of *S. pyogenes* (as listed in Table 3) from a frozen stab and grown without shaking at 37°C overnight. 4 mL of the culture were then harvested by centrifuging at 13,000 rpm in a biofuge fresco

15 (Haereus) for 5 min and the supernatant was removed. DNA was isolated from the bacterial cell pellets following the protocol of Wizard® Genomic DNA Purification Kit (Promega). The DNA pellets were finally dried on air and dissolved in 70 µl ddH₂O.

PCR and sequence analyses of S. pyogenes genes

In order to determine the sequence of an antigen from diverse S. pyogenes strains, PCR was performed with primers specific for the gene of interest. S. pyogenes strains used for these analyses are shown in Table 3. Oligonucleotide sequences as primers for PCR were designed for the selected antigens in order to be able to amplify the full gene. Sequencing was performed with dedicated primers using the PCR products as templates. The sequences of the oligonucleotides are listed in Table 4. Genomic DNA of all S. pyogenes

Strain

strains was prepared as described above. PCR was performed in a reaction volume of 25 μ l using Taq polymerase (1 U), 200 nM dNTPs, 10 pMol of each oligonucleotide and the kit according to the manufacturer's instructions (Invitrogen, The Netherlands). As standard, 30 cycles (1x: 5 min. 95°C, 30x: 30 sec. 95°C, 30 sec. 56°C, 120 sec. 72°C, 1x 4 min. 72°C) were performed, unless conditions had to be adapted for individual primer pairs. PCR samples were sequenced with the oligonucleotides as listed in Table 10. Sequencing was performed at Agowa (Germany).

Serotype

5

No.

1	Schmitz 1/94	Netherlands	1
2	Schmitz 1/12	Portugal	1
3	Schmitz 1/5	Portugal	1
4	Schmitz 2/14	Germany	1
5	Schmitz 1/74	England	3
6	Schmitz 1/35	Spain	3
7	Schmitz 1/41	France	3
8	RDN 78	unknown	3.1
9	Schmitz 1/17	Portugal	4
10	Schmitz 1/156	Switzerland	4
11	Schmitz 1/22	Spain	4
12	RDN 60	unknown	5
13	Schmitz 1/174	Austria	6
14	Schmitz 1/97	Belgium	6
15	Schmitz 1/29	Spain	9
16	Schmitz 1/92	Netherlands	11
17	Schmitz 1/39	Spain	12
18	Schmitz 1/248	Poland	12
19	Schmitz 1/59	England	12
20	RDN 02	unknown	19
21	Schmitz 1/76	England	22
22	Schmitz 1/177	Austria	22
23	Schmitz 1/43	France	22
24	Schmitz 2/32	Germany	22
25	RDN 136	unknown	22.2
26	Schmitz 1/136	Germany	25
27	Schmitz 1/56	France	28
28	Schmitz 1/108	Belgium	28
29	Schmitz 1/85	Netherlands	28
30	Schmitz 2/50	Germany	28
31	Schmitz 1/194	Italy	44
32	Schmitz 1/234	Turkey	44
33	Schmitz 1/103	Belgium	44
34	Schmitz 1/253	Poland	49
35	Schmitz 1/141	Germany	49
36	Schmitz 1/123	Germany	49

Table 3: S. pyogenes clinical isolates utilized for the present study.

Country of origin

37	Schmitz 2/30	Germany	66 or 90
38	Schmitz 1/144	Germany	76
39	Schmitz 1/99	Belgium	78
40	RDN 120	unknown	81
41	Schmitz 1/142	Germany	83
42	Schmitz 1/176	Austria	83
43	Schmitz 1/25	Spain	83
44	RDN 75	unknown	85
45	Schmitz 2/46	Germany	89
46	Schmitz 2/9	Germany	90
47	Schmitz 2/23	Germany	90
48	RDN 116	unknown	94
49	Schmitz 1/55	France	118
50	Schmitz 1/68	England	118
51	Schmitz 1/3	Portugal	118

Table 4: Oligonucleotides used for sequence conservation analyses. Shown are the ORF and primer names, orientation of the primer relative to the gene, the sequence, and the
position relative to the gene. Oligonucleotides were used for both PCR amplification of the gene or gene fragment and subsequent sequence analyses.

ORF	Primer name	Orientation	Sequence S	SEQ ID NO:	Position relative to gene
	210-4752	sense	TGACCTTCAAATCATTGCTGA	209	-103 to -82
	210-4759	antisense	TTTTGCACTTCTGGTGTCAA	210	1014 to 1034
Spy0269	210-4754	sense	TTGCCAAAGCTAGTCCAGGT	211	931 to 951
	210-4761	antisense	AGTATTATCAATGCGCTCACG	212	2028 to 2049
	210-4756	sense	AAAAGCTCATTTGCAATATCTAAGG	213	1967 to 1992
	210-4763	antisense	GCTGGTGAATCTGATTTTTCAA	214	2875 to 2897
	210-4575	sense	TCTTGTGAGGTAAGTCATTACCTTAG	215	-79 to -53
	210-4576	antisense	TTCATCATCTGGTTCTGTATTAGG	216	516 to 540
Spy0292	210-4577	sense	GGTCGTCAATTCAACTGGC	217	464 to 483
	210-4578	antisense	GCGATCATTGTGGATGATTTC	218	1031 to 1052
	210-4579	sense	AAACTGTCAAACTTGTAGCCC	219	946 to 967
	210-4580	antisense	TGTTAGGATTGGCCTAGTTTG	220	1304 to 1325
	210-4588	sense	TGAGTTAATGATTAACATTAAACTGGT	221	-56 to -29
	210-4591	antisense	TGACATAAGCAAATTGATGCG	222	1387 to 1408
	210-4592	sense	CCATCTATTCAGAGTCTGTCGAC	223	1327 to 1350
Spy0416	210-4595	antisense	CCTTGTCACTAGCATGGTAGAC	224	2802 to 2824
	210-4596	sense	TTGCAGCCTTCAAAGGTG	225	2749 to 2767
	210-4599	antisense	AAGACACATTACCAGCTCTATCTTC	226	4128 to 4153
	210-4600	sense	CAGATGGTTCTTACACCATTTC	227	4063 to 4085
	210-4603	antisense	AATCTCAAAGAAAGGTCAGACTG	228	4982 to 5005
	210-5497	sense	AAAGCTCGTCATTTTATATGATTT	229	-195 to -171
Spy0488	210-4767	antisense	TTTAATGAGAGTTGTCATTCGTTCA	230	497 to 522
	210-4765	sense	TTTTCTTGTTCAACCGCAAG	231	404 to 424
	210-4766	antisense	GCGCTCACAGCTACTTCAGA	232	1052 to 1072
Spy0872	210-4581	sense	CAAAATCATAGTAAACTTGATCTATAA	CG 233	-55 to -26
	210-4584	antisense	GAAGAATTAGTTGCAGTTCCG	234	1103 to 1124
	210-4585	sense	GTTGCTGTAGCACCAGGTATC	235	1005 to 1026

	210-4587	antisense	CCAGCACGAATTAGATCATCTAG	236	2111 to 2134
Spy0985	210-4768	sense	CTGAAGAGCGCCAAACAACT	237	-63 to -43
0,0000	210-4771	antisense	TCGAAGAAGTAACCTTTGATTAATGT	238	864 to 890
Spy1536	210-4772	sense	GCTCTAGTCGTGTGAGAGAGCTAA	239	-90 to -66
0001000	210-4775	antisense	TGTCTATCTGGTTCAACCGTTTT	240	1089 to 1112
Spy1666	210-4780	sense	GTGGCTAAGTCAGTGCTTGCT	241	-80 to -59
0001000	210-4783	antisense	AAGTTTTTATTCGTTTTTGCAAGG	242	1055 to 1079
Spy1727	210-4776	sense	GATCATTGACTAAGTAGCCTAAAACAA	243	-76 to -49
0001121	210-4779	antisense	CCAAAAACGTCATGCCAAC	244	879 to 898

RESULTS

Gene conservation analysis of selected streptococcal antigens

5 The PCR and sequencing of the 9 selected genes was performed as described under Methods. Table 3 shows the strains used for sequencing, while Table 4 lists the oligonucleotides employed for the PCR and sequencing analyses.

Sequence analyses of Spy0269

- 10 Sequences were obtained from all 51 strains. The level of amino acid sequence identity ranged from 98.7% to 100% as compared to the sequence of Spy0269 from *S. pyogenes* SF370. Table 5 lists all 36 amino acid positions which showed a distinct amino acid as compared to Spy0269 from *S. pyogenes* SF370.
- **Table 5: Gene conservation of Spy0269.**¹, observed amino acid at respective position in any of the sequenced genes of the respective *S. pyogenes* strains.

Position in SF370 gene	Alignment position	Amino acid in SF370 gene	AA change ¹	AA change ²	Strains with the respective change ¹	Strains with the respective change ²
30	30	V			Schm1_142, Schm1_177, Schm1_43, RDN75	
68	68	D	E		Schm1_76, Schm1_92, Schm1_142, Schm1_176, Schm1_177, Schm1_25, Schm1_43, Schm2_32, RDN136, RDN136,	
73	73	т	A		Schm1_142, Schm1_177, Schm1_43	

80	80	E	K	Schm1_55,
				Schm1_68,
				Schm1_3,
				Schm2_23,
				Schm2_30
83	83	E	ĸ	Schm1_17,
ļ ļ		ļ		Schm1_59,
				Schm1_97
94	94	E	ĸ	Schm1_142,
94	94			
				Schm1_177,
				Schm1_43
97	97	н	N	Schm1_99,
•				Schm2_14,
				Schm2_46
150	150	A	V	Schm1_74,
				Schm1_35,
1		1	1	Schm1_141,
(1	Schm1_174,
				Schm1_41,
				Schm2_9,
ļ		1	1	Schm2_50,
				RDN60, RDN78,
		<u>↓</u>		RDN75
230	230	A	G	Schm1_35
249	249	E	D	Schm1_103
276	276	A	V	Schm1_56,
2.0	2.0			Schm1_108
279	279	G	D	Schm1_55,
í í				Schm1_68,
				Schm1_3,
				Schm2_23,
				Schm2_30
307	307	Α	G	Schm1_92
482	482	Н	R	Schm1_17,
Į				Schm1_56,
				Schm1_76,
ļ				Schm1_92,
				Schm1_142,
				Schm1_253,
			1	Schm1_108,
		1		
				Schm1_141,
				Schm1_174,
				Schm1_176,
(
				Schm1_177,
				Schm1_177, Schm1_25,
				Schm1_177, Schm1_25, Schm1_43,
	L			Schm1_177, Schm1_25, Schm1_43, Schm1_59,
				Schm1_177, Schm1_25, Schm1_43, Schm1_59,
				Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97,
				Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99,
	1			Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123,
				Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136,
				Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14,
				Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14,
				Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_32,
				Schm1_177, Schm1_25, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46,
				Schm1_177, Schm1_25, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_14, Schm2_32, Schm2_46, Schm2_50,
				Schm1_177, Schm1_25, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02,
				Schm1_177, Schm1_25, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136,
				Schm1_177, Schm1_25, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02,
				Schm1_177, Schm1_25, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN120,
495	495	N		Schm1_177, Schm1_25, Schm1_25, Schm1_59, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN116
485	485	N	ĸ	Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN116
485	485	N	ĸ	Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN116 Schm1_39, Schm1_55,
485	485	N	ĸ	Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN116 Schm1_39, Schm1_55,
485	485	N	ĸ	Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN16 Schm1_39, Schm1_68,
485	485	N	ĸ	Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN136, Schm1_39, Schm1_55, Schm1_56,
485	485	Ν	ĸ	Schm1_177, Schm1_25, Schm1_43, Schm1_59, Schm1_97, Schm1_123, Schm1_136, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN16 Schm1_39, Schm1_68,

					······································
				Schm1_22,	
				Schm1_29,	
			1 1	Schm2_23,	
				Schm2_30,	
				RDN75	
537	537	G	IS I	Schm1_76,	
			1 1	Schm1_92,	
				Schm1_142,	
1					
				Schm1_176,	1
				Schm1_177,	
				Schm1 25,	
				Schm1_43,	
				Schm2_32,	
			1 1		1
				RDN136	
577	577	Q	Ē	Schm1_39,	
				Schm1_76,	
				Schm1_92,	
	1	1		Schm1_142,	1
1				Schm1_141,	
				Schm1_156,	
				Schm1_174,	
		1			
1				Schm1_176,	
1				Schm1_177,	}
1				Schm1_248,	
				Schm1_22,	
				Schm1_25,	
				Schm1_29,	
				Schm1_43,	1
			1	Schm2_32,	
				Schm2_50,	
			1 1	RDN60,	
				_RDN136	
602	602	G	R	Schm2_46	
605	605	R	K	Schm1_174	h
610	610	A	V	Schm1_74,	
				Schm1_76,	
				Schm1_35,	
}				Schm1_176,	
				Schm1_25,	
	1			Schm1_41,	ļ
				Schm2_9,	
				Schm2_9, Schm2_32,	
				Schm2_9, Schm2_32, RDN136,	
				Schm2_9, Schm2_32, RDN136, RDN78	
636	636	L	M	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, <u>RDN78</u> Schm1_74, Schm1_76, Schm1_35,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_176, Schm1_25,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_176, Schm1_25,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, <u>RDN78</u> Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_176, Schm1_25, Schm1_41,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, <u>RDN78</u> Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_41, Schm2_9,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, <u>RDN78</u> Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_41, Schm2_9, Schm2_32,	
636	636	L	M	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_41, Schm2_9, Schm2_32, RDN136,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_41, Schm2_9, Schm2_32, RDN136, RDN78	
636	636	E	м	Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_41, Schm2_9, Schm2_32, RDN136,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_41, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_36, Schm1_25, Schm1_41, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_76,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_25, Schm1_41, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_36, RDN78 Schm1_74, Schm1_76, Schm1_36, RDN78	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_176, Schm1_25, Schm1_25, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm2_32, RDN136, RDN78 Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm2_41, Schm2_32, RDN136, RDN136, RDN78 Schm1_74, Schm2_32, RDN136, RDN78 Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_35,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm2_41, Schm2_32, RDN136, RDN136, RDN78 Schm1_74, Schm2_32, RDN136, RDN78 Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_35,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm1_25, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_76, Schm2_32, RDN136, RDN78 Schm1_76, Schm1_76, Schm1_76, Schm1_35, Schm1_35, Schm1_35, Schm1_35, Schm1_41,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm1_25, Schm2_9, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_76, Schm1_9, Schm1_9, Schm1_9, Schm1_9,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm1_25, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_76, Schm1_41, Schm2_9, Schm1_35, Schm1_76, Schm1_35, Schm1_35, Schm1_25, Schm1_25, Schm1_41, Schm2_32,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm1_25, Schm1_41, Schm2_9, Schm1_41, Schm2_32, RDN78 Schm1_76, Schm1_35, Schm1_35, Schm1_35, Schm1_25, Schm1_41, Schm2_32, RDN136,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm1_25, Schm1_41, Schm2_9, Schm1_41, Schm2_32, RDN78 Schm1_76, Schm1_35, Schm1_35, Schm1_35, Schm1_25, Schm1_41, Schm2_32, RDN136,	
				Schm2_9, Schm2_32, RDN136, RDN78 Schm1_74, Schm1_76, Schm1_35, Schm1_25, Schm1_25, Schm2_9, Schm2_32, RDN136, RDN78 Schm1_76, Schm1_41, Schm2_9, Schm1_35, Schm1_76, Schm1_35, Schm1_35, Schm1_25, Schm1_25, Schm1_41, Schm2_32,	

	·			Caberd 400
650			+	Schm1_108
650	650	<u>v</u>	<u>E</u>	Schm2_9
666	666	F	<u> </u>	Schm1_22
700	700	A	T	Schm1_17,
				Schm1_39,
				Schm1_55,
				Schm1_56,
i i				Schm1_253,
				Schm1_68,
				Schm1_108,
				Schm1_156,
				Schm1 248,
				Schm1_3,
				Schm1_22,
í í				
				Schm1_29,
				Schm1_59,
				Schm1_97,
				Schm1_123,
ļ				Schm1_136,
				Schm2_23,
í í				Schm2_30,
				RDN02,
				RDN120,
[[
				RDN116
703	703	A	V	Schm2_50,
				RDN60
710	710	S	G	Schm1_17,
				Schm1_59,
				Schm1_97
733	733	E	G	Schm1_56,
		-	U	Schm1_108
750	750	A	P	Schm1_22
752	752	Р	S	Schm1_55,
				Schm1_74,
i l				Schm1_76,
				Schm1_92,
ĺ				Sahmit 140
1				
				Schm1_142, Schm1_144.
				Schm1_144,
				Schm1_144, Schm1_194,
				Schm1_144, Schm1_194, Schm1_35,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176,
	 			Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_3,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_3,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_3, Schm1_25,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_3, Schm1_25, Schm1_41,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_23, Schm1_25, Schm1_41, Schm1_43,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_23, Schm1_25, Schm1_41, Schm1_43, Schm1_99,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_23, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_103,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_23, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_103, Schm2_9,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_23,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_23, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_14, Schm2_23, Schm2_30,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_23, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_14, Schm2_23, Schm2_30,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_43, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_14, Schm2_14, Schm2_32,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_43, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_23, Schm2_30, Schm2_32, Schm2_32,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_30, Schm2_30, Schm2_32, Schm2_46, RDN136,
750	750			Schm1_144, Schm1_194, Schm1_35, Schm1_35, Schm1_68, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_43, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_23, Schm2_30, Schm2_32, Schm2_32, Schm2_346, RDN136, RDN78
758	758	P	L	Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_176, Schm1_234, Schm1_234, Schm1_234, Schm1_41, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_30, Schm2_30, Schm2_32, Schm2_46, RDN136, RDN78
758 764	758 764	P	L	Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_43, Schm1_43, Schm1_99, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_32, Schm2_46, RDN136, RDN78 Schm1_92
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_99, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_46, RDN136, RDN78 Schm1_74, Schm1_74, Schm1_76,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_99, Schm2_9, Schm2_14, Schm2_30, Schm2_46, RDN136, RDN78 Schm1_74, Schm1_74, Schm1_92,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_46, RDN136, RDN78 Schm1_76, Schm1_92, Schm1_142,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_46, RDN136, RDN78 Schm1_76, Schm1_92, Schm1_142,
				Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_234, Schm1_234, Schm1_25, Schm1_41, Schm1_99, Schm2_9, Schm2_14, Schm2_30, Schm2_46, RDN136, RDN78 Schm1_74, Schm1_74, Schm1_92,

					Schm1_35, Schm1_176, Schm1_177, Schm1_234, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_99, Schm2_9, Schm2_14, Schm2_32, Schm2_46, RDN136, RDN78	
765	765	D	E		Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_35, Schm1_176, Schm1_177, Schm1_234, Schm1_25, Schm1_41, Schm1_43, Schm1_99, Schm1_99, Schm2_9, Schm2_14, Schm2_32, Schm2_46, RDN136, RDN78	
794	794	L	F	н	Schm1_22	Schm2_23, Schm2_30
873	873	К	R		Schm1_55, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_35, Schm1_68, Schm1_174, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_23, Schm1_25, Schm1_41, Schm1_41, Schm1_43, Schm1_99, Schm1_103, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_30, Schm2_30, Schm2_30, Schm2_30, Schm2_30, Schm2_30, Schm2_30, Schm2_30, Schm2_30, Schm2_30,	

RDN60,
RDN136,
RDN78, RDN75

Sequence analyses of Spy0292

Sequences were obtained from all 51 strains. The level of amino acid sequence identity ranged from 97.3% to 100% as compared to the sequence of Spy0292 from *S. pyogenes* SF370. Table 6 lists all 36 amino acid positions which showed a distinct amino acid as compared to Spy0292 from *S. pyogenes* SF370.

Table 6: Gene conservation of Spy0292.¹, observed amino acid at respective position in any of the sequenced genes of the respective *S. pyogenes* strains.², second possible amino acid observed at the respective position.³, third possible amino acid observed at the respective position.

Position in	Alignment position	Amino acid	AA change ¹	AA change ²	AA change ³	Strains with	Strains with	Strains with
SF370	position	in	change	change	change	respective	respective	respective
gene		SF370	i			change ¹	change ²	change ³
gene		gene					, energe	3 -
21	21	S	N			Schm1 136		
32	32	A	V			RDN02		
45	45	E	к			RDN60		
48	48	A	Т			Schm1_56,		
						Schm1_108,		
l I						Schm1_85		
50	50	E	ĸ	·		RDN75		
57	57	V	1			Schm2_50		
58	58	S	T			Schm2_50		
65	65	L	M			Schm1_141,		
1						Schm1_156,		
						Schm1_174		
68	68	ĸ	Q	<u>N</u>	l	Schm2_30	Schm2_50	
88	88	Y	D	l		Schm2_30		
89	89	E	D			Schm2_30		
93	93	N	Y			Schm2_50		
95	95	Т	S	<u> </u>		Schm2_30		
96	96		M			Schm2_30		
101	101	L	P			Schm2_30	:	
121	121	N	[l			Schm2_50		
122	122	S	Т			Schm2_50		
128	128	A	Р	S		RDN60	RDN60	
137	137	K	N			Schm2_30		
141	141	K	E	Q		Schm1_17	Schm2_50	
147	147	R	L	W		Schm1_17	Schm2_50	RDN60
148	148	Q	L			Schm2_30, RDN60		
152	152	s	F	<u> </u>	┼────	RDN120	<u> </u>	
152	152	<u> </u>		<u>├</u>	<u> </u>	Schm1 55,		
104	104					Schm1_68,		
						Schm1_3,		
					1	Schm1_29,		
1		1			1	Schm2_23,		
			}		l l	Schm2_30		1
165	165	н	L	<u> </u>	<u>+-</u>	RDN60	<u> </u>	

100 l	188	L	F	1		Schm1_174	1	
<u>188</u> 189	189	A	P	<u> </u>		Schm1_174		
190	190		V			Schm1 253,		
					l	Schm1_123		
214	214	A	D			Schm1_39,		
						Schm1_55,		
I						Schm1_56,		
						Schm1_76,		
[l l		1	ļ	Schm1_92,		
						Schm1_142,		
						Schm1_144,		
1]		Schm1_108,		
						Schm1_141, Schm1_156,		
				1		Schm1_174,		
						Schm1_176,		
1				}		Schm1_177,		
						Schm1_234,		
ļ		ļļļ				Schm1_248,		
		1 1				Schm1_25,		
						Schm1_43,		
					, i	Schm1_59,		
						Schm1_85,		
		1 1				Schm1_99,		
					-	Schm1_103,		
		1		1		Schm2_32,		
						Schm2_46,		
		[[Schm2_50,		
						RDN60, RDN02,		
					Į.	RDN136,		
						RDN120		
240	240	V	1	<u> </u>	<u> </u>	Schm1_92,		
			-			RDN120		
266	266	L	I			Schm1_144,		
			1	1	1	Schm1_234,		
						Schm1_103		
309	309	Y	S		1	Schm1_17,		
						Schm1_39,		
						Schm1_55,		
						Schm1_56,		
		Į į			ļ	Schm1_74, Schm1_76,		
						Schm1_92,		
			l		1	Schm1_142,		
				1		Schm1 144,		
						Schm1_35,		
]	1	Schm1_68,		
						Schm1_108,		
1		1	1			Schm1_141,		
						Schm1_156,		
					}	Schm1_174,		1
						Schm1_176,		
		l		l	l	Schm1_177,		
						Schm1_234,		
						Schm1_248,		
			1	1	1	Schm1_3,)	
					1	Schm1_22,		
					}	Schm1_25,		
		1				Schm1_29,		
				1	ļ	Schm1_41,	ļ	l
					1	Schm1_43, Schm1_59,		
			ł	l	l	Schm1_59, Schm1_85,	l	Į
				1				l l
		I	L		L	Schm1_97,	l	

				Schm1_99, Schm1_103, Schm1_136, Schm2_9, Schm2_30, Schm2_32, Schm2_50, RDN60, RDN136, RDN136, RDN75, RDN116	
314	314	Р	S	Schm1_17, Schm1_22, Schm1_97	
351	351	A	Р	Schm1_177	
371	371	G	A	Schm1_234	
386	386	Q	Н	Schm1_234	

Sequence analyses of Spy0416

Sequences were obtained from all 50 strains excluding strain Schmitz 1/74. The level of amino acid sequence identity ranged from 98.1% to 100% as compared to the sequence of Spy0416 from *S. pyogenes* SF370. Table 7 lists all 103 amino acid positions which showed a distinct amino acid as compared to Spy0416 from *S. pyogenes* SF370. The gene showed in addition an insertion of 2 amino acids after position 31, as well as several deletions of amino acids at the indicated positions (e.g. strains Schmitz 1/17 and Schmitz 1/39).

10

15

5

Table 7: Gene conservation of Spy0416.¹, observed amino acid at respective position in any of the sequenced genes of the respective *S. pyogenes* strains.², second possible amino acid observed at the respective position. Deletion or insertion refers to a missing or additional amino acid relative to Spy0416 of *S. pyogenes* SF370.

Position in SF370 gene	Alignment position	Amino acid in SF370 gene	AA change ¹	AA change ²	Strains with respective change ¹	Strains with respective change ²
21	21	1	v		Schm1_99, Schm2_46	
27	27	V	M		Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156,	

				Schm1_174, Schm1_176, Schm1_177, Schm1_248, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_59, Schm1_97, Schm1_97, Schm1_98, Schm1_97, Schm1_98, Schm1_99, Schm1_123, Schm1_99, Schm1_136, Schm2_9, Schm2_30, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN78, RDN75, RDN75, RDN116
29	29	Т	M	Schm1_17, Schm1_39, Schm1_76, Schm1_142, Schm1_35, Schm1_156, Schm1_174, Schm1_176, Schm1_176, Schm1_176, Schm1_176, Schm1_176, Schm1_176, Schm1_176, Schm1_176, Schm1_228, Schm1_228, Schm1_25, Schm1_41, Schm1_59, Schm1_97, Schm1_97, Schm2_9, Schm2_14, RDN136, RDN78, RDN75
Insertion	32	-	Т	Schm1_17, Schm1_39, Schm1_76, Schm1_142, Schm1_35, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_248, Schm1_22, Schm1_25, Schm1_41,

	22		-	Schm1_43, Schm1_59, Schm1_97, Schm1_136, Schm2_9, Schm2_14, RDN136, RDN78
Insertion	33	-	Т	Schm1_17, Schm1_22, Schm1_97
38	40	S	Т	Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_253, Schm1_35, Schm1_35, Schm1_108, Schm1_108, Schm1_141, Schm1_176, Schm1_176, Schm1_177, Schm1_248, Schm1_248, Schm1_22, Schm1_22, Schm1_29, Schm1_29, Schm1_41, Schm1_43, Schm1_99, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_30, Schm2_30, Schm2_50, RDN136, RDN136, RDN16
40	42	M	T	Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_253, Schm1_35, Schm1_68, Schm1_141, Schm1_156, Schm1_174, Schm1_177,

				Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_59, Schm1_97, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_32, Schm2_46, Schm2_50, RDN136, RDN78, RDN116
49	51	A	Т	Schm1_39, Schm1_76, Schm1_142, Schm1_35, Schm1_176, Schm1_177, Schm1_248, Schm1_25, Schm1_41, Schm1_59, Schm2_9, Schm2_14, Schm2_32, RDN60, RDN136, RDN78
54	56	Q	Ρ	Schm1_55, Schm1_68, Schm1_3, Schm1_29, Schm2_23, Schm2_30
55	57	Н	Ρ	Schm1_55, Schm1_253, Schm1_68, Schm1_3, Schm1_29, Schm1_99, Schm1_123, Schm2_23, Schm2_30, Schm2_32, Schm2_46, RDN116
67	69	к	Q	Schm1_17, Schm1_55, Schm1_56, Schm1_253, Schm1_68, Schm1_108,

					Schm1_3, Schm1_22, Schm1_29, Schm1_85, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN120, RDN116	Salura 1 02
68	70	S	Ρ	Т	Schm1_39, Schm1_55, Schm1_76, Schm1_142, Schm1_35, Schm1_68, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_176, Schm1_248, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm2_9, Schm2_9, Schm2_14, Schm2_23, Schm2_30, RDN136, RDN78, RDN75	Schm1_92
69	71	Q	Ρ		Schm1_17, Schm1_56, Schm1_253, Schm1_108, Schm1_22, Schm1_85, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_32, Schm2_32, Schm2_50, RDN120, RDN116	
71	73	Т	I		Schm1_253, Schm1_123, Schm2_32	
74	76	1	V		Schm1_55, Schm1_253, Schm1_68, Schm1_3, Schm1_29, Schm1_99, Schm1_123, Schm1_136,	

	1			Schm2_23,
				Schm2_30,
		1		Schm2_46
76	78	L	P	Schm1_17,
0	10	- ł	. (Schm1_55,
				Schm1_56,
{ }				Schm1_92,
				Schm1_144,
				Schm1_194,
1				Schm1_253,
				Schm1_68,
				Schm1_108,
				Schm1_141,
1 [ļ		Schm1_156,
				Schm1_174,
				Schm1_234,
{ }				Schm1_3,
				Schm1_22,
1				Schm1_29,
				Schm1_85,
				Schm1_97,
1				Schm1_99,
				Schm1_123,
				Schm1_136,
				Schm2_23,
		l i		Schm2_30,
				Schm2_46,
				Schm2_50,
				RDN60,
				RDN02,
				RDN116
77	79	ĸ	E	Schm1_55,
		1		Schm1_253,
		1		Schm1_68,
		1		Schm1_3,
				Schm1_29,
				Schm1_99,
		}		Schm1_123,
				Schm1_136,
				Schm2_23,
				Schm2_30,
				Schm2_46
			<u> </u>	
78	80	Т	1	Schm1_56,
		1		Schm1_108,
	Į	ļ		Schm1_85,
		1		Schm2_50
85	87	s	P	Schm1_17,
00	0/		1	Schm1_39,
				Schm1_55,
		1		
1	1 ']		Schm1_56,
				Schm1_76,
ļ	l l	ļ	Į	Schm1_92,
	1			Schm1_142,
				Schm1_253,
4				Schm1_250,
				Schm1_68,
	1	1	ł	Schm1_108,
			ł	Schm1_176,
				Schm1_177,
			1	Schm1_248,
	1	1		Schm1_3,
			l l	Schm1_22,
			-	Schm1_22, Schm1_25,
				Schm1_22, Schm1_25, Schm1_29,
				Schm1_22, Schm1_25,

				Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_23, Schm2_30, Schm2_50, RDN60, RDN136, RDN78
87	89	D	G	Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_142, Schm1_253, Schm1_253, Schm1_35, Schm1_108, Schm1_176, Schm1_176, Schm1_176, Schm1_177, Schm1_177, Schm1_248, Schm1_27, Schm1_28, Schm1_29, Schm1_29, Schm1_29, Schm1_41, Schm1_97, Schm1_97, Schm1_97, Schm1_97, Schm1_103, Schm1_103, Schm1_123, Schm2_9, Schm2_14, Schm2_30, Schm2_30, Schm2_50, RDN60, RDN136, RDN78
91	93	E	К	Schm1_99, Schm2_46, RDN116
93	95	Т	Deletion	RDN60
102	104	A	S	RDN120, RDN75, RDN116
104	106	S	Р	Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_253, Schm1_35, Schm1_68, Schm1_108,

	PCT/EP2007/006027	
63		
	Schm1_176, Schm1_177, Schm1_248, Schm1_3, Schm1_25, Schm1_29, Schm1_29, Schm1_41, Schm1_43, Schm1_43, Schm1_59, Schm1_99, Schm1_123, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN136, RDN78,	

107	109	N	Deletion	Schm1_3, Schm1_25, Schm1_29, Schm1_41, Schm1_59, Schm1_59, Schm1_99, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_30, Schm2_30, Schm2_50, RDN60, RDN136, RDN78, RDN75, RDN116	
107	109 112	<u>N</u> S	Deletion P	Schm1_92 Schm1_17,	
110				Schm1_39, Schm1_56, Schm1_76, Schm1_92, Schm1_142, Schm1_1253, Schm1_35, Schm1_135, Schm1_141, Schm1_174, Schm1_176, Schm1_176, Schm1_176, Schm1_177, Schm1_177, Schm1_22, Schm1_22, Schm1_41, Schm1_59, Schm1_43, Schm1_97, Schm1_99, Schm1_99, Schm1_103, Schm1_123, Schm1_99, Schm1_136, Schm2_9, Schm2_14, Schm2_32, Schm2_46, Schm2_46, Schm2_6, RDN78, RDN78, RDN78, RDN75, RDN116	
183	185	A	V	RDN75	

215	217	E	G		Schm1_17, Schm1_92, Schm1_22, Schm1_97, Schm1_99, Schm2_46, RDN116	
228	230	A	Deletion		Schm1_17, Schm1_56, Schm1_92, Schm1_108, Schm1_22, Schm1_85, Schm1_97, Schm2_50, RDN120	
229	231	E	Deletion	D	Schm1_17, Schm1_56, Schm1_92, Schm1_108, Schm1_22, Schm1_85, Schm1_97, Schm2_50, RDN120, RDN116	Schm1_144, Schm1_194, Schm1_253, Schm1_234, Schm1_99, Schm1_123, Schm1_136, Schm2_46, RDN02
230	232	<u>A</u>	Deletion		RDN116	
238	240	Н	N		Schm1_17, Schm1_92, Schm1_22, Schm1_97	
273	275	D	E		Schm1_92, Schm1_99, Schm2_46, RDN120, RDN116	
308	310	A	Т		Schm1_56, Schm1_108, Schm1_85, Schm2_50	
320	322	1	V		Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_141, Schm1_168, Schm1_141, Schm1_176, Schm1_176, Schm1_176, Schm1_176, Schm1_234, Schm1_234, Schm1_248, Schm2_248, Schm2_248, Schm2_2	

.

				Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_97, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN136, RDN136, RDN136, RDN120, RDN15, RDN116
428	430	T	A	Schm1_142
429	431	v	A	Schm1_17, Schm1_22, Schm1_97
431	433	E	G	Schm1_253, Schm1_123
434	436	N	S	RDN116
449	451	V	F	Schm1_177
453	455	D	N	Schm1_142, Schm1_35, Schm1_141, Schm1_174, Schm1_176, Schm1_177, Schm1_248, Schm1_25, Schm1_41, Schm1_59, Schm1_123, Schm1_136, Schm2_9, RDN136
		Į		RDN136
478	480	Ν	К	Schm1_17, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_176, Schm1_176, Schm1_234, Schm1_234, Schm1_22, Schm1_25, Schm1_97, RDN60, RDN02, RDN136, RDN120, RDN116

.

481	483	D	Ν	Schm1_55, Schm1_68, Schm1_3, Schm1_29, Schm1_136, Schm2_23, Schm2_30
484	486	G	D	Schm1_17, Schm1_92, Schm1_144, Schm1_194, Schm1_234, Schm1_22, Schm1_97, RDN02
493	495	Р	<u> </u>	RDN120
512	514	V	L	Schm1_253, Schm1_123
519	521	P	S	Schm1_253, Schm1_123
530	532	A	S	Schm1_141, Schm1_156, Schm1_174
535	537	I	V	RDN120
547	549	A	V	Schm1_35, Schm1_41, Schm2_9
553	555	G	Т	RDN116
560	562	E	V	RDN02, RDN116
630	632	V	1	RDN75
668	670	T	M	RDN116
689	691	G	D	Schm1_39, Schm1_248, Schm1_59, Schm2_14
706	708	<u> </u>	V	RDN02
723	725	D	A	Schm1_39, Schm1_55, Schm1_92, Schm1_144, Schm1_144, Schm1_194, Schm1_253, Schm1_1253, Schm1_35, Schm1_108, Schm1_108, Schm1_108, Schm1_141, Schm1_174, Schm1_174, Schm1_234, Schm1_248, Schm1_248, Schm1_29, Schm1_41, Schm1_234, Schm1_3, Schm1_3, Schm1_28, Schm1_29, Schm1_103, Schm1_103, Schm1_136, Schm2_9, Schm2_30, Schm2_50, RDN60,

1 1				RDN02,
				RDN78,
1	1	1		RDN120,
				RDN116
734	736	T	A	RDN02
743	745	R	Н	RDN116
749	751	н	R	Schm1_17,
				Schm1_39,
				Schm1_55,
{ }				Schm1_56,
				Schm1_76,
				Schm1_92,
]]				Schm1_142,
4 4				Schm1_144,
				Schm1_194,
				Schm1_253,
1 1				Schm1_35,
				Schm1_68,
		I		Schm1_108,
				Schm1_141,
				Schm1_156,
				Schm1_174,
				Schm1_176,
				Schm1_177,
				Schm1_234,
				Schm1 248,
				Schm1_3,
				Schm1_22,
				Schm1_25,
				Schm1_29,
1				Schm1_41,
				Schm1_43,
{ }				Schm1_59,
				Schm1_85,
				Schm1_97,
1				Schm1_99,
				Schm1_103,
				Schm1_123,
				Schm1_136,
				Schm2_9,
			1	Schm2_14,
				Schm2_23,
				Schm2_30,
				Schm2_32,
				Schm2 46,
				RDN60,
				RDN02,
		{	1	RDN136,
			1	RDN78,
				RDN78, RDN120,
]]	RDN720, RDN75,
				RDN116
770	772	R	ĸ	RDN60,
		L	L	RDN120
804	806	D	A	Schm1_55,
				Schm1_68,
		1	}	Schm1_248,
				Schm1_3,
				Schm1_29,
				Schm2_23,
				Schm2_30,
				RDN02,
		1		RDN120,
				RDN75
874		+		Schm1_35,
	876	Т	M	

1				Schm1_41,
				Schm1_103,
				Schm1_136,
				Schm2_9,
				RDN78
876	878	S	С	Schm1_94
913	915	N	S	RDN60
951	953	Р	S	Schm1_76,
			-	Schm1_177,
				Schm1_43
991	993	н	Y	Schm1_17,
501	000			Schm1_39,
				Schm1_55,
				Schm1_56,
				Schm1_142,
				Schm1_144,
				Schm1_194,
				Schm1_35,
		Į		Schm1_68,
				Schm1_108,
				Schm1_141,
				Schm1_156,
		·		Schm1_174,
				Schm1_176,
				Schm1_234,
				Schm1_248,
				Schm1_3,
				Schm1_22,
			}	Schm1_25,
				Schm1_29,
		ł	Į	Schm1_41,
				Schm1_59,
				Schm1_85,
]		Schm1_97,
				Schm1_99,
	[Schm1_136,
				Schm2_9,
		ļ		Schm2_14,
				Schm2_23,
				Schm2_30,
		1		Schm2_46,
				Schm2_50,
				RDN60,
				RDN02,
		1	ļ	RDN78,
		1		RDN120,
1				RDN116
1053	1055	V	A	Schm1_94,
				Schm1_12X,
	1	1		Schm1_5
1078	1080	E	A	Schm1_92,
		ļ		Schm1_142,
				Schm1_176,
				Schm1_25,
		1	1	Schm1_99,
1				Schm2_23,
		}	}	Schm2_30,
1			1	Schm2_46
1080	1082	N	s	Schm1_35,
				Schm1_41,
				Schm2_9,
		1		RDN78
1227	1229	т_т	1	Schm1_76
1238	1240	v.	Â	Schm1_17,
1200	1240			Schm1_39,
L	<u> </u>	J		

Image: Sector 250, RDN60, RDN02, RDN136, RDN78, RDN78, RDN120, RDN75, RDN116 1241 1243 I V Schm1_253, Schm1_253, Schm1_123 1302 1304 D G Schm1_123 1313 1315 D G Schm1_55, Schm1_56, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_76, Schm1_76, Schm1_76, Schm1_74, Schm1_144, Schm1_155, Schm1_168, Schm1_108, Schm1_141, Schm1_144, Schm1_144, Schm1_144, Schm1_155, Schm1_168, Schm1_144, Schm1_144						Schm1_55, Schm1_76, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_35, Schm1_35, Schm1_188, Schm1_176, Schm1_176, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_248, Schm1_248, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_43, Schm1_59, Schm1_99, Schm1_99, Schm1_99, Schm1_136, Schm1_136, Schm1_136, Schm1_136, Schm1_136, Schm1_136, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_32, Schm2_46,	
Image: Non-state index in the image: Non-state index in						RDN02, RDN136, RDN78, RDN120,	
1241 1243 I V Schm1_253, Schm1_123 1302 1304 D G Schm1_253, Schm1_253, Schm1_123 1313 1315 D G Schm1_39, Schm1_56, Schm1_56, Schm1_76, Schm1_92, Schm1_94, Schm1_142, Schm1_144, Schm1_144, Schm1_142, Schm1_144, Schm1_144, Schm1_123, Schm1_144, Schm1_123, Schm1_144, Schm1_124, Schm1_144, Schm1_144, Schm1_108, Schm1_144,							
1302 1304 D G Schm1_253, Schm1_123 1313 1315 D G Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_94, Schm1_142, Schm1_144, Schm1_144, Schm1_12X, Schm1_12X, Schm1_35, Schm1_68, Schm1_108, Schm1_141,	1241	1243	1	V		Schm1_253,	
1313 1315 D G Schm1_17, Schm1_39, Schm1_55, Schm1_6, Schm1_76, Schm1_92, Schm1_94, Schm1_142, Schm1_144, Schm1_144, Schm1_12X, Schm1_12X, Schm1_108, Schm1_108, Schm1_141,	1302	1304	D	G	<u> </u>	Schm1_253,	
Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_94, Schm1_142, Schm1_144, Schm1_144, Schm1_12X, Schm1_12X, Schm1_12X, Schm1_108, Schm1_108, Schm1_141,	1313	1315	D	G		Schm1_17,	
Schm1_56, Schm1_76, Schm1_92, Schm1_94, Schm1_142, Schm1_144, Schm1_253, Schm1_12X, Schm1_35, Schm1_68, Schm1_108, Schm1_141,						Schm1_39,	
Schm1_92, Schm1_94, Schm1_142, Schm1_144, Schm1_253, Schm1_12X, Schm1_35, Schm1_68, Schm1_108, Schm1_141,						Schm1_56,	
Schm1_142, Schm1_144, Schm1_253, Schm1_12X, Schm1_35, Schm1_68, Schm1_108, Schm1_141,						Schm1_92,	
Schm1_144, Schm1_253, Schm1_12X, Schm1_35, Schm1_68, Schm1_108, Schm1_141,							
Schm1_12X, Schm1_35, Schm1_68, Schm1_108, Schm1_141,						Schm1_144,	
Schm1_68, Schm1_108, Schm1_141,						Schm1_12X,	
Schm1_108, Schm1_141,							
						Schm1_108,	
	L				<u> </u>		

	1	1		I	Schm1_174,	
					Schm1_176,	
					Schm1_177,	
					Schm1_234,	
					Schm1 248,	
]]					Schm1_3,	
					Schm1_5,	
\ \		1				
					Schm1_22,	
					Schm1_25,	
					Schm1_29,	
					Schm1_41.	
					Schm1_43,	
					Schm1_59,	
l				ļ	Schm1_85,	
					Schm1_97,	
					Schm1_99,	
1 1				•	Schm1_103,	
					Schm1_123,	
					Schm1_136,	
1 1				1		
	i				Schm2_9,	
1				l	Schm2_14,	Į
				1	Schm2_23,	
					Schm2_30,	
				l I	Schm2_32,	
					Schm2_46,	
					Schm2_50,	
						1
					RDN60,	
					RDN02,	
1				1	RDN136,	1
					RDN78,	
					RDN120,	Į į
					RDN75,	1
					RDN116	
						<u> </u>
1322	1324	V	1		RDN120	
1349	1351	V	M		RDN02	
1355	1357	P	S		Schm1_234,	1
					Schm1_136,	1
		l			RDN75	
1204	1266				Schm1_156	
1364	1366	R	E			
1365	1367	D	<u> </u>		Schm1_156	
1393	1395	A	V		Schm1_35,	
					Schm1 41,	1
1					Schm2_9,	§
1405	4407	<u> </u>	<u> </u>		RDN78	
1425	1427	A	V		RDN02	
1479	1481	N	V K		RDN02 RDN60	
		A N V	<u>V</u> К I		RDN02 RDN60 Schm1_141,	
1479	1481	N	V K I		RDN02 RDN60	
1479	1481	N	V K I		RDN02 RDN60 Schm1_141, Schm1_156,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174	
1479	1481	N	V K I M		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39, Schm1_55,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39, Schm1_55, Schm1_56,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_142,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_142, Schm1_142, Schm1_144,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_142, Schm1_142, Schm1_144, Schm1_194,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_144, Schm1_144, Schm1_253,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_144, Schm1_144, Schm1_144, Schm1_194, Schm1_35,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_144, Schm1_144, Schm1_253,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_144, Schm1_144, Schm1_144, Schm1_144, Schm1_164, Schm1_68,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_142, Schm1_142, Schm1_144, Schm1_144, Schm1_144, Schm1_144, Schm1_144, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_185, Schm1_35, Schm1_35, Schm1_68, Schm1_108,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_174 Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_142, Schm1_142, Schm1_142, Schm1_144, Schm1_184, Schm1_185, Schm1_35, Schm1_35, Schm1_108, Schm1_141,	
1479 1483	1481 1485	N V	K I		RDN02 RDN60 Schm1_141, Schm1_156, Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_142, Schm1_142, Schm1_144, Schm1_144, Schm1_144, Schm1_144, Schm1_144, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_184, Schm1_185, Schm1_35, Schm1_35, Schm1_68, Schm1_108,	

				Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_248, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_59, Schm1_97, Schm1_97, Schm1_99, Schm1_103, Schm1_103, Schm1_136, Schm2_9, Schm2_14, Schm2_30, Schm2_32, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN1166	
1505 1516	<u>1507</u> 1518	D	G	Schm2_50 Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_141, Schm1_176, Schm1_176, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_248, Schm1_248, Schm1_25, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_123, Schm1_123, Schm1_123,	

.

1522	1524	E	G	Schm2_9, Schm2_14, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN136, RDN78, RDN120, RDN75, RDN116 Schm1_99,
				Schm2_32, Schm2_46
1538	1540	G	D	Schm1_17, Schm1_22, Schm1_97
1545	1547	S	Т	Schm2_50
1555	1557	Ν	D	Schm1_35, Schm1_41, Schm2_9, RDN78
1560	1562	T	A	Schm1_17, Schm1_144, Schm1_194, Schm1_35, Schm1_234, Schm1_22, Schm1_41, Schm1_97, Schm1_103, Schm1_136, Schm2_32, Schm2_32, Schm2_32, Schm2_32, Schm2_32, Schm2_32, Schm2_50
1580	1582	D	G	Schm1_144, Schm1_194, Schm1_234, Schm1_136 Schm1_142,
1587	1589	V	A	Schm1_176, Schm1_25
1591	1593	N	S	RDN75
1598	1600	A	V	Schm1_17, Schm1_22, Schm1_97
1605	1607	S	Т	Schm1_17, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_68, Schm1_108,

•

				Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_248, Schm1_22, Schm1_25, Schm1_25, Schm1_29, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_59, Schm1_59, Schm1_99, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_23,
				Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN78, RDN120, RDN75, RDN116
1608	1610	S	Р	Schm1_144, Schm1_194, Schm1_234, Schm1_136
1609	1611	A	Deletion	Schm1_130 Schm1_142, Schm1_176, Schm1_25, RDN120
1610	1612	Т	Deletion	Schm1_142, Schm1_176, Schm1_25, RDN120
1617	1619	Т	A	Schm1_17, Schm1_39, Schm1_56, Schm1_92, Schm1_35, Schm1_108, Schm1_141, Schm1_174, Schm1_174, Schm1_248, Schm1_22, Schm1_41, Schm1_59, Schm1_59, Schm1_99, Schm1_99, Schm2_9, Schm2_14, Schm2_23,

				Schm2_30, Schm2_46, Schm2_50, RDN60, RDN78, RDN116
1622	1624	G	S	Schm1_142, Schm1_176, Schm1_25, RDN120
1642	1644	к	T	Schm1_144

Sequence analyses of Spy0488

Sequences were obtained from all 51 strains. The level of amino acid sequence identity ranged from 85.4% to 100% as compared to the sequence of Spy0488 from S. pyogenes 5 SF370. Table 8 lists all 49 amino acid positions which showed a distinct amino acid as compared to Spy0488 from S. pyogenes SF370. The genes from several strains (e.g. Schmitz 1/55) possessed furthermore a different N terminus, with an addition of 25 amino acids and a frame-shift for the first 16 amino acids relative to Spy0488 from S. pyogenes

SF370. 10

> Table 8: Gene conservation of Spy0488.¹, observed amino acid at respective position in any of the sequenced genes of the respective S. pyogenes strains.², second possible amino acid observed at the respective position. Insertion refers to an additional amino acid relative to Spy0488 of S. pyogenes SF370.

Position in SF370 gene	Alignment position	Amino acid in SF370 gene	AA change ¹	AA change ²	Strains with respective change ¹	Strains with respective change ²
Insertion	1		Μ		Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_168, Schm1_174, Schm1_176, Schm1_177, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85,	

15

				Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	2		Μ	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_92, Schm1_142, Schm1_144, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_68, Schm1_108, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_177, Schm1_234, Schm1_248, Schm1_25, Schm1_28, Schm1_29, Schm1_41, Schm1_99, Schm1_99, Schm1_99, Schm1_103, Schm1_123, Schm2_9, Schm2_9, Schm2_9, Schm2_30, Schm2_31, Schm2_46, Schm2_50, RDN60, RDN78, RDN120, RDN75, RDN116
Insertion	3	-	М	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_156, Schm1_141, Schm1_176, Schm1_177,

WO 2008/0	03515			PCT/EP2007/006027		
				76		
					Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116	
Insertion	4	-	L		Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141,	

				Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	4			Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_23, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_36, Schm2_30, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	5	-	R	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	6	-	D	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_156, Schm1_141, Schm1_156, Schm1_174,

				Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	7	-	V	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_25, Schm1_29, Schm1_59, Schm1_22, Schm1_59, Schm1_29, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	8		К	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_234, Schm1_248, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	9	-	V	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141,

Insertion	10	-	к		Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116 Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68,	
					Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116	
Insertion	11	_	Μ	Т	Schm1_39, Schm1_55, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_174, Schm1_234, Schm1_248, Schm1_29, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, RDN60, RDN136, RDN78, RDN120, RDN75	Schm1_56, Schm1_108, Schm1_22, Schm1_85, Schm1_97, Schm2_50, RDN02, RDN116
Insertion	12	-	S		Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177,	

.

WO 2008/003515

1		1	1	Schm1_234, Schm1_248,
				Schm1_3, Schm1_22
1		1		Schm1_25, Schm1_29,
				Schm1 41, Schm1 43,
	ļ	ļ		Schm1 59, Schm1 85,
	•			Schm1_97, Schm1_99,
				Schm1_103, Schm1_123,
1		1		Schm1_136, Schm2_9,
				Schm2_23, Schm2_30,
		ļ		Schm2_32, Schm2_46,
				Schm2_50, RDN60, RDN02, RDN136, RDN78,
				RDN120, RDN75, RDN116
Insertion	13	-	S	Schm1_39, Schm1_55,
				Schm1_56, Schm1_74,
				Schm1_76, Schm1_92,
				Schm1_142, Schm1_144,
				Schm1_194, Schm1_253,
				Schm1_35, Schm1_68,
				Schm1_108, Schm1_141,
				Schm1_156, Schm1_174,
				Schm1_176, Schm1_177,
				Schm1_234, Schm1_248,
				Schm1_3, Schm1_22,
				Schm1_25, Schm1_29,
				Schm1 41, Schm1 43,
				Schm1_59, Schm1_85,
				Schm1_97, Schm1_99,
				Schm1 103, Schm1 123,
				Schm1_136, Schm2_9,
				Schm2_23, Schm2_30,
				Schm2_32, Schm2_46,
				Schm2_50, RDN60,
1 1				RDN02, RDN136, RDN78,
				RDN120, RDN75, RDN116
la cartina				Schm1_39, Schm1_55,
Insertion	14	-	L	Schm1_56, Schm1_74,
1				Schm1_76, Schm1_92, Schm1_142, Schm1_144,
	i i			Schm1_194, Schm1_253,
				Schm1_35, Schm1_68,
				Schm1_108, Schm1_141,
				Schm1_156, Schm1_174,
				Schm1_176, Schm1_177,
l I				Schm1_234, Schm1_248,
				Schm1_3, Schm1_22,
l				Schm1_25, Schm1_29,
				Schm1_41, Schm1_43,
				Schm1_59, Schm1_85,
				Schm1_97, Schm1_99,
				Schm1_103, Schm1_123,
ļļļ	ļ		Į	Schm1_136, Schm2_9,
				Schm2_23, Schm2_30,
				Schm2_32, Schm2_46,
1	1			Schm2_50, RDN60,
				RDN02, RDN136, RDN78,
		ł	ļ	RDN120, RDN75, RDN116
Insertion	15		L	Schm1 39, Schm1 55,
moortion		1		Schm1_56, Schm1_74,
1		1		Schm1_76, Schm1_92,
	1			Schm1_142, Schm1_144,
	1		l	Schm1_194, Schm1_253,
1 I		1		
]	
				Schm1_35, Schm1_68,
				Schm1_35, Schm1_68, Schm1_108, Schm1_141,
				Schm1_35, Schm1_68,

				Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	16	-	V	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_174, Schm1_176, Schm1_174, Schm1_234, Schm1_177, Schm1_234, Schm1_248, Schm1_25, Schm1_29, Schm1_25, Schm1_29, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	17	-	G	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_234, Schm1_248, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	18	-	с	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141,

01	FC 1/EF200	//00002/
81		
	Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116	

				Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43,
				Schm1_59, Schm1_85,
	1			Schm1_97, Schm1_99,
				Schm1 103, Schm1 123,
		ļ		Schm1_136, Schm2_9,
				Schm2_23, Schm2_30,
				Schm2_32, Schm2_46,
	1			Schm2_50, RDN60,
				RDN02, RDN136, RDN78,
			1	RDN120, RDN75, RDN116
			A	Schm1 39, Schm1 55,
Insertion	19	-	A	Schm1_56, Schm1_74,
				Schm1_76, Schm1_92,
				Schm1 142, Schm1 144,
		I		
				Schm1_194, Schm1_253,
				Schm1_35, Schm1_68,
				Schm1_108, Schm1_141,
				Schm1_156, Schm1_174,
	l			Schm1_176, Schm1_177,
				Schm1_234, Schm1_248,
				Schm1_3, Schm1_22,
				Schm1_25, Schm1_29,
				Schm1_41, Schm1_43,
	1		1	Schm1_59, Schm1_85,
				Schm1_97, Schm1_99,
				Schm1_103, Schm1_123,
				Schm1_136, Schm2_9,
				Schm2_23, Schm2_30,
				Schm2_32, Schm2_46,
				Schm2_50, RDN60,
				RDN02, RDN136, RDN78,
				RDN120, RDN75, RDN116
Insertion	20	-	A	Schm1_39, Schm1_55,
				Schm1_56, Schm1_74,
				Schm1_76, Schm1_92,
]	Schm1_142, Schm1_144,
				Schm1_194, Schm1_253,
			1	Schm1_35, Schm1_68,
				Schm1_108, Schm1_141,
		Į	l	Schm1_156, Schm1_174,
				Schm1_176, Schm1_177,
				Schm1_234, Schm1_248,
			1	Schm1_3, Schm1_22,
				Schm1_25, Schm1_29,
		l	ł	Schm1_41, Schm1_43,
				Schm1_59, Schm1_85,
				Schm1_97, Schm1_99,
1]	1	Schm1_103, Schm1_123,
				Schm1_136, Schm2_9,
		1	1	Schm2_23, Schm2_30,
				Schm2_32, Schm2_46,
[[Schm2_50, RDN60,
				RDN02, RDN136, RDN78,
				RDN120, RDN75, RDN116
Insertion	21	-	Т	Schm1_39, Schm1_55,
				Schm1_56, Schm1_74,
1		ł	ł	Schm1_76, Schm1_92,
		1	1	
				Schm1_142, Schm1_144,
				Schm1_142, Schm1_144, Schm1_194, Schm1_253,

				Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_248, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	22	-	L	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_234, Schm1_248, Schm1_23, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_32, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	23	-		Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
Insertion	24	-	V	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253,

Insertion	25		S		Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm2_32, Schm2_30, Schm2_32, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116 Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_156, Schm1_144, Schm1_156, Schm1_144, Schm1_176, Schm1_177, Schm1_176, Schm1_177, Schm1_176, Schm1_177, Schm1_33, Schm1_22, Schm1_35, Schm1_248, Schm1_3, Schm1_248, Schm1_36, Schm1_248, Schm1_36, Schm1_99, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_32, Schm2_30, Schm2_32, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78,	
2	27	R	S		RDN120, RDN75, RDN116 Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_176, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_25, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_29, Schm1_97, Schm1_99, Schm1_103, Schm1_99, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116	Saherd 74
3	28	Q	S	G	Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_253, Schm1_68, Schm1_108,	Schm1_74, Schm1_92, Schm1_144, Schm1_194,

				Schm1_141, Schm1_156, Schm1_35, Schm1_174, Schm1_176, Schm1_234, Schm1_177, Schm1_248, Schm1_41, Schm1_3, Schm1_22, Schm1_103, Schm1_25, Schm1_29, Schm2_9, Schm1_43, Schm1_59, RDN78 Schm1_99, Schm1_123, Schm1_136, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN75, RDN116
4	29		Т	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_23, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
5	30	Q	V	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_234, Schm1_248, Schm1_23, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_30, Schm2_9, Schm1_136, Schm2_9, Schm2_30, Schm2_30, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
6	31	S	A	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_156, Schm1_141,

7	32		Α	Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
	32			Schm1_39, Schm1_39, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_99, Schm1_103, Schm1_99, Schm1_103, Schm1_99, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN160, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
8	33	R	D	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_234, Schm1_248, Schm1_25, Schm1_29, Schm1_25, Schm1_29, Schm1_97, Schm1_99, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_32, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
9	34	L	S	KDN120, KDN75, KDN16 Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141,

	PCT/EP2007/006027
Schm1_156, Sch	nm1_174,

				Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
10	35		V	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_177, Schm1_234, Schm1_248, Schm1_234, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_97, Schm1_99, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_30, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
11	36	D	H	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_177, Schm1_234, Schm1_248, Schm1_234, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_30, Schm2_30, Schm2_30, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
12	37	V	S	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68,

				Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_59, Schm1_85, Schm1_103, Schm1_99, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
13	38	L	S	Schm1_39, Schm1_55, RDN78 Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_25, Schm1_29, Schm1_59, Schm1_29, Schm1_41, Schm1_248, Schm1_3, Schm1_29, Schm1_97, Schm1_99, Schm1_103, Schm1_85, Schm1_97, Schm1_99, Schm1_136, Schm2_9, Schm1_136, Schm2_9, Schm2_32, Schm2_30, Schm2_32, Schm2_30, Schm2_50, RDN60, RDN02, RDN136, RDN120, RDN75, RDN116 Image: Schm16
14	39	E	D	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_177, Schm1_234, Schm1_248, Schm1_23, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_32, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
15	40	L	R	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253,

				Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_25, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
16	41	A	R	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_25, Schm1_29, Schm1_59, Schm1_99, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm1_136, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
30	55	S	F	Schm1_99, Schm1_136,
35	60	S	Y	Schm2_46 RDN75
50	75	A	Т	Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
53	78	N	D	Schm1_253, Schm1_99, Schm1_123, Schm1_136,

	1 1	1		Schm2_46, RDN120
56	81	S		Schm1_39, Schm1_55,
50		Ŭ	•	Schm1 56, Schm1 76,
				Schm1_92, Schm1_144,
				Schm1_194, Schm1_68,
				Schm1 108, Schm1 141,
				Schm1_156, Schm1_174,
				Schm1 177, Schm1 234,
				Schm1_248, Schm1_3,
				Schm1_22, Schm1_29,
				Schm1_43, Schm1_59,
				Schm1_85, Schm1_97,
				Schm1 99, Schm1_103,
				Schm1 136, Schm2 23,
				Schm2 30, Schm2 32,
				Schm2_46, Schm2_50,
				RDN60, RDN02, RDN136,
				RDN120, RDN75, RDN116
	05			Schm1 248, Schm1 59
60	85	D	G	
69	94	D		Schm1_39, Schm1_55, Schm1 56, Schm1 76,
			ł	
	.			Schm1_92, Schm1_253,
			l	Schm1_68, Schm1_108,
			1	Schm1_141, Schm1_156, Schm1_174, Schm1_177
				Schm1_174, Schm1_177,
				Schm1_248, Schm1_3,
				Schm1_22, Schm1_29,
				Schm1_43, Schm1_59,
				Schm1_85, Schm1_97,
				Schm1_99, Schm1_123,
	1		1	Schm1_136, Schm2_23,
				Schm2_30, Schm2_32,
			{	Schm2_46, Schm2_50,
				RDN60, RDN02, RDN136,
				RDN120
75	100	Q	<u>н</u>	Schm2_32
76	101		Т	Schm1_39, Schm1_55,
				Schm1_56, Schm1_76,
				Schm1_144, Schm1_194,
		ļ		Schm1_253, Schm1_68,
				Schm1_108, Schm1_141,
				Schm1_156, Schm1_174,
				Schm1_177, Schm1_234,
				Schm1_248, Schm1_3,
1	1	1		Schm1_22, Schm1_29,
				Schm1_43, Schm1_59,
Į	Į	[l	Schm1_85, Schm1_97,
			1	Schm1_99, Schm1_103,
		1		Schm1_123, Schm1_136,
	1	1	1	Schm2_23, Schm2_30,
		i	1	Schm2_32, Schm2_46,
	Į.	l	ļ	Schm2_50, RDN60,
				RDN02, RDN136, RDN120
87	112	F	Ĺ	Schm1_253, Schm1_123
93	118	G	E	Schm1_99, Schm2_46
112	137	- v	A	Schm1_253, Schm1_123
117	142	1	Т	Schm1_39, Schm1_55,
			1	Schm1_56, Schm1_74,
ļ		l	Į	Schm1_76, Schm1_92,
ł	1			Schm1_253, Schm1_35,
				Schm1_68, Schm1_108,
1	1		1	Schm1_141, Schm1_156,
			1	Schm1_174, Schm1_177,
1		1	1	Schm1_248, Schm1_3,
				Schm1_22, Schm1_29,
L		<u> </u>	L	

127 157 163 174	<u>152</u> <u>182</u> 188 199	H D V K	Y G L T	Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_123, Schm1_136, Schm2_9, Schm2_23, Schm2_30, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116 Schm1_39 RDN75 RDN75 Schm1_55, Schm1_68, Schm1_3, Schm1_29, Schm2_23, Schm2_30
183	208	G	R	RDN75
184	209	G	S	Schm1_56, Schm1_108, Schm1_85, Schm2_50, RDN02
188	213	F	L	Schm1_92, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_234, Schm1_41, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_46, RDN78
198	223	P	S	Schm1_92
199	224	к	R	Schm1_56, Schm1_108, Schm1_85, Schm2_50, RDN02
201	226	R	G	Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_108, Schm1_177, Schm1_234, Schm1_41, Schm1_43, Schm1_41, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_32, Schm2_46, Schm2_50, RDN02, RDN136, RDN78, RDN120
202	227	Q	L	Schm1_144, Schm1_194, Schm1_35, Schm1_234, Schm1_41, Schm1_99, Schm1_103, Schm1_136, Schm2_9, Schm2_46, RDN78
206	231	Т	I	Schm1_56, Schm1_108, Schm1_85, Schm2_50, RDN02
209	234	D	A	Schm1_92, Schm1_144, Schm1_194, Schm1_35, Schm1_234, Schm1_41, Schm1_99, Schm1_103, Schm1_136, Schm2_9, Schm2_46, RDN78
217	242	Р	S	Schm1_56, Schm1_108, Schm1_85, Schm2_50, RDN02
221 222	246	W	С	Schm1_76, Schm1_177, Schm1_43, RDN136
	247	Γ K	E	Schm1_56, Schm1_108,

				Schm1_85, Schm2_50, RDN02
232	257	A	T	Schm1_39, Schm1_22, Schm1_97
235	260	S	F	Schm1_253, Schm1_123
238	263	Т	I	Schm1_248, Schm1_59
258	283	A	V	Schm1_92
291	316	E	Q	Schm1_55, Schm1_68, Schm1_3, Schm1_29, Schm2_23, Schm2_30

Sequence analyses of Spy0872

- Sequences were obtained from all 51 strains. The level of amino acid sequence identity
 ranged from 98.2% to 100% as compared to the sequence of Spy0872 from *S. pyogenes*SF370. Table 9 lists all 34 acid positions which showed a distinct amino acid as compared to Spy0872 from *S. pyogenes* SF370. The gene from strain Schmitz 1/22 showed in addition an insertion of 2 amino acids after position 587.
- 10 **Table 9: Gene conservation of Spy0872.**¹, observed amino acid at respective position in any of the sequenced genes of the respective *S. pyogenes* strains. Insertion refers to an additional amino acid relative to Spy0872 of *S. pyogenes* SF370.

Position in SF370 gene	Alignment position	Amino acid in SF370 gene	AA change ¹	Strains with respective change ¹
67	67	G	C	Schm1_136
74	74	E	D	Schm1_76, Schm1_177, Schm1_43, RDN136
178	178	К	N ,	Schm1_7, Schm1_39, Schm1_55, Schm1_56, Schm1_74, Schm1_76, Schm1_92, Schm1_142, Schm1_144, Schm1_194, Schm1_253, Schm1_35, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_41, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm1_123, Schm1_136, Schm2_9, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
181	181	P	S	RDN60
222	222	н	Y	RDN120
228	228		A	Schm1_56, Schm1_108, Schm1_85, Schm2_50
253	253	V	1	Schm1_7, Schm1_39, Schm1_55, Schm1_56, Schm1_76, Schm1_142, Schm1_144, Schm1_194, Schm1_68, Schm1_108, Schm1_141, Schm1_156, Schm1_174, Schm1_176, Schm1_177, Schm1_234, Schm1_248, Schm1_3, Schm1_22, Schm1_25, Schm1_29, Schm1_43, Schm1_59, Schm1_85, Schm1_97, Schm1_99, Schm1_103, Schm2_14, Schm2_32, Schm2_46, Schm2_50, RDN60, RDN136, RDN120
328	328		M	Schm1_55, Schm1_56, Schm1_92, Schm1_68, Schm1_108, Schm1_3, Schm1_29, Schm1_85, Schm1_136, Schm2_23, Schm2_30, Schm2_50, RDN75

329	329	K	т	Schm1_55, Schm1_56, Schm1_92, Schm1_68,
ļ		ļļ		Schm1_108, Schm1_3, Schm1_29, Schm1_85, Schm1_136, Schm2_23, Schm2_30, Schm2_50, RDN75
336	336			Schm1_56, Schm1_108, Schm1_85, Schm2_50
337	337	A	<u> </u>	Schm1_136, RDN75
340	340	P	<u>i</u>	RDN120
393	393			Schm1_7, Schm1_39, Schm1_55, Schm1_56,
555	000		•	Schm1_74, Schm1_76, Schm1_92, Schm1_142,
				Schm1 144, Schm1_194, Schm1_253, Schm1_35,
		1 1		Schm1_68, Schm1_108, Schm1_141, Schm1_156,
				Schm1_174, Schm1_176, Schm1_177, Schm1_234,
				Schm1 248, Schm1 3, Schm1 22, Schm1 25,
				Schm1_29, Schm1_41, Schm1_43, Schm1_59,
				Schm1 85, Schm1_97, Schm1_99, Schm1_103,
				Schm1_123, Schm1_136, Schm2_9, Schm2_14,
				Schm2_23, Schm2_30, Schm2_32, Schm2_46,
		1 1		Schm2_50, RDN60, RDN02, RDN136, RDN78,
				RDN120, RDN75, RDN116
412	412	M	l	RDN120
427	427	D	Υ	Schm2_46
433	433	G	E	Schm1_7, Schm1_22, Schm1_97
444	444		<u> </u>	RDN75
478	478	Y	F	Schm1_253, Schm1_123
490	490	Т	I	Schm1_55, Schm1_68, Schm1_3, Schm1_29,
		ļ		Schm2_23, Schm2_30
492	492	F	<u>C</u>	RDN02
532	532	A	T	Schm1_144, Schm1_194, Schm1_234, Schm1_103
535	535		V	Schm1_142, Schm1_176, Schm1_25, Schm2_46, RDN116
553	553	E	Q	Schm1_142, Schm1_176, Schm1_25, Schm1_99, Schm2_32, Schm2_46, RDN116
576	576	S	R	Schm1_142, Schm1_176, Schm1_25, Schm1_99, Schm2_46, RDN116
580	580	V	I	Schm1_142, Schm1_176, Schm1_25, Schm1_99, Schm2_46, RDN116
Insertion	588			Schm1 7, Schm1_22, Schm1_97
Insertion	589	-	<u> </u>	Schm1_7, Schm1_22, Schm1_97
588	590	1	Т	RDN78
598	600	G	D	Schm1_92
600	602	Т	1	Schm1_7, Schm1_39, Schm1_55, Schm1_56,
				Schm1_74, Schm1_76, Schm1_92, Schm1_142,
			1	Schm1_144, Schm1_194, Schm1_253, Schm1_35,
				Schm1_68, Schm1_108, Schm1_141, Schm1_156,
				Schm1_174, Schm1_176, Schm1_177, Schm1_234,
				Schm1_248, Schm1_3, Schm1_22, Schm1_25,
				Schm1_29, Schm1_41, Schm1_43, Schm1_59,
				Schm1_85, Schm1_97, Schm1_99, Schm1_103,
				Schm1_123, Schm1_136, Schm2_9, Schm2_14,
				Schm2_23, Schm2_30, Schm2_32, Schm2_46,
				Schm2_50, RDN60, RDN02, RDN136, RDN78, RDN120, RDN75, RDN116
	607	v		Schm1_7, Schm1_39, Schm1_56, Schm1_76,
605	007	V I	1	Schm1_7, Schm1_39, Schm1_50, Schm1_70, Schm1_144, Schm1_194, Schm1_253, Schm1_108,
ļ				Schm1_144, Schm1_154, Schm1_174, Schm1_177,
				Schm1_147, Schm1_136, Schm1_147, Schm1_43, Schm1_248, Schm1_22, Schm1_43,
				Schm1_59, Schm1_85, Schm1_97, Schm1_103,
				Schm1_123, Schm2_14, Schm2_50, RDN60, RDN02,
				RDN136, RDN78, RDN120
620	622	L	F	Schm1_7, Schm1_142, Schm1_176, Schm1_22,
-	-			Schm1_25, Schm1_97, Schm1_99, Schm2_32,
L				Schm2_46, RDN116
625	627	Т		Schm1_7, Schm1_22, Schm1_97
634	636	S	N	Schm1_7, Schm1_142, Schm1_176, Schm1_22,
		1	1	Schm1 25, Schm1 97, Schm1 99, Schm2 46, RDN116

659	661	G	С	Schm1_253, Schm1_123
667	669	к	E	Schm1_144, Schm1_194, Schm1_234, Schm1_103, RDN120

Sequence analyses of Spy0895

Sequences were obtained from all 51 strains. The level of amino acid sequence identity ranged from 98.9% to 100% as compared to the sequence of Spy0895 from *S. pyogenes* SF370. Table 10 lists all 13 amino acid positions which showed a distinct amino acid as compared to Spy0895 from *S. pyogenes* SF370.

Table 10: Gene conservation of Spy0895.¹, observed amino acid at respective position in any of the sequenced genes of the respective *S. pyogenes* strains.

Position in SF370 gene	Alignment position	Amino acid in SF370 gene	AA change ¹	Strains with respective change ¹
19	19	Α	V	Schm1_17, Schm1_22, Schm1_97
33	33	A	V	Schm1_17, Schm1_141, Schm1_156, Schm1_174, Schm1_22, Schm1_97, RDN02
	50	F	V	Schm1_253, Schm1_123
52	52	A	V	Schm1_17, Schm1_55, Schm1_68, Schm1_141, Schm1_156, Schm1_174, Schm1_3, Schm1_22, Schm1_29, Schm1_97, Schm2_30
60	60	Т	1	Schm1_56, Schm1_108, Schm1_85, Schm2_50
71	71	L		Schm1_92, Schm1_144, Schm1_194, Schm1_234, Schm1_103
138	138	Н	Q	Schm1_92, Schm1_144, Schm1_194, Schm1_234, Schm1_103
188	188	R	Р	Schm1_174
238	238	R	С	Schm1_55, Schm1_76, Schm1_68, Schm1_177, Schm1_3, Schm1_29, Schm1_43, Schm2_30, RDN136
242	242	Y	С	Schm1_136
252	252	к	Т	Schm1_56, Schm1_108, Schm1_85, Schm2_50
255	255	S	G	Schm1_56, Schm1_108, Schm1_85, Schm2_50
256	256	L	F	RDN60

Sequence analyses of Spy1536

15 Sequences were obtained from all 51 strains. The level of amino acid sequence identity ranged from 99.1% to 100% as compared to the sequence of Spy1536 from *S. pyogenes* SF370. Table 11 lists all 8 amino acid positions which showed a distinct amino acid as compared to Spy1536 from *S. pyogenes* SF370. The gene from strain Schmitz 2/14 showed in addition an insertion of 3 amino acids after position 207.

Table 11: Gene conservation of Spy1536.¹, observed amino acid at respective position in any of the sequenced genes of the respective *S. pyogenes* strains. Insertion refers to an additional amino acid relative to Spy1536 of *S. pyogenes* SF370.

Position in SF370 gene	Alignment position	Amino acid in SF370 gene	AA change ¹	Strains with respective change ¹
5	5	K	N	Schm1_12, Schm2_9, Schm1_136
92	92	G	R	Schm1_142
97	97	A	T	Schm1_5, Schm1_74
125	125	Р	S	Schm1_123
126	126	V	A	Schm1_142
183	183	V	1	Schm1_94, RDN78, Schm1_97, Schm1_59, Schm1_76, RDN136, Schm1_177, Schm2_32, Schm1_141, Schm1_144, RDN120, Schm1_25, Schm1_176, RDN75_85, Schm2_46, Schm2_23, Schm1_55
Insertion	208	-	ĸ	Schm2_14
Insertion	209	-	N	Schm2_14
Insertion	210	-	G	Schm2_14
333	336	V	4	Schm1_12, Schm1_35, Schm2_9, Schm1_174, Schm1_136, Schm1_234, Schm1_68
337	340	Q	E	Schm1_43, Schm1_108

Sequence analyses of Spy1666

Sequences were obtained from 50 strains. The sequence from strain RDN120 was not determined. The level of amino acid sequence identity ranged from 98.2 to 100% as compared to the sequence of Spy1666 from *S. pyogenes* SF370. Table 12 lists all 18 amino acid positions which showed a distinct amino acid as compared to Spy1666 from *S. pyogenes* SF370.

15 **Table 12: Gene conservation of Spy1666.**¹, observed amino acid at respective position in any of the sequenced genes of the respective *S. pyogenes* strains.

Position in SF370 gene	Alignment position	Amino acid in SF370 gene	AA change ¹	Strains with respective change'
3	3	S	Р	Schm1_17, Schm1_22, Schm1_97, Schm1_136, Schm1_17, Schm1_22, Schm1_97, Schm1_136
11	11	L	V	Schm1_17, Schm1_22, Schm1_97, Schm1_136, Schm1_17, Schm1_22, Schm1_97, Schm1_136
45	45	D	Ň	Schm1_17, Schm1_22, Schm1_97, Schm1_136, Schm1_17, Schm1_22, Schm1_97, Schm1_136
67	67	G	S	Schm1_17, Schm1_22, Schm1_97, Schm1_136, Schm1_17, Schm1_22, Schm1_97, Schm1_136
69	69	E	Q	Schm1_17, Schm1_22, Schm1_97, Schm1_136, Schm1_17, Schm1_22, Schm1_97, Schm1_136
90	90	К	Q	Schm1_142, Schm1_176, Schm1_25, Schm2_46, Schm1_142, Schm1_176, Schm1_25, Schm2_46
106	106	R		RDN136, RDN78, RDN136, RDN78

120	120		F	Schm1_136, Schm1_136
149	149	L	S	RDN78, RDN78
167	167	Т	N	RDN75, RDN75
204	204	т	A	Schm1_253, Schm1_103, Schm1_123, Schm1_253, Schm1_103, Schm1_123
217	217	Р	S	Schm1_39, Schm1_248, Schm1_59, Schm1_39, Schm1_248, Schm1_59
251	251	Q	H	Schm1_97, Schm1_97
252	252	D	E	Schm1_76, Schm1_141, Schm1_156, Schm1_174, Schm1_177, Schm1_43, Schm2_32, RDN136, Schm1_76, Schm1_141, Schm1_156, Schm1_174, Schm1_177, Schm1_43, Schm2_32, RDN136
259	259	L	F	Schm1_92, RDN75, Schm1_92, RDN75
292	292	L	F	RDN116, RDN116
302	302	к	T	Schm1_17, Schm1_142, Schm1_176, Schm1_22, Schm1_25, Schm1_97, Schm2_46, Schm1_17, Schm1_142, Schm1_176, Schm1_22, Schm1_25, Schm1_97, Schm2_46
319	319	Ť	A	Schm1_76, Schm1_141, Schm1_156, Schm1_174, Schm1_177, Schm1_43, Schm2_32, RDN136, Schm1_76, Schm1_141, Schm1_156, Schm1_174, Schm1_177, Schm1_43, Schm2_32, RDN136

Sequence analyses of Spy1727

5

No sequence variation was observed on the amino acid sequence level in any of the analyzed 51 gene sequences obtained from the listed *S. pyogenes* strains.

SEQUENCE DATA FOR AMINO ACID SEQUENCES

Spy0269 1.

1.1 Full length Spy0269

> Spy0269 / SF370 (serotype 1); SEQ ID NO: 57 MDLEQTKPNQVKQKIALTSTIALLSASVGVSHQVKADDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKT LSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELH NAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELE

- KAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASG 10 YIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLP PVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGA FNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESN IANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTL
- KOSDSLNLOVROLNDTKGSLRTELLAAKAKOAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAKK 15 AHLOYLRDFKLNPNRLQVIRERIDNTKODLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLAN EKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQT SEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQRALKAGVVMLAAVGLTGFRFRKESK

Antigenic fragment Spy0269-1 20 1.2

> Spy0269-1 / SF370 (serotype 1); SEQ ID NO: 1

DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS 25 RLKSSAPSTODSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKHNPNAPV

30

5

Homologous sequences of other S. pyogenes isolates and/or serotypes 1.3

> Spy0269-1 / Schmitz 2/14 (serotype 1); SEQ ID NO: 58

- DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINNLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT 35 SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS RLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI
- 40 NFLRVDKRNPNAPV

> Spy0269-1 / Schmitz 1/156 (serotype 4); SEQ ID NO: 59 DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEONIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS

- 45 RLKSSAPSTODSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKHNPKAPV
- 50
- > Spy0269-1 / Schmitz 1/59 (serotype 12); SEQ ID NO: 60 DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTKLATALTKTTAEINHLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS
- RLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA 55 DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKRNPNAPV

> Spy0269-1 / Schmitz 1/177 (serotype 22); SEQ ID NO: 61 DDRASGETKASNTHDDSLPKPETIQEAKATIEAVEKALSQQKAELTELATALTKTTAKINHLKEQQDNEQKAL TSAOEIYTNTLASSEETLLAOGAEHORELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS

- RLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA 5 DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKRNPNAPV
- > Spy0269-1 / Schmitz 1/43 (serotype 22); SEQ ID NO: 62 10 DDRASGETKASNTHDDSLPKPETIQEAKATIEAVEKALSQQKAELTELATALTKTTAKINHLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS RLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA
- DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG 15 VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKRNPNAPV

> Spy0269-1 / Schmitz 1/136 (serotype 25); SEQ ID NO: 63

DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKAL 20 TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS RLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI 25 NFLRVDKRNPNAPV

> Spy0269-1 / Schmitz 1/85 (serotype 28); SEQ ID NO: 64 DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKAL

- TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT30 SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS RLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI 35 NFLRVDKHNPNAPV

> Spy0269-1 / Schmitz 2/50 (serotype 28); SEQ ID NO: 65 DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQVDQHSKETALSEQKASISAETTRAQDLVEQVKT SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS

- 40 RLKSSAPSTODSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKRNPNAPV
- 45
- > Spy0269-1 / Schmitz 1/123 (serotype 49); SEQ ID NO: 66 DDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS
- RLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA 50 DRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKRNPNAPV
- > Spy0269-1 / Schmitz 1/176 (serotype 83); SEQ ID NO: 67 55 DDRASGETKASNTHDDSLPKPETIQEAKATIEAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKAL TSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKT SEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELS RLKSSAPSTODSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPA DRNRFVDPDNLTPEVONELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPG 60

VSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAI NFLRVDKRNPNAPV

2. Spy0292

2.1 Full length Spy0292

> Spy0292 / SF370 (serotype 1); SEQ ID NO: 68

- MIKRLISLVVIALFFAASTVSGEEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKG KLNWDSPVTISNYPYELTTNYTISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQL RQWGISDAKVVNSTGLTNHFLGANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFAGQTIY SYNYMLKGMPCYREGVDGLFVGYSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLIN FQKVQLIENNKPVKTLYVLDSPEKTVKLVAQNSLFFIKPIHTKTKNTVHITKKSSTMIAPLSKGQVLGRATLQ DKHLIGQGYLDTPPSINLILQKNISKSFFLKVWWNRFVRYVNTSL
- 15

5

2.2 Antigenic fragment Spy0292-1

 > Spy0292-1 / SF370 (serotype 1); SEQ ID NO: 2 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT
 20 ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC

2.3 Homologous sequences of other S. pyogenes isolates and/or serotypes

- 25 > Spy0292-1 / Schmitz 1/39 (serotype 12); SEQ ID NO: 69 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 30 > Spy0292-1 / Schmitz 1/55 (serotype 118); SEQ ID NO: 70 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDTKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 35 > Spy0292-1 / Schmitz 1/56 (serotype 28); SEQ ID NO: 71 EEYSVTAKHAIAVDLESGKVLYEKDTKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 40 > Spy0292-1 / Schmitz 1/74 (serotype 3); SEQ ID NO: 72 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 45 > Spy0292-1 / Schmitz 1/76 (serotype 22); SEQ ID NO: 73 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 50 > Spy0292-1 / Schmitz 1/92 (serotype 11); SEQ ID NO: 74 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 55 > Spy0292-1 / Schmitz 1/94 (serotype 1); SEQ ID NO: 75 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 60 > Spy0292-1 / Schmitz 1/142 (serotype 83); SEQ ID NO: 76

35

60

EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC

- 5 > Spy0292-1 / Schmitz 1/144 (serotype 76); SEQ ID NO: 77 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC
- 10 > Spy0292-1 / Schmitz 1/194 (serotype 44); SEQ ID NO: 78 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFC

15 2.4 Antigenic fragment Spy0292-3

> Spy0292-3 / SF370 (serotype 1); SEQ ID NO: 3 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFAGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENOMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE

2.5 Homologous sequences of other S. pyogenes isolates and/or serotypes

- 25 > Spy0292-3 / Schmitz 1/39 (serotype 12); SEQ ID NO: 79 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFDGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE 30
 - > Spy0292-3 / Schmitz 1/55 (serotype 118); SEQ ID NO: 80 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDTKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFDGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE
- > Spy0292-3 / Schmitz 1/56 (serotype 28); SEQ ID NO: 81 EEYSVTAKHAIAVDLESGKVLYEKDTKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG
 40 ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFDGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENOMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE
 - > Spy0292-3 / Schmitz 1/74 (serotype 3); SEQ ID NO: 82 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT
- 45 ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFAGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE
- > Spy0292-3 / Schmitz 1/76 (serotype 22); SEQ ID NO: 83
 50 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT
 ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG
 ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFDGQTIYSYNYMLKGMPCYREGVDGLFVG
 YSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE
- 55 > Spy0292-3 / Schmitz 1/92 (serotype 11); SEQ ID NO: 84 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFDGQTIYSYNYMLKGMPCYREGVDGLFIG YSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE

> Spv0292-3 / Schmitz 1/94 (serotype 1); SEQ ID NO: 85

EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFAGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENOMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE

5

10

> Spy0292-3 / Schmitz 1/142 (serotype 83); SEQ ID NO: 86 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFDGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE

- > Spy0292-3 / Schmitz 1/144 (serotype 76); SEQ ID NO: 87 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT LSNUDLDEPKYTYKELLSALVVNNANSPALALAEKIGGTEPKEVDKMKKOLBOWGISDAKVVNSTGLTNHFLG
- 15 ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFDGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENQMRVITVVINADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE

> Spy0292-3 / Schmitz 1/194 (serotype 44); SEQ ID NO: 88

20 EEYSVTAKHAIAVDLESGKVLYEKDAKEVVPVASVSKLLTTYLVYKEVSKGKLNWDSPVTISNYPYELTTNYT ISNVPLDKRKYTVKELLSALVVNNANSPAIALAEKIGGTEPKFVDKMKKQLRQWGISDAKVVNSTGLTNHFLG ANTYPNTEPDDENCFCATDLAIIARHLLLEFPEVLKLSSKSSTIFAGQTIYSYNYMLKGMPCYREGVDGLFVG YSKKAGASFVATSVENQMRVITVVLNADQSHEDDLAIFKTTNQLLQYLLINFQKVQLIE

25 **3.** Spy0416A

3.1 Full length Spy0416A

> Spy0416A / SF370 (serotype 1); SEQ ID NO: 89

- 30 ADELSTMSEPTITNHAQQQAQHLTNTELSSAESKSQDTSQITLKTNREKEQSQDLVSEPTTTELADTDAASMA NTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAE SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD
- 35 YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE STDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGAGLLNIDGAVTSGL YVTGKDNYGSISLGNITDTMTFDVTVHNLSNKDKTLRYDTELLTDHVDPQKGRFTLTSHSLKTYQGGEVTVPA
- 40 NGKVTVRVTMDVSQFTKELTKQMPNGYYLEGFVRFRDSQDDQLNRVNIPFVGFKGQFENLAVAEESIYRLKSQ GKTGFYFDESGPKDDIYVGKHFTGLVTLGSE

3.2 Antigenic fragment Spy0416A-1

- 45 > Spy0416A-1 / SF370 (serotype 1); SEQ ID NO: 4 ADELSTMSEPTITNHAQQQAQHLTNTELSSAESKSQDTSQITLKTNREKEQSQDLVSEPTTTELADTDAASMA NTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAE
- VIKTEETDGSHDIDWTQTDDDTKYESHGMHVIGIVAGNSKEAAAIGERFEGIAPEAQVMFMKVFANDIMGSAE
 SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE STDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA
- 55

3.3 Homologous sequences of other S. pyogenes isolates and/or serotypes

> Spy0416A-1 / Schmitz 1/7 (serotype 4); SEQ ID NO: 90

ADELTTTSEPTITNHAQQQAQHLTNTELSSAESQSPDTSQITPKTNREKEQPQGLVSEPTTTELADTDAASMA 60 NTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA

RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFGDFDEDWENFEFDAEPKAIKKNKIYRPQSTQAPKETVI KTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESL FIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYG LVGSPSTGRTPTSVAAINSKWVIQRLMTAKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKEST DAGYKAQDVKDKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGK AMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTSMA SPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA

- > Spy0416A-1 / Schmitz 1/39 (serotype 12); SEQ ID NO: 91
- 10 ADELTTTSEPTITNHTQQQAQHLTNTELSSAESKPQDTSQITLKTNREKEQPQGLVSEPTTTELADTDAAPMA NTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAE SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD
 15 YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE
- 15 YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE STDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA
- 20 > Spy0416A-1 / Schmitz 1/55 (serotype 118); SEQ ID NO: 92 ADELTTTSEPTITNHAQQQAPPLTNTELSSAESQPQDTSQVTPETNREKEQPQGLVSEPTTTELADTDAAPMA NTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAE
- 25 SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE STDAGYNAQNVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA 30
 - > Spy0416A-1 / Schmitz 1/56 (serotype 28); SEQ ID NO: 93 ADELTTTSEPTITNHAQQQAPPLTNTELSSAESQPQDTSQVTPETNREKEQPQGLVSEPTTTELADTDAAPMA NTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET
- VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAE SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE STDAGYNAQNVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS
 MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA
 - > Spy0416A-1 / Schmitz 1/94 (serotype 1); SEQ ID NO: 94 ADELSTMSEPTITNHAQQQAQHLTNTELSSAESKSQDTSQITLKTNREKEQSQDLVSEPTTTELADTDAASMA NTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET
- 45 RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAE SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE STDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF
 50 GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA
- > Spy0416A-1 / Schmitz 1/253 (serotype 49); SEQ ID NO: 95 ADELTTTSEPTITNHAQQQAQPLTNTELSSAESQSPDISQVTPETNREKEQPQGLVSEPTTTELADTDAAPMA
 55 NTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDADAEPKAIKKHKIYRPQSTQAPKET VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAE SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKGLENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE
 60 STDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGALGLLIFNNKSGQSNRSMRLTANGMGIPSAFISHEF

GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA

- > Spy0416A-1 / Schmitz 1/174 (serotype 6); SEQ ID NO: 96
 5 ADELTTTSEPTITNHAQQQAQHLTNTELSSAESKPQDTSQITPKTNREKEQSQDLVSEPTTTELADTDAASMA
 NTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA
 RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET
 VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAE
 SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD
- 10 YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKNIKDSLGYDKSHQFAYVKE STDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTSNGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA
- 15 > Spy0416A-1 / Schmitz 1/176 (serotype 83); SEQ ID NO: 97 ADELTTTSEPTITNHTQQQAQHLTNTELSSAESKPQDTSQITLKTNREKEQPQGLVSEPTTTELADTDAAPMA NTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKET VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAE
- 20 SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKNIKDSLGYDKSHQFAYVKE STDAGYKAQDVKGKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS MASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA
- 25
- > Spy0416A-1 / Schmitz 1/234 (serotype 44); SEQ ID NO: 98 ADELSTMSEPTITNHAQQQAQHLTNTELSSAESKSQDTSQITPKTNREKEQSQDLVSEPTTTELADTDAASMA NTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDADAEPKAIKKHKIYRPQSTQAPKET
- VIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAE SLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPD YGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKE STDAGYKAQDVKDKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEF GKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTS
 MASPOIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA

> Spy0416A-1 / Schmitz 1/22 (serotype 4); SEQ ID NO: 99

- ADELTTTSEPTITNHAQQQAQHLTNTELSSAESQSPDTSQITPKTNREKEQPQGLVSEPTTTELADTDAASMA NTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLA 40 RQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFGDFDEDWENFEFDAEPKAIKKNKIYRPQSTQAPKETVI KTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESL FIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYG LVGSPSTGRTPTSVAAINSKWVIQRLMTAKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKEST DAGYKAQDVKDKIALIERDPNKTYDEMIALAKKHGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGK
- 45 AMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTSDGYLKPDITAPGGDIYSTYNDNHYGSQTGTSMA SPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPETKTTTSPRQQGA

3.4 Antigenic fragment Spy0416A-6

- $0 \rightarrow \text{Spy}(416) = 6 / \text{SF370} (\text{servitype 1}) \cdot \text{SEO ID NO: 5}$
- 50 > Spy0416A-6 / SF370 (serotype 1); SEQ ID NO: 5 AVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED WENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE AAATGERFLGIAPEAQVMFMRVFANDIMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLN
 55 HGKAIYSESVDFKDIKDSL

3.5 Homologous sequences of other S. pyogenes isolates and/or serotypes

- > Spy0416A-6 / Schmitz 1/7 (serotype 4); SEQ ID NO: 100
- 60 AVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFGDFDED

WENFEFDAEPKAIKKNKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAA ATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKA KKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTAKELENRADLNHG KATYSESVDFKDIKDSL

5

> Spv0416A-6 / Schmitz 1/39 (serotype 12); SEQ ID NO: 101 AVIDTGIDPAHOSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED WENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE AAATGERFLGIAPEAOVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLN

10 HGKAIYSESVDFKDIKDSL

> > Spy0416A-6 / Schmitz 1/55 (serotype 118); SEQ ID NO: 102 AVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED

WENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE 15 AAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLN HGKATYSESVDFKDIKDSL

- > Spy0416A-6 / Schmitz 1/56 (serotype 28); SEQ ID NO: 103 20 AVIDTGIDPAHOSMRISDVSTAKVKSKEDMLAROKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED WENFEFDAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAA ATGERFLGIAPETQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKA KKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLNHG 25
- KAIYSESVDFKDIKDSL

> Spy0416A-6 / Schmitz 1/94 (serotype 1); SEQ ID NO: 104 AVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED WENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE AAATGERFLGIAPEAQVMFMRVFANDIMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE

30 KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLN HGKAIYSESVDFKDIKDSL

> Spy0416A-6 / Schmitz 1/253 (serotype 49); SEQ ID NO: 105

- AVIDTGIDPAHOSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED 35 WENFEFDADAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE AAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKGLENRADLN HGKAIYSESVDFKDIKDSL
- 40

45

> Spy0416A-6 / Schmitz 1/174 (serotype 6); SEQ ID NO: 106 AVIDTGIDPAHOSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED WENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE AAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLN HGKAIYSESVDFKNIKDSL

> Spy0416A-6 / Schmitz 1/176 (serotype 83); SEQ ID NO: 107

- AVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED WENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE 50 AAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLN HGKATYSESVDFKNIKDSL
- > Spy0416A-6 / Schmitz 1/234 (serotype 44); SEQ ID NO: 108 55 AVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDFDED WENFEFDADAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKE AAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIE KAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADLN HGKAIYSESVDFKDIKDSL 60

> Spy0416A-6 / Schmitz 1/22 (serotype 4); SEQ ID NO: 109 AVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFGDFDED

WENFEFDAEPKAIKKNKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSKEAA
 ATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAIEKA
 KKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTAKELENRADLNHG
 KAIYSESVDFKDIKDSL

3.6 Antigenic fragment Spy0416A-7

- 10
- > Spy0416A-7 / SF370 (serotype 1); SEQ ID NO: 6

SQITLKTNREKEQSQDLVSEPTTTELADTDAASMANTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN SKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA

15 SKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA DLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGA LGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS

20 3.7 Homologous sequences of other S. pyogenes isolates and/or serotypes

> Spy0416A-7 / Schmitz 1/7 (serotype 4); SEQ ID NO: 110

 SQITPKTNREKEQPQGLVSEPTTTELADTDAASMANTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFGDF
 DEDWENFEFDAEPKAIKKNKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSK EAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAI EKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTAKELENRADL NHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYKAQDVKDKIALIERDPNKTYDEMIALAKKHGALG VLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS

30

60

> Spy0416A-7 / Schmitz 1/39 (serotype 12); SEQ ID NO: 111 SQITLKTNREKEQPQGLVSEPTTTELADTDAAPMANTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN CKEAAATCEPELCIAPEAQVMEMPUFANDVMCSAESLEIKALEDAVALCADVINUSLCTANCAQUSCSKELME

35 SKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA DLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGA LGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS

 40 > Spy0416A-7 / Schmitz 1/55 (serotype 118); SEQ ID NO: 112 SQVTPETNREKEQPQGLVSEPTTTELADTDAAPMANTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN SKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME
 45 AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA

45 ATEKAKKAGVSVVVAAGNEKVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMIVKELENKA DLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQNVKGKIALIERDPNKTYDEMIALAKKHGA LGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS

> Spy0416A-7 / Schmitz 1/56 (serotype 28); SEQ ID NO: 113

 50 SQITPKINREKEQPQGLVSEPTTTELADTDAAPMANTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSK EAAATGERFLGIAPETQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAI EKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRADL
 55 NHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGALG VLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS

> Spy0416A-7 / Schmitz 1/94 (serotype 1); SEQ ID NO: 114 SQITLKTNREKEQSQDLVSEPTTTELADTDAASMANTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF

DEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN SKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA DLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGA LGVLIFNNKPGOSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS

5

> Spy0416A-7 / Schmitz 1/253 (serotype 49); SEQ ID NO: 115 SOVTPETNREKEQPQGLVSEPTTTELADTDAAPMANTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDADAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN SKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME

- AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKGLENRA DLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGA LGLLIFNNKSGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS
- 15

10

> Spy0416A-7 / Schmitz 1/174 (serotype 6); SEQ ID NO: 116 SOITPKTNREKEQSQDLVSEPTTTELADTDAASMANTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN

SKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME 20 AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA DLNHGKAIYSESVDFKNIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKHGA LGVLIFNNKPGQSNRSMRLTSNGMGIPSAFISHEFGKAMSQLNGNGTGS

> Spv0416A-7 / Schmitz 1/176 (serotype 83); SEQ ID NO: 117 25 SQITLKTNREKEQPQGLVSEPTTTELADTDAAPMANTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN SKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME

- AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA 30 DLNHGKAIYSESVDFKNIKDSLGYDKSHQFAYVKESTDAGYKAQDVKGKIALIERDPNKTYDEMIALAKKHGA LGVLIFNNKPGOSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS
 - > Spy0416A-7 / Schmitz 1/234 (serotype 44); SEQ ID NO: 118
- SQITPKTNREKEQSQDLVSEPTTTELADTDAASMANTGSDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG 35 KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFEDF DEDWENFEFDADAEPKAIKKHKIYRPOSTOAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGN SKEAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLME AIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTVKELENRA DLNHGKAIYSESVDFKDIKDSLGYDKSHOFAYVKESTDAGYKAQDVKDKIALIERDPNKTYDEMIALAKKHGA
- 40 LGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS

> Spy0416A-7 / Schmitz 1/22 (serotype 4); SEQ ID NO: 119

- SQITPKTNREKEQPQGLVSEPTTTELADTDAASMANTGPDATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQG KVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSWINDKVVFAHNYVENSDNIKENQFGDF 45 DEDWENFEFDAEPKAIKKNKIYRPQSTQAPKETVIKTEETDGSHDIDWTQTDDDTKYESHGMHVTGIVAGNSK EAAATGERFLGIAPEAQVMFMRVFANDVMGSAESLFIKAIEDAVALGADVINLSLGTANGAQLSGSKPLMEAI EKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMTAKELENRADL NHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYKAQDVKDKIALIERDPNKTYDEMIALAKKHGALG VLIFNNKPGOSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGS 50

3.8 Full length Spy0416B

> Spy0416B / SF370 (serotype 1); SEQ ID NO: 56

HVDPQKGRFTLTSHSLKTYQGGEVTVPANGKVTVRVTMDVSQFTKELTKQMPNGYYLEGFVRFRDSQDDQLNR VNIPFVGFKGQFENLAVAEESIYRLKSQGKTGFYFDESGPKDDIYVGKHFTGLVTLGSETNVSTKTISDNGLH 55 TLGTFKNADGKFILEKNAQGNPVLAISPNGDNNQDFAAFKGVFLRKYQGLKASVYHASDKEHKNPLWVSPESF KGDKNFNSDIRFAKSTTLLGTAFSGKSLTGAELPDGHYHYVVSYYPDVVGAKRQEMTFDMILDRQKPVLSQAT FDPETNRFKPEPLKDRGLAGVRKDSVFYLERKDNKPYTVTINDSYKYVSVEDNKTFVERQADGSFILPLDKAK LGDFYYMVEDFAGNVAIAKLGDHLPQTLGKTPIKLKLTDGNYQTKETLKDNLEMTQSDTGLVTNQAQLAVVHR NQPQSQLTKMNQDFFISPNEDGNKDFVAFKGLKNNVYNDLTVNVYAKDDHQKQTPIWSSQAGASVSAIESTAW 60

- > Spy0872-2 / Schmitz 1/94 (serotype 1); SEQ ID NO: 125 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLATTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY 60
- 50 > Spy0872-2 / Schmitz 1/56 (serotype 28); SEQ ID NO: 124 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWGAAOAVOPFGNILOVIOMTGOHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY VTSNLESSTKVNSAGKHSIISKVFRNRDGNIVSSEIISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT 55
- > Spy0872-2 / Schmitz 1/55 (serotype 118); SEQ ID NO: 123 45 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDIPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY VTSNLESSTKVNSAGKHSIISKVFRNRDGNIVSSEVISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT
- AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV 40 VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY VTSNLESSTKVNSAGKHSIISKVFRNRDGNIVSSEIISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT
- VTSNLESSTKVNSAGKHSIIIISKVFRNRDGNIVSSEIISDLLTSTENTNNSFGKKEITTNKNTISNSTLPIT > Spy0872-2 / Schmitz 1/39 (serotype 12); SEQ ID NO: 122
- > Spy0872-2 / Schmitz 1/7 (serotype 4); SEQ ID NO: 121 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWEAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK 35 VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY
- VTSNLESSTKVNSAGKHSIISKVFRNRDGNTVSSEVISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT 30 Homologous sequences of other S. pyogenes isolates and/or serotypes 4.3
- > Spv0872-2 / SF370 (serotype 1); SEQ ID NO: 7 25 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLATTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY
- Antigenic fragment Spy0872-2 4.2
- STENTNNSLGKKETTTNKNTISSSTLPIT
- NSALLQDEPTVKVFNKMKFEYGTLGNHEFDEGLDEFNRIMTGQAPDPESTINDITKQYEHEASHQTIVIANVI DKKTKDIPYGWKPYAIKDIAINDKIVKIGFIGVVTTEIPNLVLKQNYEHYQFLDVAETIAKYAKELQEQHVHA 15 IVVLAHVPATSKDGVVDHEMATVMEKVNQIYPEHSIDIIFAGHNHQYTNGTIGKTRIVQALSQGKAYADVRGT LDTDTNDFIKTPSANVVAVAPGIKTENSDIKAIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNL ATTAOLTIAKKTFPTVDFAMTNNGGIRSDLVVKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDE NQTYFLQMSGLTYTYTDNDPKNSDTPFKIVKVYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAI NTDTEAFITYITNLEASGKTVNATIKGVKNYVTSNLESSTKVNSAGKHSIISKVFRNRDGNTVSSEVISDLLT 20

DQVDVQFLGVNDFHGALDNTGTAYTPSGKIPNAGTAAQLGAYMDDAEIDFKQANQDGTSIRVQAGDMVGASPA

- Full length Spy0872 10 4.1

5

- 4. Spy0872
- KALPST

> Spy0872 / SF370 (serotype 1); SEQ ID NO: 120

YGITARGSKVMPGDYQYVVTYRDEHGKEHQKQYTISVNDKKPMITQGRFDTINGVDHFTPDKTKALDSSGIVR EEVFYLAKKNGRKFDVTEGKDGITVSDNKVYIPKNPDGSYTISKRDGVTLSDYYYLVEDRAGNVSFATLRDLK AVGKDKAVVNFGLDLPVPEDKQIVNFTYLVRDADGKPIENLEYYNNSGNSLILPYGKYTVELLTYDTNAAKLE SDKIVSFTLSADNNFQQVTFKITMLATSQITAHFDHLLPEGSRVSLKTAQDQLIPLEQSLYVPKAYGKTVQEG TYEVVVSLPKGYRIEGNTKVNTLPNEVHELSLRLVKVGDASDSTGDHKVMSKNNSQALTASATPTKSTTSATA

- 60 HSELTANKRAHSAKLRVAKKIRK
- > Spy1666 / SF370 (serotype 1); SEQ ID NO: 132 55 TKEFHHVTVLLHETVDMLDIKPDGIYVDATLGGSGHSAYLLSKLGEEGHLYCFDQDQKAIDNAQVTLKSYIDK GQVTFIKDNFRHLKARLTALGVDEIDGILYDLGVSSPQLDERERGFSYKQDAPLDMRMDRQSLLTAYEVVNTY PFNDLVKIFFKYGEDKFSKQIARKIEQARAIKPIETTTELAELIKAAKPAKELKKKGHPAKQIFQAIRIEVND ELGAADESIQDAMELLALDGRISVITFHSLEDRLTKQLFKEASTVDVPKGLPLIPEDMKPKFELVSRKPILPS
- > Spy1536 / SF370 (serotype 1); SEQ ID NO: 131 IEMPGGAYDIRTVLQVNGKEDKRKGAYQFVAVGISRASLAQLLYAWLTPFTEISTAEDTTGGYSDADFLRINQ FYMETSQNAAIYQALSLAGKPVTLDYKGVYVLDVNNESTFKGTLHLADTVTGVNGKQFTSSAELIDYVSHLKL 50 GDEVTVQFTSDNKPKKGVGRIIKLKNGKNGIGIALTDHTSVNSEDTVIFSTKGVGGPSAGLMFTLDIYDQITK EDLRKGRTIAGTGTIGKDGEVGDIGGAGLKVVAAAEAGADIFFVPNNPVDKEIKKVNPNAISNYEEAKRAAKR LKTKMKIVPVTTVQEALVYLRK
- > Spy0895 / SF370 (serotype 1); SEQ ID NO: 9 TNNQTLDILLDVYAYNHAFRIAKALPNIPKTALYLLEMLKERRELNLAFLAEHAAENRTIEDQYHCSLWLNQS LEDEQIANYILDLEVKVKNGAIIDFVRSVSPILYRLFLRLITSEIPNFKAYIFDTKNDQYDTWHFQAMLESDH EVFKAYLSQKQSRNVTTKSLADMLTLTSLPQEIKDLVFLLRHFEKAVRNPLAHLIKPFDEEELHRTTHFSSQA 45 FLENIITLATFSGVIYRREPFYFDDMNAIIKKELSLWRQSIV
- EKEKPASDVKVRPAEVGSWLEPATALPSVEMSAEDRLKS 40
- > Spv0488 / SF370 (serotype 1); SEQ ID NO: 8 35 LRQIQSIRLIDVLELAFGVGYKEETTSQFSSDQPSQVVLYRGEANTVRFAYTNQMSLMKDIRIALDGSDKSLT AQIVPGMGHVYEGFQTSARGIFTMSGVPESTVPVANPNVQTKYIRYFKVIDDMHNTMYKGTVFLVQPQAWKYT MKSVDQLPVDDLNHIGVAGIERMTTLIKNAGALLTTGGSGAFPDNIKVSINPKGRQATITYGDGSTDIIPPAV LWKKGSVKEPTEADQSVGTPTPGIPGKFKRDQSLNEHEAMVNVEPLSHVVKDNIKVIDEKSTGRFEPFRPNED

5. Further Sequences

- > Spy0872-2 / Schmitz 1/22 (serotype 4); SEQ ID NO: 130 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWEAAOAVOPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY 30 VTSNLESSTKVNSAGKHSIIIISKVFRNRDGNIVSSEIISDLLTSTENTNNSFGKKEITTNKNTISNSTLPIT
- > Spy0872-2 / Schmitz 1/234 (serotype 44); SEQ ID NO: 129 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKTKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY VTSNLESSTKVNSAGKHSIISKVFRNRDGNIVSSEIISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT 25
- > Spy0872-2 / Schmitz 1/177 (serotype 22); SEQ ID NO: 128 15 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY VTSNLESSTKVNSAGKHSIISKVFRNRDGNIVSSEIISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT 20
- > Spy0872-2 / Schmitz 1/176 (serotype 83); SEQ ID NO: 127 AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV 10 VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTYTYTDNDPKNSDTPFKIVK VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLVGAINTDTEAFITYITNLQASGKTVNATIKGVKNY VTSNLERSTKINSAGKHSIISKVFRNRDGNIVSSEVISDLLTSTENTNNSFGKKETTTNKNTISNSTLPIT
- AIINHANDIVKTVTERKIGTATNSSTISKTENIDKESPVGNLVTTAQLTIAKKTFPTVDFAMTNNGGIRSDLV VKNDRTITWGAAQAVQPFGNILQVIQMTGQHIYDVLNQQYDENQTYFLQMSGLTFTYTDNDPKNSDTPFKIVK 5 VYKDNGEEINLTTTYTVVVNDFLYGGGDGFSAFKKAKLIGAINTDTEAFITYITNLEASGKTVNATIKGVKNY VTSNLESSTKVNSAGKHSIISKVFRNRDGNIVSSEIISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT
- > Spy0872-2 / Schmitz 1/253 (serotype 49); SEQ ID NO: 126
- VTSNLESSTKVNSAGKHSIISKVFRNRDGNTVSSEVISDLLTSTENTNNSLGKKETTTNKNTISSSTLPIT

> Spy1727 / SF370 (serotype 1); SEQ ID NO: 10 VTTTEQELTLTPLRGKSGKAYKGTYPNGECVFIKLNTTPILPALAKEQIAPQLLWAKRMGNGDMMSAQEWLNG RTLTKEDMNSKQIIHILLRLHKSKKLVNQLLQLNYKIENPYDLLVDFEQNAPLQIQQNSYLQAIVKELKRSLP

5 EFKSEVATIVHGDIKHSNWVITTSGMIFLVDWDSVRLTDRMYDVAYLLSHYIPRSRWSEWLSYYGYKNNDKVM QKIIWYGQFSHLTQILKCFDKRDMEHVNQEIYALRKFREIFRKK

SEQUENCE DATA FOR DNA SEQUENCES

1. Spy0269

10 1.1 Full length Spy0269

> Spy0269 / SF370 (serotype 1); SEQ ID NO: 133

- ATGGACTTAGAACAAACGAAGCCAAACCAAGTTAAGCAGAAAATTGCTTTAACCTCAACAATTGCTTTATTGA GTGCCAGTGTAGGCGTATCTCACCAAGTCAAAGCAGATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATAC TCACGACGATAGTTTACCAAAACCAGAAACAATTCAAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACT CTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGCTACCGCTCTGACAAAAACTACTGCTGAAATCAACCACT TAAAAGAGCAGCAAGATAATGAACAAAAGCTTTAACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAG TAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAACATCAAAGAGAGTTAACAGCTACTGAAAACAGACTAT
- 20 AATGCTCAAGCAGATCAACATTCAAAAGAGACTGCATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTA CTCGAGCTCAAGATTTAGTGGAACAAGTCAAAACGTCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAG CAATCCTGATGCTATCACTAAAGCAGCTCAAACGGCTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAG AAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAAAGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGA AAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGTCGTCTTAAATCCTCAGGCTCCGTCTCAAGATAGCAT
- 25 TGTGGGTAATAATACCATGAAAGCACCGCAAGGCTATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGT TATATTGGATCAGCTAGTTACAATAATTATTACAAAGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAG GTAATCAATTAAATCAATACCAAGATATTCCAGCAGATCGTAATCGCTTTGTTGATCCCGATAATTTGACACC AGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTCACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCA CCAGTTACTGTTACAGCAGGATCACAAGAATTTGCAAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTA

- 40 AGCCGCACTGCACCAGACAGAAGCCTTAGCAGAGCAAGCCGCAGCCAGAGTGACAGCACTGGTGGCTAAAAAA GCTCATTTGCAATATCTAAGGGACTTTAAATTGAATCCTAACCGCCTTCAAGTGATACGTGAGCGCATTGATA ATACTAAGCAAGATTTGGCTAAAACTACCTCATCTTTGTTAAATGCACAAGAAGCTTTAGCAGCCTTACAAGC TAAACAAAGCAGTCTAGAAGCTACTATTGCTACCACAGAACACCAGTTGACTTTGCTTAAAACCTTAGCTAAC GAAAAGGAATATCGCCACTTAGACGAAGATATAGCTACTGTGCCTGATTTGCAAGTAGCTCCACCTCTTACGG
- 45 GCGTAAAACCGCTATCATATAGTAAGATAGATACATCTCCGCTTGTTCAAGAAATGGTTAAAGAAACGAAACA ACTATTAGAAGCTTCAGCAAGATTAGCTGCTGAAAATACAAGTCTTGTAGCAGAAGCGCTTGTTGGCCAAACC TCTGAAATGGTAGCAAGTAATGCCATTGTGTCTAAAATCACATCTTCGATTACTCAGCCCTCATCTAAGACAT CTTATGGCTCAGGATCTTCTACAACGAGCAATCTCATTTCTGATGTGATGAAAGTACTCAAAGAGCTCTTAA AGCAGGAGTCGTCATGTTGGCAGCTGTCGGCCTCACAGGATTTAGGTTCCGTAAGGAATCTAAGTGA
- 50

1.2 Antigenic fragment Spy0269-1

> Spy0269-1 / SF370 (serotype 1); SEQ ID NO: 11

GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC 55 AAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAGCAAGATAATGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCCGAGCTCCAAGATTTAGTGGAACAAGTCAAAAGC

- 5 ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATTCCAGCA GATCGTAATCGCTTTGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC ACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCACCAGTTACTGTTACAGCAGGATCACAAGAATTTGC AAGATTACTTAGTACCAGCTATAAGAAAAACTCATGGTAATACAAGACCATCATTTGTCTACGGACAGCCAGGG

15 1.3 Homologous sequences of other S. pyogenes isolates and/or serotypes

> Spy0269-1 / Schmitz 2/14 (serotype 1); SEQ ID NO: 134 GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC AAGAGGCAAAGGCAACTATTGAGAGAGGCGAAAAAAACTCTCAGTCAAAAAGCAGAACTGACAGAGCTTGC AAGAGGCAAAGGCAACTATTGATGAGAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC

- 20 TACCGCTCTGACAAAAACTACTGCTGAAATCAACAACTTAAAAGAGCAGCAAGATAATGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCCGAGCTCCAAGATTTAGTGGAACAAGTCAAAACG TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG
- 25 CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCCAATACCAAGATATTCCAGCA
- AACTTTTTACGTGTAGATAAACGTAACCCTAATGCGCCTGTT

> Spy0269-1 / Schmitz 1/156 (serotype 4); SEQ ID NO: 135

- GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC 40 AAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAGAAAAAGCAGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGGAGCTCCAAGATTTAGTGGAACAAGTCAAAAG
- 45 TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA
- 50 AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATTCCAGCA GATCGTAATCGCTTTGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC ACATGATTAATAGTGTAAGGAGACAATTAGGTCTACCACCAGTTACTGTCACAGCAGGATCACAAGAATTTGC AAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTAATACAAGACCATCATTTGTCTACGGACAGCCAGGG GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA 55
- 55 TTCGAAATGATGATAACATGTACGAGAATATCGGTGCTTTTAACGATGCATACTGTGAATGGTATTAAACG TGGTATTTATGACAGTATCAAGTATATGCTCTTTACAGATCATTTACACGGAAATACATATGGTCATGCTATT AACTTTTTACGTGTAGATAAACATAACCCTAAGGCGCCTGTT

> Spy0269-1 / Schmitz 1/59 (serotype 12); SEQ ID NO: 136

60 GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC

AAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAAAGCTTGC TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAAGATAATGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC

- 5 ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCAAGATTTAGTGGAACAAGTCAAAACG TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCCACCGCAAGGCT
- 10 ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATTCCAGCA GATCGTAATCGCTTTGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC ACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCACCAGTTACTGTTACAGCAGGATCACAAGAATTTGC AAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTAATACAAGACCACATCATTGTCACGGACAGCCAGGG

- 20 > Spy0269-1 / Schmitz 1/177 (serotype 22); SEQ ID NO: 137 GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC AAGAGGCAAAGGCAACTATTGAAGCAGTTGAAAAAGCTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC TACCGCTCTGACAAAAACTACTGCTAAAATCAACCACTTAAAAGAGCAGCAAGATAATGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC
- 25 ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCAAGATTTAGTGGAACAAGTCAAAAGG TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGTAATCCTGATGCTATCACTAAAGCAGCTCAAACGG CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAAATCAAAAAGCTAA AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT
- 30 CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATTCCAGCA GATCGTAATCGCTTTGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGGTTTGCAGCTC ACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCACCAGTTACTGTCACAGCAGGATCACAAGAATTTGC
- 35 AAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTAATACAAGACCATCATTGTCTACGGACAGCCAGGG GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA TTCGAAATGATGATAACATGTACGAGAATATCGGTGCTTTTAACGATGTGCATACTGTGAATGGTATTAAACG TGGTATTTATGACAGTATCAAGTATATGCTCTTTACAGATCATTTACACGGAAATACATATGGCCATGCTATT AACTTTTTACGTGTAGATAAACGTAACCCTAATGCGCCTGTT
- 40
- > Spy0269-1 / Schmitz 1/43 (serotype 22); SEQ ID NO: 138 GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAAACCAGAAACAATTC AAGAGGCAAAGGCAACTATTGAAGCAGTTGAAAAAGCTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC TACCGCTCTGACAAAAAACTACTGCTAAAAACCACTTAAAAGAGCAGCAAGAAAAGCAGAAACAAAAAGCTTTA CACCGCTCTGACAAAAAACTACTGCTAAAAATCAACCACTTAAAAGAGCAGCAAGAATAATGAACAAAAAGCTTTA
- 45 ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCAAGATTTAGTGGAACAAGTCAAAACG TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGTAATCCTGATGCTATCACTAAAGCAGCTCAAACGG CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA
- 50 AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATTCCAGCA GATCGTAATCGCTTTGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC
- 55 ACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCACCAGTTACTGTCACAGCAGGATCACAAGAATTTGC AAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTAATACAAGACCATCATTGTCTACGGACAGCCAGGG GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA TTCGAAATGATGATAACATGTACGAGAATATCGGTGCTTTTAACGATGTGCATACTGTGAATGGTATTAAACG TGGTATTTATGACAGTATCAAGTATATGCTCTTTACAGATCATTTACACGGAAATACATATGGCCATGCTATT
 60 AACTTTTTAGACAGTATAAACCCTATATCCCCTGTT
- 60 AACTTTTTACGTGTAGATAAACGTAACCCTAATGCGCCTGTT

> Spy0269-1 / Schmitz 1/136 (serotype 25); SEQ ID NO: 139 GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC AAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC

- TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAAGATAATGAACAAAAAGCTTTA 5 ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCAAGATTTAGTGGAACAAGTCAAAACG TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG
- CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA 10 AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATTCCAGCA
- GATCGTAATCGCTTTGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC 15 ACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCACCAGTTACTGTTACAGCAGGATCACAAGAATTTGC AAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTAATACAAGACCATCATTTGTCTACGGACAGCCAGGG GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA TTCGAAATGATGATAACATGTACGAGAATATCGGTGCTTTTAACGATGTGCATACTGTGAATGGTATTAAACG 20
- AACTTTTTACGTGTAGATAAACGTAACCCTAATGCGCCTGTT

> Spy0269-1 / Schmitz 1/85 (serotype 28); SEQ ID NO: 140

- GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC AAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC 25 TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAAGATAATGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCAAGATTTAGTGGAACAAGTCAAAACG
- TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG 30 CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA
- 35 AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATtAAATCAATACCAAGatattccagca gatcqtaatcqctttGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC ACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCACCAGTTACTGTTACAGCAGGATCACaagaatttgc aagattacttagtaccagctataagaaaactcatggtaatacaagaccatcatttgtctACGGACAGCCAGGG GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA
- TTCGAAATGATGATAACATGTACGAGAATATCGGTGCTTTTAACGATGTGCATACTGTGAATGGTATTAAACG 40 AACTTTTTACGTGTAGATAAACATAACCCTAATGCGCCTGTT

> Spy0269-1 / Schmitz 2/50 (serotype 28); SEQ ID NO: 141

- GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC 45 AAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAAGATAATGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGTAGATCAACATTCAAAAGAGACTGC
- ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCAAGATTTAGTGGAACAAGTCAAAACG 50 TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT
- ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA 55 AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATtCCAGCA GATCGTAATCGCTTTGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC ACATGATTAATAGTGTAAGAAGAACAATTAGGTCTACCACCAGTTACTGTTACAGCAGGATCACAAGAATTTGC AAGATTACTTAGTACCAGCTATAAGAAGACTCATGGTAATACAAGACCATCATTTGTCTACGGACAGCCAGGG
- GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA 60

- 5 > Spy0269-1 / Schmitz 1/123 (serotype 49); SEQ ID NO: 142 GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC AAGAGGCAAAGGCAACTATTGATGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAAGATAATGAACAAAAAGCTTTA ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC
- 10 ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCAAGATTTAGTGGAACAAGTCAAAAGG TCTGAACAAAATATTGCTAAGCTCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT
- 15 CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATTAAATCAATACCAAGATATtCCAGCA GAtcgtaatcgctttGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC ACATGATTAATAGTGTAAGGAGACAATTAGGTCTACCACCAGTTACTGTTACAGCAGGATCACAAGAATTTGC
- 20 AAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTAATACAAGACCATCATTTGTCTACGGACAACCAGGG GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA TTCGAAATGATGATAACATGTACGAGAATATCGGTGCTTTTAACGATGTGCATACTGTGAATGGTATTAAACG TGGTATTTATGACAGTATCAAGTATATGCTCTTTACAGATCATTTACACGGAAATACATATGGCCATGCTATT AACTTTTTACGTGTAGATAAACGTAACCCTAATGCGCCTGTT
- 25

> Spy0269-1 / Schmitz 1/176 (serotype 83); SEQ ID NO: 143 GATGATAGAGCCTCAGGAGAAACGAAGGCGAGTAATACTCACGACGATAGTTTACCAAAACCAGAAACAATTC AAGAGGCAAAGGCAACTATTGAAGCAGTTGAAAAAACTCTCAGTCAACAAAAAGCAGAACTGACAGAGCTTGC TACCGCTCTGACAAAAACTACTGCTGAAATCAACCACTTAAAAGAGCAGCAAGATAACGAACAAAAAGCTTTA

- 30 ACCTCTGCACAAGAAATTTACACTAATACTCTTGCAAGTAGTGAGGAGACGCTATTAGCCCAAGGAGCCGAAC ATCAAAGAGAGTTAACAGCTACTGAAACAGAGCTTCATAATGCTCAAGCAGATCAACATTCAAAAGAGACTGC ATTGTCAGAACAAAAAGCTAGCATTTCAGCAGAAACTACTCGAGCTCCAAGATTTAGTGGAACAAGTCAAAACG TCTGAACAAAATATTGCTAAGCTCCAATGCTATGATTAGCAATCCTGATGCTATCACTAAAGCAGCTCAAACGG CTAATGATAATACAAAAGCATTAAGCTCAGAATTGGAGAAGGCTAAAGCTGACTTAGAAAATCAAAAAGCTAA
- 35 AGTTAAAAAGCAATTGACTGAAGAGTTGGCAGCTCAGAAAGCTGCTCTAGCAGAAAAAGAGGCAGAACTTAGT CGTCTTAAATCCTCAGCTCCGTCTACTCAAGATAGCATTGTGGGTAATAATACCATGAAAGCACCGCAAGGCT ATCCTCTTGAAGAACTTAAAAAATTAGAAGCTAGTGGTTATATTGGATCAGCTAGTTACAATAATTATTACAA AGAGCATGCAGATCAAATTATTGCCAAAGCTAGTCCAGGTAATCAATtAAATCAATACCAAGatATTCCAGCA GatcgtaatcgctttGTTGATCCCGATAATTTGACACCAGAAGTGCAAAATGAGCTAGCGCAGTTTGCAGCTC
- 40 ACATGATTAATAGTGTAAGAAGACAATTAGGTCTACCACCAGTTACTGTCACAGCAGGATCACAAGAATTTGC AAGATTACTTAGTACCAGCTATAAGAAAACTCATGGTAATACAAGACCATCATTGTCTACGGACAGCCAGGG GTATCAGGGCATTATGGTGTTGGGCCTCATGATAAAACTATTATTGAAGACTCTGCCGGAGCGTCAGGGCTCA TTCGAAATGATGATAACATGTACGAGAATATCGGTGCTTTTAACGATGTGCATACTGTGAATGGTATTAAACG TGGTATTTATGACAGTATCAAGTATATGCTCTTTACAGATCATTTACACGGAAATACATATGGCCATGCTATT
 45 AACTTTTTACGTGTAGATAAACGTAACCCTAATGCGCCTGTT
- 43 AACTTTTTACGIGIAGATAAACGIAACCCIAAIGCGC

2. Spy0292

2.1 Full length Spy0292

50

10 2.2 Antigenic fragment Spy0292-1

20

15

2.3 Homologous sequences of other S. pyogenes isolates and/or serotypes

> Spy0292-1 / Schmitz 1/39 (serotype 12); SEQ ID NO: 145

GCTAATACTTATCCTAATACAGAACCAGATGATGAAAATTGTTTTTGC

GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG
 25 ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC
 TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT
 ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAAAAAAA
 CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA
 ACAATTAAGACAATGGGGCATTTCCGATGCAAAGGTCGTCAATTCAACTGGCTTAACCAATTTTTAAGGA
 30 GCTAATACTTATCCTAATACAGAACCATGCGAACCAAATTGTTTTGC

> Spy0292-1 / Schmitz 1/55 (serotype 118); SEQ ID NO: 146 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC

- 40

> Spy0292-1 / Schmitz 1/56 (serotype 28); SEQ ID NO: 147 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGAACTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATACTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT

- 50 > Spy0292-1 / Schmitz 1/74 (serotype 3); SEQ ID NO: 148 GAAGAGTATTCGGTAACTGCTAAACATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAGGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG
- - > Spy0292-1 / Schmitz 1/76 (serotype 22); SEQ ID NO: 149
- 60 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG

> Spy0292-1 / Schmitz 1/92 (serotype 11); SEQ ID NO: 150

- - > Spy0292-1 / Schmitz 1/94 (serotype 1); SEQ ID NO: 151 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAAACCTATCTGGTTTACAAAGAAGTTTC
- 25

5

- > Spy0292-1 / Schmitz 1/142 (serotype 83); SEQ ID NO: 152 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAGGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT
- 35 > Spy0292-1 / Schmitz 1/144 (serotype 76); SEQ ID NO: 153 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCTGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG

```
> Spy0292-1 / Schmitz 1/194 (serotype 44); SEQ ID NO: 154
```

- 45 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCTGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG CCAATAGCCCCGCTATTGCTTTAGCTGGAAAAAATAGGCGGAACCGAACCCAAATTGTTGACAAAAATGAAAAA

2.4 Antigenic fragment Spy0292-3

- 55 > Spy0292-3 / SF370 (serotype 1); SEQ ID NO: 13 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAG ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG CCAATTGCCCCCCTTTTCCTCCAAAAATATACCGCCCAACCTCTTCAAGTGCGTTAGTTGTTAATAACG
- 60 CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA

2.5 Homologous sequences of other S. pyogenes isolates and/or serotypes

10

> Spy0292-3 / Schmitz 1/39 (serotype 12); SEQ ID NO: 155 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAAGTTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT

- 25 > Spy0292-3 / Schmitz 1/55 (serotype 118); SEQ ID NO: 156 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTTACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG

> Spy0292-3 / Schmitz 1/56 (serotype 28); SEQ ID NO: 157

- 40 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATACTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAA

> Spy0292-3 / Schmitz 1/74 (serotype 3); SEQ ID NO: 158

GGCATCTCTTATTAGAATTTCCAGAAGTACTGAAATTATCTAGCAAATCCTCCACTATTTTTGCTGGACAAAC CATTTACAGTTATAATTACATGCTTAAAGGCATGCCTTGTTATCGAGAAGGCGTGGATGGTCTTTTTGTTGGT TATTCTAAAAAAGCCGGTGCTTCTTTTGTAGCTACTAGTGTCGAAAATCAAATGAGGGTTATTACAGTAGTTT AATTAATTTTCAAAAAGTCCAGTTAATTGAA

5

> Spy0292-3 / Schmitz 1/76 (serotype 22); SEQ ID NO: 159 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCTGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC

- TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT 10 ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA GCTAATACTTATCCTAATACAGAAccagATGATGAAAATTGTTTTTGCGCCACTGATTTAGCTATTATTGCCA
- GGCATCTCTTATTAGAATTTCCAGAAGTACTGAAATTATCTAGCAAATCCTCCACTATTTTTGATGGACAAAC 15 CATTTACAGTTATAATTACATGCTTAAAGGCATGCCTTGTTATCGAGAAGGCGTGGATGGTCTTTTTGTTGGT TATTCTAAAAAAGCCGGTGCTTCTTTTGTAGCTACTAGTGTCGAAAATCAAATGAGGGTTATTACAGTAGTTT AATTAATTTTCAAAAAGTCCAGTTAATTGAA 20
 - > Spy0292-3 / Schmitz 1/92 (serotype 11); SEQ ID NO: 160 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT
- ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG 25 CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA GCTAATACTTATCCTAATACAGAACCAGATGATGaaaATTGTTTTTGCGCCACTGATTTAGCTATTATTGCCA GGCATCTCTTATTAGAATTTCCAGAAGTACTGAAATTATCTAGCAAATCCTCCACTATTTTTGATGGACAAAC
- CATTTACAGTTATAATTACATGCTTAAAGGCATGCCTTGTTATCGAGAAGGCGTGGATGGTCTTTTTATTGGT 30 TATTCTAAAAAAGCCGGTGCTTCTTTTGTAGCTACTAGTGTCGAAAATCAAATGAGGGTTATTACAGTAGTTT AATTAATTTTCAAAAAGTCCAGTTAATTGAA
- > Spy0292-3 / Schmitz 1/94 (serotype 1); SEQ ID NO: 161 35 GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG
- CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA 40 GCTAATACTTATCCTAATACAGAACCAGATGATGAAAATTGTTTTGCGCCACTGATTTAGCTATTATTGCCA GGCATCTCTTATTAGAATTTCCAGAAGTACTGAAATTATCTAGCAAATCCTCCACTATTTTTGCTGGACAAAC CATTTACAGTTATAATTACATGCTTAAAGGCATGCCTTGTTATCGAGAAGGCGTGGATGGTCTTTTTGTTGGT
- TATTCTAAAAAAGCCGGTGCTTCTTTTGTAGCTACTAGTGTCGAAAATCAAATGAGGGTTATTACAGTAGTTT 45 AATTAATTTTCAAAAAGTCCAGTTAATTGAA

> Spy0292-3 / Schmitz 1/142 (serotype 83); SEQ ID NO: 162

- GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG 50 ATGCTAAAGAGGTTGTCCCAGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA
- 55 GCTAATACTTATCCTAATACAGAAccagaTGATGAAAATTGTTTTTGCGCCACTGATTTAGCTATTATTGCCA GGCATCTCTTATTAGAATTTCCAGAAGTACTGAAATTATCTAGCAAATCCTCCACTATTTTTGATGGACAAAC CATTTACAGTTATAATTACATGCTTAAAGGCATGCCTTGTTATCGAGAAGGCGTGGATGGTCTTTTTGTTGGT TATTCTAAAAAAGCCGGTGCTTCTTTTGTAGCTACTAGTGTCGAAAATCAAATGAGGGTTATTACAGTAGTTT 60

AATTAATTTTCAAAAAGTCCAGTTAATTGAA

> Spy0292-3 / Schmitz 1/144 (serotype 76); SEQ ID NO: 163

GAAGAGTATTCGGTAACTGCTAAGCATGCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCTGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC 5 TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA GCTAATACTTATCCTAATACAGAaccagaTGATGAAAATTGTTTTTGCGCCACTGATTTAGCTATTATTGCCA

- 10 GGCATCTCTTATTAGAATTTCCAGAAGTACTGAAATTATCTAGCAAATCCTCCACTATTTTTGATGGACAAAC CATTTACAGTTATAATTACATGCTTAAAGGCATGCCTTGTTATCGAGAAGGCGTGGATGGTCTTTTTGTTGGT TATTCTAAAAAAGCCGGTGCTTCTTTTGTAGCTACTAGTGTCGAAAATCAAATGAGGGTTATTACAGTAGTTA 15 AATTAATTTTCAAAAAGTCCAGTTAATTGAA
 - > Spy0292-3 / Schmitz 1/194 (serotype 44); SEQ ID NO: 164 GAAGAGTATTCGGTAACTGCTAAGCATGCCGATTGCCGTTGACCTTGAAAGTGGCAAAGTTTTATACGAAAAAG ATGCTAAAGAAGTTGTCCCTGTCGCCTCAGTCAGTAAGCTCTTGACAACCTATCTGGTTTACAAAGAAGTTTC
- TAAGGGCAAGCTAAATTGGGATAGTCCTGTAACTATTTCTAACTACCCTTATGAACTCACTACAAACTATACT 20 ATTAGTAACGTTCCTCTTGATAAGAGAAAATATACCGTTAAAGAACTTTTAAGTGCGTTAGTTGTTAATAACG CCAATAGCCCCGCTATTGCTTTAGCTGAAAAAATAGGCGGAACCGAACCCAAATTTGTTGACAAAATGAAAAA
- GCTAATACTTATCCTAATACAGAACCAGATGATGAAAATTGTTTTTGCGCCACTGATTTAGCTATTATTGCCA GGCATCTCTTATTAGAATTTCCAGAAGTACTGAAATTATCTAGCAAATCCTCCACTATTTTTGCTGGACAAAC 25 CATTTACAGTTATAATTACATGCTTAAAGGCATGCCTTGTTATCGAGAAGGCGTGGATGGTCTTTTTGTTGGT TATTCTAAAAAAGCCGGTGCTTCTTTTGTAGCTACTAGTGTCGAAAATCAAATGAGGGTTATTACAGTAGTTT AATTAATTTTCAAAAAGTCCAGTTAATTGAA
- 30

з. Spy0416A

3.1 Full length Spy0416A

- 35 > Spy0416A / SF370 (serotype 1); SEQ ID NO: 165 GCAGATGAGCTAAGCACAATGAGCGAACCAACAATCACGAATCACGCTCAACAACAAGCGCAACATCTCACCA ATACAGAGTTGAGCTCAGCTGAATCAAAATCTCAAGACACATCACAAATCACTCTCAAGACAAATCGTGAAAA AATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACCGCCAGTCAATACAGATGTTCACGATTGGGTAA
- AAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGCAAGGTTGTCGCAGTTATTGACACAGGGATCGA 40 TCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAAAATCAAAAGAAGAAGACATGCTAGCA CGCCAAAAAGCCGCCGGTATTAATTATGGGAGTTGGATAAATGATAAAGTTGTTTTTGCACATAATTATGTGG AAAATAGCGATAATATCAAAGAAAAATCAATTCGAGGATTTTGATGAGGACTGGGAAAACTTTGAGTTTGATGC
- GTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGACGATGACACCAAATACG 45 AGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTT TTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACATCATGGGATCAGCTGAA TCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCG CTAATGGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATC
- AGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATGATCCATTGGCGACAAATCCAGAC 50 TATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA TTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTATTCAGA GTCTGTCGACTTTAAAGACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAAAGAG TCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAAAATTGCTTTAATTGAACGTGATCCCAATAAAA
- CCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCTCTGGGAGTACTTATTTTAATAACAAGCCTGG 55 TCAATCAAACCGCTCAATGCGTCTAACAGCTAATGGGATGGGGATACCATCTGCTTTCATATCGCACGAATTT GGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGTTTAGAGTTTGACAGTGTGGTCTCAAAAGCAC CGAGTCAAAAAGGCAATGAATGAATCATTTTTCAAATTGGGGCCTAACTTCTGATGGCTATTTAAAACCTGA CATTACTGCACCAGGTGGCGATATCTATTCTACCTATAACGATAACCACTATGGTAGCCAAACAGGAACAAGT
- ATGGCCTCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATACCTAGAAAAGACTCAGCCAAACTTGC 60

CAAAAGAAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC AAAAACGACCACCTCACCGCGTCAGCAAGGGGCAGGATTACTTAATATTGACGGAGCTGTCACTAGCGGCCTT TATGTGACAGGAAAAGACAACTATGGCAGTATATCATTAGGCAACATCACAGATACGATGACGTTTGATGTGA CTGTTCACAACCTAAGCAATAAAGACAAAACATTACGTTATGACACAGAATTGCTAACAGATCATGTAGACCC ACAAAAGGGCCGCTTCACTTTGACTTCTCACTCCTTAAAAACGTACCAAGGAGGAGAAGTTACAGTCCCAGCC

- 5 AATGGAAAAGTGACTGTAAGGGTTACCATGGATGTCTCACAGTTCACAAAAGAGCTAACAAAACAGATGCCAA ATGGTTACTATCTAGAAGGTTTTGTCCGCTTTAGAGATAGTCAAGATGACCAACTAAATAGAGTAAACATTCC TTTTGTTGGTTTTAAAGGGCAATTTGAAAACTTAGCAGTTGCAGAAGAGTCCATTTACAGATTAAAATCTCAA GGCAAAACTGGTTTTTACTTTGATGAATCAGGTCCAAAAGACGATATCTATGTCGGTAAACACTTTACAGGAC TTGTCACTCTTGGTTCAGAG 10

Antigenic fragment Spy0416A-1 3.2

> Spy0416A-1 / SF370 (serotype 1); SEQ ID NO: 14

- GCAGATGAGCTAAGCACAATGAGCGAACCAACAATCACGAATCACGCTCAACAACAAGCGCAACATCTCACCA 15 ATACAGAGTTGAGCTCAGCTGAATCAAAATCTCAAGACACATCACAAATCACTCTCAAGACAAATCGTGAAAA AATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACCGCCAGTCAATACAGATGTTCACGATTGGGTAA AAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGCAAGGTTGTCGCAGTTATTGACACAGGGATCGA TCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAAAATCAAAAGAAGAAGACATGCTAGCA
- 20 CGCCAAAAAGCCGCCGGTATTAATTATGGGAGTTGGATAAATGATAAAGTTGTTTTTGCACATAATTATGTGG AAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTTGATGAGGACTGGGAAAACTTTGAGTTTGATGC GTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGACGATGACACCAAATACG
- AGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTT 25 TTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACATCATGGGATCAGCTGAA TCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCG CTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAAGCTAAAAAAGCCGGTGTATC AGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATCATTGGCGACAAATCCAGAC
- TATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA 30 TTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTATTCAGA GTCTGTCGACTTTAAAGACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAAAGAG TCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAÀAATTGCTTTAATTGAACGTGATCCCAATAAAA CCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCTCTGGGAGTACTTATTTTTAATAACAAGCCTGG
- TCAATCAAACCGCTCAATGCGTCTAACAGCTAATGGGATGGGGATACCATCTGCTTTCATATCGCACGAATTT 35 GGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGTTTAGAGTTTGACAGTGTGGTCTCAAAAGCAC CGAGTCAAAAAGGCAATGAAATGAATCATTTTTCAAATTGGGGCCTAACTTCTGATGGCTATTTAAAACCTGA CATTACTGCACCAGGTGGCGATATCTATTCTACCTATAACGATAACCACTATGGTAGCCAAACAGGAACAAGT ATGGCCTCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATACCTAGAAAAGACTCAGCCAAACTTGC
- CAAAAGAAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC 40 AAAAACGACCACCTCACCGCGTCAGCAAGGGGGCA

Homologous sequences of other S. pyogenes isolates and/or serotypes 3.3

- > Spy0416A-1 / Schmitz 1/7 (serotype 4); SEQ ID NO: 166 45 GCAGATGAGCTAACCACAACGAGTGAACCAACAATCACGAATCACGCTCAACAACAAGCGCAACATCTCACCA ATACAGAGTTGAGCTCAGCTGAATCACAATCCCCAGACACATCACAAATCACTCCCAAGACAAATCGTGAAAA AATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACCGCCAGTCAATACAGATGTTCACGATTGGGTAA
- AAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGCAAGGTTGTCGCAGTTATTGACACAGGGATCGA 50 TCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAAAATCAAAAGAAGAAGACATGCTAGCA CGCCAAAAAGCCGCCGGTATTAATTATGGGAGTTGGATAAATGATAAAGTTGTTTTTGCACATAATTATGTGG AAAATAGCGATAATATCAAAGAAAATCAATTCGGGGATTTTGATGAGGACTGGGAAAACTTTGAGTTTGATGC
- AAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGACGATGACACCAAATACGAGTCAC 55 ACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGG AATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACGTCATGGGATCAGCTGAATCACTC TTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATG GGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGT
- TGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATCATTGGCAACAAATCCAGACTATGGT 60

- - GACCACCTCACCGCGTCAGCAAGGGGCA

```
> Spy0416A-1 / Schmitz 1/39 (serotype 12); SEQ ID NO: 167
```

- 25 AGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTT TTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACGTCATGGGATCAGCTGAA TCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCG CTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATC AGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATCATTGGCAACAAATCCAGAC
- 30 TATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA TTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTaTTCAGA GTCTGTCGActttaaaGACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCaAAGAG TCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAAAATTGCTTTAATTGAACGTGATCCCAATAAAA CCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGAGTACTTATTTTTAATAACAAGCCTGG
- 40 CAAAAGAAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC AAAAACGACCACCTCACCGCGTCAGCAAGGGGCA

> Spy0416A-1 / Schmitz 1/55 (serotype 118); SEQ ID NO: 168

- 60 TTCAACGTCTAATGACGGTCAAAGAATTGGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTaTTCAGA

GTCTGTCGACTTTAAAGACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAaAGAG TCAACTGATGCGGGTTATAACGCACAAAACGTTAAAGGTAAAATTGCTTTAATTGAACGTGATCCCAATAAA CCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGAGTACTTATTTTTAATAACAAGCCTGG TCAATCAAACCGCTCAATGCGTCTAACAGGCTAATGGGATGGGGATACCATCTGCTTTCATATCGCACGAATTT GGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGTTTAGAGTTTGACAGTGTGGTCTCAAAAGCAC

> Spy0416A-1 / Schmitz 1/56 (serotype 28); SEQ ID NO: 169 GCAGATGAGCTAACCACAACGAGTGAACCAACAATCACGAATCACGCTCAACAAGCGCAACATCTCACCA ATACAGAGTTGAGCTCAGCTGAATCACAATCCCCCAGACACCATCACAAATCACTCCCCAAGATAAATCGTGAAAA

- 25 TTTATCAAAGCTATCGAAGATGCCGTGGCCTTAGGAGCAGATGTGATCAACCTGAGTCTTGGGACCGCTAATG GTGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGT TGTAGCAGGAGAAATGAGCGCGTCTATGGATCTGACCATGATGATCCATTGGCAACAAATCCAGACTATGGT TTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCCAGCTATAAACAGTAAGTGGGTGATTCAAC GTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTaTTCAGAGTCTGT

40

- 45 AATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACCGCCAGTCAATACAGATGTTCACGATTGGGTAA AAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGCAAGGTTGTCGCAGTTATTGACACAGGGATCGA TCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAAAATCAAAAGAAGACATGCTAGCA CGCCAAAAAGCCGCCGGTATTAATTATGGGAGTTGGATAAATGATAAAGTTGTTTTTGCACATAATTATGTGG AAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTTGATGAGGACTGGGAAAACTTGAGTTTGAGGTTGGAG
- 55 CTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATC AGTTGTTGTAGCAGCAGGAAATGAGCGCGCGTCTATGGATCTGACCATGATGATCCATTGGCGACAAATCCAGAC TATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA TTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTATTCAGA GTCTGTCGACTTTAAAGACATAAAAGATAGCTTAGGTAAATCGCATCAATTGCCTAATGTCCAAAGAG
- 60 TCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAAAATTGCTTTAATTGAACGTGATCCCAATAAAA

- 5 CATTACTGCACCAGGTGGCGATATCTATTCTACCTATAACGATAACCACTATGGTAGCCAAACAGGAACAAGT ATGGCCTCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATACCTAGAAAAGACTCAGCCAAACTTGC CAAAAGAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC AAAAACGACCACCTCACCGCGTCAGCAAGGGGCA

- 20 GTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGACGATGACACCAAATACG AGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTT TTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACGTCATGGGATCAGCTGAA TCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCG CTAATGGGGCACAGCTTAGTGGCAGCAGCACTCTAATGGAAGCAATTGAAAAAAGCTAAAAAAGCCGGTGTATC
- 25 AGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATGATCCATTGGCAACAAATCCAGAC TATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA TTCAACGTCTAATGACGGTCAAAGGATTAGAAAACCGTGCCGATTTAaACCATGGTAAAGCCATCTATTCAGA GTCTGTCGACTTTAAAGACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAAaGAG TCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAAAATTGCTTTAATTGAACGTGATCCCAATAAAA
- 35 ATGGCCTCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATACCTAGAAAAGACCCAGCCAAACTTGC CAAAAGAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC AAAAACAACCACCTCACCGCGTCAGCAAGGGGCA

> Spy0416A-1 / Schmitz 1/174 (serotype 6); SEQ ID NO: 172

- 50 AGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTT TTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACGTCATGGGATCAGCTGAA TCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCG CTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATC AGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATCATCGCAACAAATCCAGAC
- 55 TATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA TTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTaTTCAGA GTCTGTCGACTTTAAAaACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAAaGAG TCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAAAATTGCTTTAATTGAACGTGATCCCAATAAAA CCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGAGTACTTATTTTTAATAACAAACCTGG
 60 TCAATCAAACCGCTCAATGCGCCTAACATCTAATGGGATGGGAATACCATCTGCTTTCATATCGCACGACATTT

GGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGTTTAGAGTTTGACAGTGTGGTCTCAAAAGCAC CGAGTCAAAAAGGCAATGAAATGAATCATTTTTCAAATTGGGGCCTAACTTCTGATGGCTATTTAAAAACCTGA CATTACTGCACCAGGTGGCGATATCTACTCTACCTATAACGATAACCACTATGGTAGCCAAACAGGAACAAGT ATGGCCTCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATACCTAGAAAAGACTCAGCCAAACTTGC CAAAAGAAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC

5 AAAAACGACCACCTCACCGCGTCAGCAAGGGGCA

> Spy0416A-1 / Schmitz 1/176 (serotype 83); SEQ ID NO: 173

- GCAGATGAGCTAACCACAACGAGTGAACCAACAATCACGAATCACAACAACAAGCGCAACATCTCACCA ATACAGAGTTGAGCTCAGCTGAATCAAAACCTCAAGACACATCACAAATCACTCTCAAGACAAATCGTGAAAA 10 AATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACCGCCAGTCAATACAGATGTTCACGATTGGGTAA AAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGCAAGGTTGTCGCAGTTATTGACACAGGGATCGA TCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAAAATCAAAAGAAGAAGACATGCTAGCA
- CGCCAAAAAGCCGCCGGTATTAATTATGGGAGTTGGATAAATGATAAAGTTGTTTTTGCACATAATTATGTGG 15 AAAATAGCGATAATATCAAAGAAAAATCAATTCGAGGATTTTGATGAGGACTGGGAAAACTTTGAGTTTGATGC GTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGACGATGACACCAAATACG AGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTT
- TTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACGTCATGGGATCAGCTGAA 20 TCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCG CTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATC AGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATCCATTGGCAACAAATCCAGAC TATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA
- TTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTATTCAGA 25 GTCTGTCGACTTTAAAAAACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAAAGAG TCAACTGATGCGGGTTATAAAGCACAAGACGTTAAAGGTAAAATTGCTTTAATTGAACGTGATCCCAATAAAA CCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGAGTACTTATTTTTAATAACAAGCCTGG TCAATCAAACCGCTCAATGCGTCTAACAGCTAATGGGATGGGGATACCATCTGCTTTCATATCGCACGAATTT
- GGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGTTTAGAGTTTGACAGTGTGGTCTCAAAAGCAC 30 CGAGTCAAAAAGGCAATGAAATGAATCATTTTTCAAATTGGGGGCCTAACTTCTGATGGCTATTTAAAACCTGA CATTACTGCACCAGGTGGCGATATCTACTCTACCTATAACGATAACCACTATGGTAGCCAAACAGGAACAAGT ATGGCCTCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATACCTAGAAAAGACTCAGCCAAACTTGC CAAAAGAAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC AAAAACGACCACCTCACCGCGTCAGCAAGGGGGCA 35

> Spy0416A-1 / Schmitz 1/234 (serotype 44); SEQ ID NO: 174 GCAGATGAGCTAAGCACAATGAGTGAACCAACAATCACGAATCACGCTCAACAACAAGCGCAACATCTCACCA ATACAGAGTTGAGCTCAGCTGAATCAAAATCTCAAGACACATCACAAATCACTCCCAAGACAAATCGTGAAAA

- 40 AATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACCGCCAGTCAATACAGATGTTCACGATTGGGTAA AAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGCAAGGTTGTCGCAGTTATTGACACAGGGATCGA TCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAAAATCAAAAGAAGAAGACATGCTAGCA CGCCAAAAAGCCGCCGGTATTAATTATGGGAGTTGGATAAATGATAAAGTTGTTTTTGCACATAATTATGTGG
- AAAATAGCGATAATATCAAAGAAAAATCAATTCGAGGATTTTGATGAGGACTGGGAAAACTTTGAGTTTGATGC 45 GTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGACGATGACACCAAATACG AGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTT TTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACGTCATGGGATCAGCTGAA
- TCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCG 50 CTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATC AGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATGACCCATTGGCAACAAATCCAGAC TATGGTTTGGTTGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGA TTCAACGTCTAATGACGGTCAAAGAATTGGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTaTTCAGA
- GTCTGTCGACTTŁAAAGACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAAAGAG 55 TCAACTGATGCGGGTTATAAAGCACAAGACGTTAAAGATAAAATTGCTTTAATTGAACGTGATCCCAATAAAA CCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGGGGTACTTATTTTAATAACAAGCCTGG TCAATCAAACCGCTCAATGCGTCTAACAGCTAATGGGATGGGGATACCATCTGCTTTCATATCGCACGAATTT GGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGTTTAGAGTTTGACAGTGTGGTCTCAAAAGCAC
- CGAGTCAAAAAGGCAATGAAATGAATCATTTTTCAAATTGGGGGCCTAACTTCTGATGGCTATTTAAAACCTGA 60

CATTACTGCACCAGGCGGCGATATCTACTCTACCTATAACGATAACCACTATGGTAGCCAAACAGGAACAAGT ATGGCCTCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATATCTAGAAAAGACTCAGCCAAACTTGC CAAAAGAAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGAC AAAAACGACCACCTCACCGCGTCAGCAAGGGGGCA

5

> Spy0416A-1 / Schmitz 1/22 (serotype 4); SEQ ID NO: 175 GCAGATGAGCTAACCACAACGAGTGAACCAACAATCACGAATCACGCTCAACAACAAGCGCAACATCTCACCA ATACAGAGTTGAGCTCAGCTGAATCACAATCCCCAGACACATCACAAATCACTCCCAAGACAAATCGTGAAAA AATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACCGCCAGTCAATACAGATGTTCACGATTGGGTAA 10 AAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGCAAGGTTGTCGCAGTTATTGACACAGGGATCGA TCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAAAATCAAAAGAAGAAGACATGCTAGCA CGCCAAAAAGCCGCCGGTATTAATTATGGGAGTTGGATAAATGATAAAGTTGTTTTTGCACATAATTATGTGG AAAATAGCGATAATATCAAAGAAAATCAATTCGGGGATTTTGATGAGGACTGGGAAAACTTTGAGTTTGATGC 15 AAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGACGATGACACCAAATACGAGTCAC ACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGG AATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACGTCATGGGATCAGCTGAATCACTC TTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATG GGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGT 20 TGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATGATCCATTGGCAACAAATCCAGACTATGGT TTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTATAAACAGTAAGTGGGTGATTCAAC GTCTAATGACGGCCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGTAAAGCCATCTATTCAGAGTCTGT CGACTTTAAAGACATAAAAGATAGCCTAGGTTATGATAAATCGCATCAATTTGCTTATGTCAAAGAGTCAACT GATGCGGGTTATAAAGCACAAGACGTTAAAGATAAAATTGCTTTAATTGAACGTGATCCCAATAAAACCTATG 25 ACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGAGTACTTATTTTTAATAACAAGCCTGGTCAATC AAACCGCTCAATGCGTCTAACAGCTAATGGGATGGGGATACCATCTGCTTTCATATCGCACGAATTTGGTAAG GCCATGTCCCAATTAAATGGCAATGGTACAGGAAGTTTAGAGTTTGACAGTGTGGTCTCAAAAGCACCGAGTC AAAAAGGCAATGAAATGAATCATTTTTCAAATTGGGGGCCTAACTTCTGATGGCTATTTAAAACCTGACATTAC TGCACCAGGTGGCGATATCTACTCTACCTATAACGATAACCACTATGGTAGCCAAACAGGAACAAGTATGGCC

30 TCTCCTCAGATTGCTGGCGCCAGCCTTTTGGTCAAACAATACCTAGAAAAGACTCAGCCAAACTTGCCAAAAG AAAAAATTGCTGATATCGTTAAGAACCTATTGATGAGCAATGCTCAAATTCATGTTAATCCAGAGACAAAAAC GACCACCTCACCGCGTCAGCAAGGGGGCA

35 3.4 Antigenic fragment Spy0416A-6

> Spy0416A-6 / SF370 (serotype 1); SEQ ID NO: 15 GCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAA

- TGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTTGATGAGGAC 40 TGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATCGTCCCCAAT CAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACA AACAGACGATGACACCAAAATACGAGTCACAGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAA GCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA
- ACGACATCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGT 45 GATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAA AAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATG ATCCATTGGCGACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGC AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAAC
- CATGGTAAAGCCATCTATTCAGAGTCTGTCGACTTTAAAGACATAAAAGATAGCCTA 50

Homologous sequences of other S. pyogenes isolates and/or serotypes 3.5

> Spv0416A-6 / Schmitz 1/7 (serotype 4); SEQ ID NO: 176

GCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAA 55 TGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGGGGGATTTTGATGAGGAC AGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGA CGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCT 60

GCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACG TCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAA CCTGAGTCTTGGAACCGCTAATGGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCT AAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATGATCCAT

TGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTAT 5 AAACAGTAAGTGGGTGATTCAACGTCTAATGACGGCCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGT AAAGCCATCTATTCAGAGTCTGTCGActttaaagacataaaagatagccta

> Spy0416A-6 / Schmitz 1/39 (serotype 12); SEQ ID NO: 177

- GCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAA 10 TGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTTGATGAGGAC TGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATCGTCCCCAAT CAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACA
- AACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAA 15 GCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA ACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGT GATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAA AAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATG
- ATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGC 20 AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAAC CATGGTAAAGCCATCTaTTCAGAGTCTGTCGActttaaaGACATAAAAGATAGCCTA

> Spv0416A-6 / Schmitz 1/55 (serotype 118); SEQ ID NO: 178

- GCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAA 25 TGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTTGATGAGGAC TGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATCGTCCCCAAT CAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACA
- AACAGACGATGACACCAAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAA 30 GCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA ACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCCTTAGGAGCAGATGT GATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAA AAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATG
- 35 ATCCATTGGCGACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTAGC AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTGGAAAACCGTGCCGATTTAAAC CATGGTAAAGCCATCTaTTCAGAGTCTGTCGACTTTAAAGACATAAAAGATAGCCTA

> Spy0416A-6 / Schmitz 1/56 (serotype 28); SEQ ID NO: 179

- 40 GCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAA TGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTTGATGAGGAC TGGGAAAACTTTGAGTTTGATGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATCGTCCCCAATCAACCC AGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACAAACAGA
- 45 CGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGTAAAGAAGCCGCT GCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGACCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACG TCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCCTTAGGAGCAGATGTGATCAA CCTGAGTCTTGGGACCGCTAATGGTGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCT AAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATGATCCAT
- TGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTAT 50 AAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGT AAAGCCATCTaTTCAGAGTCTGTCGACTTtAAAGACATAAAAGATAGCCTA

> Spy0416A-6 / Schmitz 1/94 (serotype 1); SEQ ID NO: 180

- GCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTGCTAAAGTAA 55 TGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTTGATGAGGAC TGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATCGTCCCCAAT CAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGACACA AACAGACGATGACACCAAATACGAGTCACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAA 60

GCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA ACGACATCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGT GATCAACCTGAGTCTTGGAACCGCTAATGGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAA AAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATG

5 ATCCATTGGCGACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGC AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAAC CATGGTAAAGCCATCTATTCAGAGTCTGTCGACTttAAAGACATAAAAGATAGCCTA

> Spy0416A-6 / Schmitz 1/253 (serotype 49); SEQ ID NO: 181

- 15 AACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCĊGGTAATAGCAAAGAA GCCGCTGCTACTGGAGAACGCTTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA ACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGT GATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAA AAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGAATCTGACCATGATG
- 20 ATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGC AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGGATTAGAAAACCGTGCCGATTTAAAC CATGGTAAAGCCATCTATTCAGAGTCTGTCGACTTTAAAGACATAAAAGATAGCCTA

> Spy0416A-6 / Schmitz 1/174 (serotype 6); SEQ ID NO: 182

- **30** AACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAA GCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA ACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGT GATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAAATTGAA AAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATG
- 35 ATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCCTCAACAGGTCGAACACCAACATCAGTGGC AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAAAC CATGGTAAAGCCATCTaTTCAGAGTCTGTCGACTTTAAAaACATAAAAGATAGCCTA

> Spy0416A-6 / Schmitz 1/176 (serotype 83); SEQ ID NO: 183

- 45 AACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAA GCCGCTGCTACTGGAGAACGCTTTTTTAGGAATTGCACCAGAGGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA ACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGT GATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAA AAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATGATG
- 50 ATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGC AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTAAAAC CATGGTAAAGCCATCTATTCAGAGTCTGTCGACTTTAAAAAACATAAAAGATAGCCTA

> Spy0416A-6 / Schmitz 1/234 (serotype 44); SEQ ID NO: 184

GCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTGCCA ACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGT GATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAGCCTCTAATGGAAGCAATTGAA AAAGCTAAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGCTCTAATGGAACCATGATG

5 ACCCATTGGCAACAAATCCAGACTATGGTTTGGTTGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGC AGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTGGAAAACCGTGCCGATTTAAAC CATGGTAAAGCCATCTaTTCAGAGTCTGTCGACTTtAAAGACATAAAAGATAGCCTA

> Spy0416A-6 / Schmitz 1/22 (serotype 4); SEQ ID NO: 185

- 15 CGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAAGAAGCCGCT GCTACTGGAGAACGCTTTTTTAGGAATTGCACCAGAGGGCCCAAGTCATGTTCATGCGTGTTTTTGCCAACGACG TCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGATGTGATCAA CCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATTGAAAAAGCT AAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTAGTGATCAT
- 20 TGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGTGGCAGCTAT AAACAGTAAGTGGGTGATTCAACGTCTAATGACGGCCAAAGAATTAGAAAACCGTGCCGATTTAAACCATGGT AAAGCCATCTATTCAGAGTCTGTCGACTTTAAAGACATAAAAGATAGCCTA

3.6 Antigenic fragment Spy0416A-7

25

> Spy0416A-7 / SF370 (serotype 1); SEQ ID NO: 16 TCACAAATCACTCTCAAGACAAATCGTGAAAAAGAGCAATCACAAGATCTAGTCTCTGAGCCAACCACAACTG AGCTAGCTGACACAGATGCAGCATCAATGGCTAATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC >> common concert a man and concert a co

- 35 CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG TTTTTGCCAACGACATCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGG AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAGCACGCCTCTAATGGAA GCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCT

- 50

3.7 Homologous sequences of other S. pyogenes isolates and/or serotypes

- > Spy0416A-7 / Schmitz 1/7 (serotype 4); SEQ ID NO: 186 TCACAAATCACTCCCAAGACAAATCGTGAAAAAGAGCAACCACAAGGTCTAGTCTCTGAGCCAACCACAACTG AGCTAGCTGACACAGATGCAGCATCAATGGCTAATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC

.

GAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTG CCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGA TGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATT GAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATG ATGATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGT 5 GGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGCCAAAGAATTAGAAAACCGTGCCGATTTA AACCATGGTAAAGCCATCTATTCAGAGTCTGTCGActttaaagacataaaagatagcctaggttatgataaAT CGCATCAATTTGCTTATGTCAAaGAGTCAACTGATGCGGGTTATAAAGCACAAGACGTTAAAGATAAAATTGC TTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGA GTACTTATTTTTAATAACAAGCCTGGTCAATCAAACCGCTCAATGCGTCTAACAGCTAATGGGATGGGGATAC 10 CATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGT > Spy0416A-7 / Schmitz 1/39 (serotype 12); SEQ ID NO: 187 TCACAAATCACTCTCAAGACAAATCGTGAAAAAGAGCAACCACAAGGTCTAGTCTCTGAGCCAACCACAACTG AGCTAGCTGACACAGATGCAGCACCAATGGCTAATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACC 15 GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTT GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAACACAAGATCTATC 20 GTCCCCAATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGA CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG TTTTTGCCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGG AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAA 25 GCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTG ACCATGATGATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAAC ATCAGTGGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCC GATTTAAACCATGGTAAAGCCATCTaTTCAGAGTCTGTCGActttaaaGACATAAAAGATAGCCTAGGTTATG ATAAATCGCATCAATTTGCTTATGTCaAAGAGTCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAA 30 AATTGCTTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCC GGATACCATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAG 35 > Spy0416A-7 / Schmitz 1/55 (serotype 118); SEQ ID NO: 188 TCACAAGTAACTCCAGAGACAAATCGTGAAAAAGAGCAACCACAAGGTCTAGTCTCTGAGCCAACAACAACTG AGCTAGCTGACACAGATGCAGCACCAATGGCTAATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG 40 TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAAATCAATTCGAGGATTTT GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATC GTCCCCAATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGA CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT 45 AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG TTTTTGCCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCCTTAGG AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAA GCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTG ACCATGATGATCCATTGGCGACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAAC 50 ATCAGTAGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTGGAAAACCGTGCC

> Spy0416A-7 / Schmitz 1/56 (serotype 28); SEQ ID NO: 189

60 TCACAAATCACTCCCAAGATAAATCGTGAAAAAGAGCAACCACAAGGTCTAGTCTCTGAGCCAACCACAACTG

AGCTAGCTGACACAGATGCAGCACCAATGGCTAATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGGTACAAAGGACAAGGT AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTT 5 GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATCGTCCCC AATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGAC ACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGTAAA GAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGACCCAAGTCATGTTCATGCGTGTTTTTG CCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCCTTAGGAGCAGA 10 TGTGATCAACCTGAGTCTTGGGACCGCTAATGGTGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATT GAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATG ATGATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGT GGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCCGATTTA AACCATGGTAAAGCCATCTaTTCAGAGTCTGTCGACTTLAAAGACATAAAAGATAGCCTAGGTTATGATAAAT

15 CGCATCAATTTGCTTATGTCAAAGAGTCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAAAATTGC TTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGA GTACTTATTTTTAATAACAAGCCTGGTCAATCAAACCGCTCAATGCGCCTAACAGCTAATGGGATGGGGATAC CATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGT 20

> Spy0416A-7 / Schmitz 1/94 (serotype 1); SEQ ID NO: 190 TCACAAATCACTCTCAAGACAAATCGTGAAAAAGAGCAATCACAAGATCTAGTCTCTGAGCCAACCACAACTG AGCTAGCTGACACAGATGCAGCATCAATGGCTAATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC

- AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG 25 TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTT GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATC GTCCCCAATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGA
- CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT 30 AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG TTTTTGCCAACGACATCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGG AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAA GCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTG
- ACCATGATGATCCATTGGCGACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAAC 35 ATCAGTGGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCC GATTTAAACCATGGTAAAGCCATCTATTCAGAGTCTGTCGACTttAAAGACATAAAAGATAGCCTAGGTTATG ATAAATCGCATCAATTTGCTTATGTCaAAGAGTCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAA AATTGCTTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCT
- 40 GGATACCATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAG т

> Spy0416A-7 / Schmitz 1/253 (serotype 49); SEQ ID NO: 191

- TCACAAGTAACTCCAGAGACAAATCGTGAAAAAGAGCAACCACAAGGTCTAGTCTCTGAGCCAACAACAACTG 45 AGCTAGCTGACACAGATGCAGCACCAATGGCTAATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG
- TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTT 50 GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGATGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATC GTCCCCAATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGA CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG
- TTTTTGCCAACGACGTCATGGGATÇAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGG 55 AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAA GCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTG ACCATGATGATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAAC ATCAGTGGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGGATTAGAAAACCGTGCC GATTTAaACCATGGTAAAGCCATCTATTCAGAGTCTGTCGACTTTAAAGACATAAAAGATAGCCTAGGTTATG 60

ATAAATCGCATCAATTTGCTTATGTCAAaGAGTCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAA AATTGCTTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCC GGATACCATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAG Т

5

10

> Spy0416A-7 / Schmitz 1/174 (serotype 6); SEQ ID NO: 192 TCACAAATCACTCCCAAGACAAATCGTGAAAAAGAGCAATCACAAGATCTAGTCTCTGAGCCAACCACAACTG AGCTAGCTGACACAGATGCAGCATCAATGGCTAATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTT

- GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATC GTCCCCAATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGA 15 CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG TTTTTGCCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGG AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAA
- GCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTG 20 ACCATGATGATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAAC ATCAGTGGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCC GATTTAAACCATGGTAAAGCCATCTaTTCAGAGTCTGTCGACTTTAAAaACATAAAAGATAGCCTAGGTTATG ATAAATCGCATCAATTTGCTTATGTCAAaGAGTCAACTGATGCGGGTTATAACGCACAAGACGTTAAAGGTAA

AATTGCTTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCC 25 GAATACCATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAG Т

- > Spy0416A-7 / Schmitz 1/176 (serotype 83); SEQ ID NO: 193 30 TCACAAATCACTCTCAAGACAAATCGTGAAAAAGAGCAACCACAAGGTCTAGTCTCTGAGCCAACCACAACTG AGCTAGCTGACACAGATGCAGCACCAATGGCTAATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG
- 35 TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTT GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGAGGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATC GTCCCCAATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGA CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT
- AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG 40 TTTTTGCCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGG AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAA GCAATTGAAAAAGCCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGGAAATGAGCGCGTCTATGGATCTG ACCATGATGATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAAC
- ATCAGTGGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTAGAAAACCGTGCC 45 GATTTAAACCATGGTAAAGCCATCTATTCAGAGTCTGTCGACTTTAAAAACATAAAAGATAGCCTAGGTTATG ATAAATCGCATCAATTTGCTTATGTCAAAGAGTCAACTGATGCGGGTTATAAAGCACAAGACGTTAAAGGTAA AATTGCTTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCC CTGGGAGTACTTATTTTAATAACAAGCCTGGTCAATCAAACCGCTCAATGCGTCTAACAGCTAATGGGATGG
- GGATACCATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAG 50 Т

> Spy0416A-7 / Schmitz 1/234 (serotype 44); SEQ ID NO: 194

- TCACAAATCACTCCCAAGACAAATCGTGAAAAAGAGCAATCACAAGATCTAGTCTCTGAGCCAACAACAACTG AGCTAGCTGACACAGATGCAGCATCAATGGCTAATACAGGTTCTGATGCGACTCAAAAAAGCGCTTCTTTACC 55 GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGAGGATTTT
- GATGAGGACTGGGAAAACTTTGAGTTTGATGCAGATGCAGAGCCAAAAGCCATCAAAAAACACAAGATCTATC 60

GTCCCCAATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGA CTGGACACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAAT AGCAAAGAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTG TTTTTGCCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGG AGCAGATGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAA 5 GCAATTGAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTG ATCAGTGGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGTCAAAGAATTGGAAAACCGTGCC GATTTAAACCATGGTAAAGCCATCTaTTCAGAGTCTGTCGACTTtAAAGACATAAAAGATAGCCTAGGTTATG ATAAATCGCATCAATTTGCTTATGTCAAAGAGTCAACTGATGCGGGTTATAAAGCACAAGACGTTAAAGATAA 10 AATTGCTTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCC GGATACCATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAG 15 > Spy0416A-7 / Schmitz 1/22 (serotype 4); SEQ ID NO: 195 TCACAAATCACTCCCAAGACAAATCGTGAAAAAGAGCAACCACAAGGTCTAGTCTCTGAGCCAACCACAACTG AGCTAGCTGACACAGATGCAGCATCAATGGCTAATACAGGTCCTGATGCGACTCAAAAAAGCGCTTCTTTACC GCCAGTCAATACAGATGTTCACGATTGGGTAAAAACCAAAGGAGCTTGGGACAAGGGATACAAAGGACAAGGC AAGGTTGTCGCAGTTATTGACACAGGGATCGATCCGGCCCATCAAAGCATGCGCATCAGTGATGTATCAACTG 20 TGATAAAGTTGTTTTTGCACATAATTATGTGGAAAATAGCGATAATATCAAAGAAAATCAATTCGGGGGATTTT

AATCAACCCAGGCACCGAAAGAAACTGTTATCAAAACAGAAGAAACAGATGGTTCACATGATATTGACTGGAC ACAAACAGACGATGACACCAAATACGAGTCACACGGTATGCATGTGACAGGTATTGTAGCCGGTAATAGCAAA 25 GAAGCCGCTGCTACTGGAGAACGCTTTTTAGGAATTGCACCAGAGGCCCAAGTCATGTTCATGCGTGTTTTTG CCAACGACGTCATGGGATCAGCTGAATCACTCTTTATCAAAGCTATCGAAGATGCCGTGGCTTTAGGAGCAGA TGTGATCAACCTGAGTCTTGGAACCGCTAATGGGGCACAGCTTAGTGGCAGCAAGCCTCTAATGGAAGCAATT GAAAAAGCTAAAAAAGCCGGTGTATCAGTTGTTGTAGCAGCAGGAAATGAGCGCGTCTATGGATCTGACCATG

30 ATGATCCATTGGCAACAAATCCAGACTATGGTTTGGTCGGTTCTCCCTCAACAGGTCGAACACCAACATCAGT GGCAGCTATAAACAGTAAGTGGGTGATTCAACGTCTAATGACGGCCAAAGAATTAGAAAACCGTGCCGATTTA AACCATGGTAAAGCCATCTATTCAGAGTCTGTCGACTTTAAAGACATAAAGATAGCCTAGGTTATGATAAAT CGCATCAATTTGCTTATGTCAAAGAGTCAACTGATGCGGGTTATAAAGCACAAGACGTTAAAGATAAAATTGC TTTAATTGAACGTGATCCCAATAAAACCTATGACGAAATGATTGCTTTGGCTAAGAAACATGGAGCCCTGGGA

GTACTTATTTTAATAACAAGCCTGGTCAATCAAACCGCTCAATGCGTCTAACAGCTAATGGGATGGGGATAC 35 CATCTGCTTTCATATCGCACGAATTTGGTAAGGCCATGTCCCAATTAAATGGCAATGGTACAGGAAGT

4. Spy0872

45

40 4.1 Full length Spy0872

> Spy0872 / SF370 (serotype 1); SEQ ID NO: 196 GATCAAGTTGATGTGCAATTCCTTGGCGTCAATGATTTTCACGGCGCTCTTGATAATACCGGAACAGCTTACA CACCAAGTGGTAAAATACCAAATGCTGGGACGGCTGCTCAATTAGGTGCTTATATGGATGACGCTGAGÅTAGA CTTCAAGCAAGCAAATCAAGACGGAACAAGTATACGTGTTCAAGCTGGAGATATGGTCGGAGCCAGTCCTGCT AACTCTGCACTTTTACAAGATGAGCCTACTGTCAAAGTCTTTAACAAAATGAAATTTGAATATGGCACTCTTG

GTAATCATGAATTTGACGAAGGACTAGATGAATTTAACCGTATCATGACAGGTCAAGCGCCTGATCCTGAATC AACAATTAATGATATCACCAAACAATATGAGCACGAAGCTTCGCATCAAACCATCGTCATTGCTAATGTTATT GATAAAAAAACCAAGGATATCCCCTATGGTTGGAAACCTTATGCTATAAAAGACATAGCCATTAATGACAAAA

- TCGTTAAGATTGGCTTCATTGGTGTTGTGACTACAGAGATTCCAAATCTCGTTTTAAAGCAAAACTATGAACA 50 CTATCAATTTTTAGATGTAGCTGAAACCATTGCCAAATATGCTAAAGAACTACAAGAACAACATGTTCATGCT ATTGTGGTTTTAGCTCATGTTCCTGCAACAAGTAAAGATGGTGTTGTTGATCATGAAATGGCTACGGTTATGG AAAAAGTGAACCAAATCTATCCCGAACATAGCATTGATATTATTTTTGCAGGACATAATCATCAATACACTAA TGGAACTATCGGTAAAACACGTATCGTTCAAGCCCTCTCTCAAGGAAAAGCTTATGCAGATGTCCGTGGTACG
- CTAGATACTGATACCAATGATTTTATTAAAAACTCCATCAGCAAATGTTGTTGCTGTAGCACCAGGTATCAAAA 55 CAGAAAATTCAGATATCAAAGCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAAT CGGAACTGCAACTAATTCTTCAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTA GCAACAACGGCTCAGCTTACTATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTG GTATTCGAAGTGACCTAGTTGTCAAAAATGACCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATT TGGTAATATCCTTCAAGTCATTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAA 60

- GTGGTGGTGATGGCTTTTCAGCATTTAAAAAAGCTAAATTAATCGGAGCTATTAACACAGATACTGAAGCTTT 50 CATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTATAAAAGGGGGTTAAAAATTAT GTAACTTCAAACCTTGAAAGCTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTAGTAAGGTTTTTA GAAATCGTGATGGCAATATAGTGTCTAGTGAAATCATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA CAGCCTTGGCAAAAAAGAAACAACGACAAACAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA 55
- **GCTATAATAAATCATGCTAATGATATTGTTAAAaCAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT** CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGTAACAACGGCTCAGCTTAC TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT 45 GTCAAAAATGACCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAAACCAGACCTATTTTCTTCA AATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATACCCCCTTCAAGATAGTTAAG
- GTGGTGGTGATGGCTTTTCAGCATTTAAAAAAGCTAAATTAATCGGAGCTATTAACACAGATACTGAAGCTTT CATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTATAAAAGGGGTTAAAAATTAT GTAACTTCAAACCTTGAAAGTTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTATCATTAGTAAGG TTTTTAGAAATCGTGATGGCAATATAGTGTCTAGTGAAATCATTTCAGACCTTTTGACTTCTACTGAAAACAC TAATAACAGCTTTGGCAAAAAAGAGATAACAACAAAcaAAAATACTATCTCTAATTCCACTCTTCCAATAACA 40 > Spy0872-2 / Schmitz 1/39 (serotype 12); SEQ ID NO: 198
- > Spy0872-2 / Schmitz 1/7 (serotype 4); SEQ ID NO: 197 GCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGTAACAACGGCTCAGCTTAC 30 TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT GTCAAAAATGACCGGACCATCACCTGGGAAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAACCAGACCTATTTTCTTCA AATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATACCCCCTTCAAGATAGTTAAG 35
- 4.3
- CATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTATAAAAGGGGTTAAAAATTAT GTAACTTCAAACCTTGAAAGTTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTAGTAAGGTTTTTA GAAATCGTGATGGCAATACAGTGTCTAGTGAAGTCATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA CAGCCTTGGCAAAAAAGAAACAACAAACAAAAAAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA 25

Homologous sequences of other S. pyogenes isolates and/or serotypes

CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGCAACAACGGCTCAGCTTAC TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT 15 GTCAAAAATGACCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAACCAGACCTATTTTCTTCA AATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATACCCCCTTCAAGATAGTTAAG GTGGTGGTGATGGCTTTTCAGCATTTAAAAAAGCTAAATTAATCGGAGCTATTAACACAGATACTGAAGCTTT 20

GCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT

- Antigenic fragment Spy0872-2 10 4.2 > Spv0872-2 / SF370 (serotype 1); SEQ ID NO: 17
- CCCCCTTCAAGATAGTTAAGGTTTATAAAGACAATGGTGAAGAAATTAACTTAACAACTACTTACACCGTTGT TGTCAACGACTTTCTTTATGGTGGTGGTGGTGGTGGCTTTTCAGCATTTAAAAAAGCTAAATTAATCGGAGCTATT AACACAGATACTGAAGCTTTCATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTA TAAAAGGGGTTAAAAATTATGTAACTTCAAACCTTGAAAGTTCGACAAAAGTTAATAGTGCTGGTAAACACAG 5 TATCATTAGTAAGGTTTTTAGAAATCGTGATGGCAATACAGTGTCTAGTGAAGTCATTTCAGACCTTTTGACT CTCTTCCAATAACA

AACCAGACCTATTTTCTTCAAATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATA

TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAACCAGACCTATTTTCTTCA AATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATATCCCCCTTCAAGATAGTTAAG GTGGTGGTGATGGCTTTTCAGCATTTAAAAAAGCTAAATTAATCGGAGCTATTAATACAGATACTGAAGCTTT

- CATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTATAAAAGGGGTTAAAAATTAT 5 GTAACTTCAAACCTTGAAAGTTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTAGTAAGGTTTTTA GAAATCGTGATGGCAATATAGTGTCTAGTGAAGTCATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA CAGCCTTGGCAAAAAAGAAACAaCGACAAACAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA
- > Spy0872-2 / Schmitz 1/56 (serotype 28); SEQ ID NO: 200 10 GCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGTAACAACAGCTCAGCTTAC TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT GTCAAAAATGATCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA
- TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAAACCAGACCTATTTTCTTCA 15 AATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATACCCCCTTCAAGATAGTTAAG CATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTATAAAAGGGGGTTAAAAATTAT
- GTAACTTCAAACCTTGAAAGTTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTAGTAAGGTTTTTA 20 GAAATCGTGATGGCAATATAGTGTCTAGTGAGATCATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA CAGCCTTGGCAAAAAAGAAACAACAACAAAAAAAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA

> Spy0872-2 / Schmitz 1/94 (serotype 1); SEQ ID NO: 201

- GCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT 25 CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGCAACAACGGCTCAGCTTAC TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT GTCAAAAATGACCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAACCAGACCTATTTTCTTCA
- AATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATACCCCCTTCAAGATAGTTAAG 30 GTGGTGGTGATGGCTTTTCAGCATTTAAAAAAGCTAAATTAATCGGAGCTATTAACACAGATACTGAAGCTTT CATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTATAAAAGGGGGTTAAAAATTAT GTAACTTCAAACCTTGAAAGTTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTAGTAAGGTTTTTA GAAATCGTGATGGCAATACAGTGTCTAGTGAAGTCATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA 35
- CAGCCTTGGCAAAAAAGAAACAACAACAAACAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA

> Spv0872-2 / Schmitz 1/253 (serotype 49); SEQ ID NO: 202

- GCTATAATAAATCATGCTAATGATATTGTTAAAaCAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGTAACAACAGCTCAGCTTAC 40 TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT GTCAAAAATGATCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAACCAGACCTATTTTCTTCA AATGTCAGGTTTAACATTCACTTATACAGATAATGATCCTAAGAACTCTGATACCCCCTTCAAGATAGTTAAG
- 45 CATCACATATATCACAAATTTAGAAGCATCAGGTAAAACTGTTAATGCTACTATAAAAGGGGTTAAAAATTAT GTAACTTCAAACCTTGAAAGCTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTAGTAAGGTTTTTA GAAATCGTGATGGCAATATAGTGTCTAGTGAAATAATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA CAGCCTTGGCAAAAAAGAAACAACGACaAACAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA 50
- > Spy0872-2 / Schmitz 1/176 (serotype 83); SEQ ID NO: 203 GCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT
- CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCCCCTGTCGGTAACTTAGTAACAACGGCTCAGCTTAC TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT 55 GTCAAAAATGACCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAACCAGACCTATTTTCTTCA AATGTCAGGTTTAACATACACTTATACAGATAATGATCCTAAGAACTCTGATACCCCCTTCAAGATAGTTAAG 60
 - GTGGCGGTGATGGCTTTTCAGCATTTAAAAAAGCTAAATTAGTCGGAGCTATTAACACAGATACTGAAGCTTT

CATCACATATATCACAAATTTACAAGCATCAGGTAAAACTGTTAATGCTACTATCAAAGGGGTTAAAAATTAT GTAACTTCAAACCTTGAAAGATCAACAAAAATTAATAGTGCTGGCAAACACAGTATCATTAGTAAGGTTTTTA GAAATCGTGATGGCAATATAGTGTCTAGTGAAGTCATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA CAGCTTTGGCAAAaAAGAGACAACAACAAAAAAAATACTATCTCTAATTCCACTCTTCCAATAACA

- - CAGCCTTGGCAAAAAGAACaACGACAAACAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA
- 20 > Spy0872-2 / Schmitz 1/234 (serotype 44); SEQ ID NO: 205 GCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGTAACAACGGCTCAGCTTAC TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT GTCAAAAATGACCGGACCATCACCTGGGGAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA
- **30** GTAACTTCAAACCTTGAAAGCTCGACAAAAGTTAATAGTGCTGGTAAACACAGTATCATTAGTAAGGTTTTTA GAAATCGTGATGGCAATATAGTGTCTAGTGAAATCATTTCAGACCTTTTGACTTCTACTGAAAACACTAATAA CAGCCTTGGCAAAAAAGAAACAACGACaAACAAAAATACTATCTCTAGTTCCACTCTTCCAATAACA

> Spy0872-2 / Schmitz 1/22 (serotype 4); SEQ ID NO: 206

- 35 GCTATAATAAATCATGCTAATGATATTGTTAAAACAGTTACTGAACGAAAAATCGGAACTGCAACTAATTCTT CAACTATTTCTAAAACAGAAAATATTGATAAAGAATCTCCTGTCGGTAACTTAGTAACAACGGCTCAGCTTAC TATTGCTAAGAAAACTTTTCCAACTGTTGACTTTGCTATGACCAATAATGGTGGTATTCGAAGTGACCTAGTT GTCAAAAATGACCGGACCATCACCTGGGAAGCTGCACAGGCTGTACAACCATTTGGTAATATCCTTCAAGTCA TTCAAATGACTGGTCAACACATTTACGATGTCCTAAATCAGCAATACGATGAAAACCAGACCTATTTTCTTCA

5. Further Sequences

- 50 > Spy0488 / SF370 (serotype 1); SEQ ID NO: 18 TTGCGGCAGATTCAGTCCATTCGTCTGATAGACGTTTTGGAGTTGGCTTTTGGAGTTGGCTATAAGGAAGAAA CAACCTCTCAGTTTTCTTCGGATCAGCCCTCCCAAGTGGTTTTGTATCGAGGTGAGGCTAACACGGTTAGGTT TGCCTATACCAATCAGATGTCTCTGATGAAAGATATTCGCATTGCTTTGGATGGTTCTGATAAGTCTTTGACC GCTCAGATTGTTCCTGGTATGGGTCATGTTTATGAGGGCCTTTCAAACTTCTGCTAGAGGGATTTTTACGATGT
- 55 CAGGAGTTCCTGAAAGCACTGTTCCCGTTGCTAACCCTAATGTACAAACCAAATATATAAGGTATTTCAAAGT CATTGATGATATGCATAACACAATGTATAAAGGAACTGTTTTTCTTGTTCAACCGCAAGCTTGGAAATACACC ATGAAATCTGTTGATCAGTTACCAGTAGATGACTTGAACCATATTGGCGTTGCTGGTATTGAACGAATGACAA CTCTCATTAAAAATGCGGGGTGCCCTTTTAACCACAGGAGGTAGTGGGGCCTTTCCCAGACAATATTAAAGTATC TATTAATCCAAAAGGGGAGGCAGGCCACGATTACTTATGGGGACGGCTCTACGGATATTATTCCTCCAGCAGTT
- 60 TTATGGAAAAAAGGCTCCGTAAAAGAGCCTACTGAAGCCGATCAATCTGTCGGAACACCGACTCCTGGTATTC

CTGGTAAATTCAAACGAGACCAGAGCCTTAACGAGCATGAAGCTATGGTAAATGTCGAACCACTGTCTCATGT AGTAAAAGACAATATAAAGGTCATAGATGAAAAATCAACAGGGCGGTTTGAGCCTTTTAGACCTAATGAAGAT GAGAAGGAGAAGCCTGCCAGCGATGTTAAGGTAAGACCAGCAGAAGTTGGTAGCTGGCTAGAACCAGCGACAG CTCTTCCTAGTGTTGAAATGAGCGCTGAGGACAGGTTAAAAAGT

5

10

15

> Spy1536 / SF370 (serotype 1); SEQ ID NO: 207

- 20 ATTGAAATGCCTGGAGGCGCTTACGATATTCGGACTGTCTTACAAGTCAATGGCAAAGAAGAACAAACGAAAAG GAGCTTACCAGTTTGTTGCAGTGGGCATTAGTCGTGCCAGCCTCGCTCAGCTATTATATGCTTGGCTGACACC GTTTACTGAAATTAGTACAGCAGAAGATACAACAGGCGGATACAGCGATGCTGATTTCCTTCGAATTAATCAA TTTTACATGGAAACATCACAAAATGCAGCTATTTATCAAGCTTATCCTTAGCTGGAAAACCAGTTACATTAG ATTATAAAGGCGTATATGTTTTAGACGTAAACAACGAATCTACTTTTTAAAGGAACGCTACCTTAGCAGAAA
- **30** GTGGTGCAGGTCTTAAAGTAGTTGCAGCAGCTGAAGCTGGTGCAGATATATTTTTTGTTCCGAATAATCCTGT TGATAAGGAAATTAAAAAAGTTAATCCAAATGCTATAAGTAATTACGAAGAAGCCAAACGGGCAGCCAAACGA CTAAAGACCAAAATGAAGATTGTTCCTGTTACGACTGTTCAAGAGGCACTGGTTTATCTTCGCAAA
 - > Spy1666 / SF370 (serotype 1); SEQ ID NO: 208
- 35 ACAAAAGAATTTCATCACGTGACCGTACTCCTTCACGAAACAGTGGACATGCTTGACATAAAGCCTGATGGGA TTTATGTTGATGCGACGCTAGGTGGCTCAGGCCACTCAGCTTATTTGTTGTCCAAACTTGGTGAAGAAGGGCA CCTCTATTGTTTTGACCAAGACCAAAAGGCTATTGACAATGCACAAGTTACCCTCAAATCTTATATTGACAAA GGACAGGTAACTTTTATTAAAGATAATTTTAGACACCTCAAAGCACGTTTAACAGCGCTTGGAGTTGATGAAA TTGATGGTATCTTATATGACCTTGGTGTTTCCCAGCCCGCAATTGGATGAAAGAGAACGAGGGTTTTCTTATAA
- 40 ACAAGATGCTCCATTGGATATGCGCATGGATCGTCAGTCGCTCTTAACAGCTTACGAAGTGGTGAATACCTAT CCATTCAATGATTTGGTTAAGATTTTTTTTCAAATATGGTGAAGATAAATTCTCCAAGCAGATCGCTCGAAAAA TTGAACAAGCAAGAGCTATTAAGCCTATTGAGACAACAACAGAGTTGGCAGAATTGATTAAGGCAGCAAAGCC AGCTAAAGAGTTGAAGAAAAAAGGCCACCCTGCTAAACAGATTTTTCCAAGCTATTCGCATTGAAGTCAATGAT GAATTGGGAGCGGCCGATGAATCTATTCAGGACGCTATGGAATTATTAGCCCTTGATGGTCGTATCTCAGTTA
- 45 TTACCTTCCATTCTCTGGAAGATCGCCTAACCAAGCAGTTGTTTAAAGAAGCTAGTACGGTGGATGTGCCAAA AGGGCTTCCTCTAATTCCTGAAGATATGAAACCTAAGTTTGAACTTGTTTCACGTAAGCCGATCTTACCTAGT CATTCAGAGTTAACAGCTAATAAAAGGGCACACTCAGCCAAGCTACGTGTTGCCAAAAAAATTCGGAAA

> Spy1727 / SF370 (serotype 1); SEQ ID NO: 20

- 55 AAATGCACCCTTGCAAATTCAGCAAAATTCATACTTACAAGCTATCGTTAAAGAATTAAAACGGAGCTTACCA GAGTTCAAATCAGAAGTAGCAACGATTGTGCATGGAGATATTAAACATAGCAATTGGGTGATTACTACTAGTG GTATGATTTTTTTAGTAGATTGGGATTCTGTTCGTCTAACTGATCGGATGTATGATGTTGCTTACCTGTTGAG CCACTATATTCCACGGTCTCGTTGGTCAGAATGGCTGTCTTATTATGGCTATAAAATAATGACAAGGTTATG CAAAAAATTATTTGGTATGGTCAAATTTTCCACCTGACACAAATTCTCAAGTGTTTTGACAAGCGTGACATGG
- 60 AGCATGTGAATCAGGAGATTTATGCCCTCAGAAAATTTAGAGAAATATTTAGAAAAGAAA

Claims

A peptide consisting of one antigen of S. pyogenes of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3 or a functional active variant of one antigen of S. pyogenes of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3.

10

15

20

25

- 2. A peptide consisting of one antigen of S. pyogenes of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3 or a functional active variant of one antigen of S. pyogenes of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3, and
 - a) 1 to 350 additional amino acid residue(s), preferably 1 to 200, more preferably 1 to 150, even more preferably at most 1 to 100, still more preferably at most 1 to 50, most preferably 1, 2, 3, 4, 5, 10, 15, 20 or 25 additional amino acids residue(s) if the antigen is SEQ ID NO: 1; or
 - b) 1 to 200 additional amino acid residue(s), preferably 1 to 150, more preferably 1 to 100, even more preferably at most 1 to 50, still more preferably at most 1 to 25, most preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acids residue(s) if the antigen is SEQ ID NO: 2; or
 - c) 1 to 100 additional amino acid residue(s), preferably 1 to 75, more preferably 1 to 50, even more preferably at most 1 to 25, still more preferably at most 1 to 10, most preferably 1, 2, 3, 4 or 5 additional amino acids residue(s) if the antigen is that of SEQ ID NO: 3; or
 - d) 1 to 150 additional amino acid residue(s), preferably 1 to 100, more preferably 1 to 75, even more preferably at most 1 to 50, still more preferably at most 1 to 25, most preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acids residue(s) if the antigen is that of SEQ ID NO: 4; or
 - e) 1 to 450 additional amino acid residue(s), preferably 1 to 300, more preferably 1 to 150, even more preferably at most 1 to 100, still more

WO 2008/003515

136

preferably at most 1 to 50, most preferably 1, 2, 3, 4, 5, 10, 20, 30 or 40 additional amino acids residue(s) if the antigen is SEQ ID NO: 5; or

- f) 1 to 250 additional amino acid residue(s), preferably 1 to 200, more preferably 1 to 150, even more preferably at most 1 to 100, still more preferably at most 1 to 50, most preferably 1, 2, 3, 4, 5, 10, 15, 20 or 25 additional amino acids residue(s) if the antigen is SEQ ID NO: 6 or SEQ ID NO: 7.
- 10

5

3. The peptide of any of claims 1 or 2 further consisting of at least one amino acid residue heterologous to the antigen, preferably an additional amino acid sequence comprising a marker protein.

- 4. The peptide of any of claims 2 or 3, wherein the additional amino acid residue(s) is/are flanking the antigen C-terminally, N-terminally or C- and N-terminally.
- 15
- 5. The peptide of any of claims 1 to 4, wherein the functional active variant is essentially identical to any of the antigens of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3, but differs from the antigens of any of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3 in that it is derived from a homologous sequence of a different serotype of *S. pyogenes*, particularly wherein the serotype is M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 or M118.

25

30

- 6. The peptide of any of claims 1 to 5, wherein the functional active variant is a portion of any of the SEQ ID NOS: 1 to 7 consisting of at least 60%, preferably at least 70%, more preferably at least 80%, still more preferably at least 90%, even more preferably at least 95%, most preferably 99% of the amino acids of the antigen of any of the SEQ ID NOS: 1 to 7.
- 7. The peptide of any of claims 1 to 6, wherein the functional active variant of the antigen of any of the SEQ ID NOS: 1 to 7 has at least 50% sequence identity to the

antigen of any of the SEQ ID NOS: 1 to 7, especially at least 60%, preferably at least 70%, more preferably at least 80%, still more preferably at least 90%, even more preferably at least 95%, most preferably 99% sequence identity to the antigen of any of the SEQ ID NOS: 1 to 7.

8. The peptide of claim 7, wherein the variant is derived from the antigen of any of the SEQ ID NOS: 1 to 7 by at least one conservative amino acid substitution.

9. A peptide comprising an amino acid sequence with at least 95% sequence identity
10 to at least one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7, wherein said peptide is not Spy0269, Spy0292, Spy0416A, or Spy0872.

10. A peptide characterized in that it comprises at least 2, preferably at least 3, more preferably at least 4 antigens as defined in any of claims 1 to 9.

15

5

11. A nucleic acid coding for the peptide according to any of claims 1 to 10 or a nucleic acid complementary thereto, particularly a DNA sequence of any of the sequences of SEQ ID NOS: 11 to 17 or the corresponding RNA sequence.

- 20 12. The nucleic acid of claim 11, wherein the nucleic acid is located in a vector.
 - 13. A pharmaceutical composition, especially a vaccine, comprising
 - (i) at least one peptide according to any of claims 1 to 10 and/or
 - (ii) at least one peptide comprising or consisting of the sequence of any of the SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, or a functional active variant thereof, and
 - (iii) optionally a pharmaceutically acceptable carrier or excipient.

14. A pharmaceutical composition containing

- 30
- (i) a nucleic acid according to claim 11 and/or a nucleic acid complementary thereto and/or
 - (ii) a nucleic acid coding for the peptide comprising or consisting of the sequence of any of the SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10,

particularly a DNA sequence of any of the SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20, or a functional active variant thereof or a nucleic acid complementary thereto or the corresponding RNA sequence, and

(iii) optionally a pharmaceutically acceptable carrier or excipient.

5

- 15. The pharmaceutical composition of claim 14, wherein the nucleic acid is comprised in a vector and/or a cell.
- 16. An antibody or functional active fragment thereof which binds specifically to theantigen of claim 1.
 - 17. The antibody or functional active fragment thereof of claim 16, wherein the antibody is a monoclonal, polyclonal, chimeric or humanized antibody, or wherein the functional active fragment comprises a Fab fragment.

15

- 18. A hybridoma cell line which produces the antibody according to claim 16 or 17.
- 19. A method for producing an antibody according to claim 16 or 17, characterized by the following steps:
- 20

30

- (a) administering an effective amount of the peptide according to any of claims1 to 10 to an animal; and
 - (b) isolating the antibody produced by the animal in response to the administration of step (a) from the animal.
- 25 20. A method for producing an antibody according to claim 16 or 17, characterized by the following steps:
 - (a) contacting a B cell with an effective amount of the peptide according to any of claims 1 to 10;
 - (b) fusing the B cell of step (a) with a myeloma cell to obtain a hybridoma cell; and
 - (c) isolating the antibody produced by the cultivated hybridoma cell.

21. The method of claim 19 or 20, wherein the isolated antibody is additionally purified.

22. A pharmaceutical composition, especially a vaccine, comprising the antibody according to claim 16 or 17.

23. A pharmaceutical composition comprising the peptide as defined in claim 13 or the nucleic acid as defined in claim 14 or the antibody or functional fragment thereof according to claim 16 or 17 for the immunization of a subject against an infection or the treatment of a subject having an infection, wherein the infection is preferably a *S. pyogenes* infection.

24. Use of the peptide as defined in claim 13 or the nucleic acid as defined in claim 14 or the antibody or functional fragment thereof according to claim 16 or 17 for the manufacture of a medicament for immunization against or treatment of an infection, preferably a *S. pyogenes* infection.

25. Method of immunizing a subject against an infection or treating a subject having an infection, the method comprising

20

5

10

15

(a) administering to the patient an effective amount of the peptide as defined in claim 13 or the nucleic acid as defined in claim 14 or the antibody or functional fragment thereof according to claim 16 or 17.

26. The method of claim 25, wherein the infection is a *S. pyogenes* infection.

25

- 27. A method of diagnosing a S. pyogenes infection comprising the steps of:
 - (a) contacting a sample obtained from a subject with the peptide according to any of claims 1 to 10; and
 - (b) detecting the presence of an antibody against S. pyogenes in the sample.

30

28. A method of diagnosing a S. pyogenes infection comprising the steps of:

(a) contacting a sample obtained from a subject with the antibody according to claim 16 or 17; and

.


÷

- (b) detecting the presence of an antigen of *S. pyogenes* in the sample.
- 29. A method for identifying a ligand capable of binding to a peptide according to any of claims 1 to 10 comprising:
 - (a) providing a test system comprising the peptide,
 - (b) contacting the test system with a test compound, and
 - (c) detecting a signal generated in response to the binding of the test compound to the peptide or functional active variant.
- 10 30. Use of any of the peptide according to any of claims 1 to 10 for the isolation and/or purification and/or identification of an interaction partner of the peptide.

```
1/4
```








```
2/4
```


```
Figure 2
```






```
3/4
```


```
Figure 3
```






```
4/4
```

Figure 4





INTERNATIONAL	SEARCH REPORT

International application No PCT/EP2007/006027

TNU	SIFICATION OF SUBJECT MATTER			
INV.	C07K16/00			
According t	to International Patent Classification (IPC) or to both national classification and IPC			
B. FIELDS	S SEARCHED			
	documentation searched (classification system followed by classification symbols)	· · · · ·	,	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
C07K				
Documenta	ation searched other than minimum documentation to the extent that such documents are included in the	e fields se	arched	
Socumenta		5 110100 3B		
Electronic	data base consulted during the international search (name of data base and, where practical, search ter	rms used))	
FPO-In	nternal, WPI Data			· · ·
	ncernar, wri Data			
		,		
		`	······································	
		·	Determent to the	
Category*	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to cla	IITI NO.
Х	WO 2005/032582 A2 (CHIRON CORP [US];	j	1-30	
	GRANDI GUIDO [US]; TELFORD JOHN [US];	l		
	BENSI GIULIANO) 14 April 2005 (2005-04-14)			
	page 26, line 23 - page 53, line 25;	· ·		
т. с	claims 2,11,27; sequence 122			
)		
· .				
۰. ر				
•				
•				
· .				
• .				
• .				
• .				
• .				
• .				
Furt	rther documents are listed in the continuation of Box C.			
/	categories of cited documents : "T" later document published atte	er the Inte	mational filing date	
* Special o	categories of cited documents : nent defining the general state of the art which is not T' later document published atter or priority date and not in cor cited to understand the prior	r the Inte	the application but	
* Special o *A* docum consid	categories of cited documents : nent defining the general state of the art which is not idered to be of particular relevance document but published an explorational T' later document published atter or priority date and not in con- cited to understand the prince invention	er the Inte offict with ciple or the	the application but eory underlying the	
* Special o *A* docum consid	categories of cited documents : nent defining the general state of the art which is not idered to be of particular relevance r document but published on or after the international date	er the Inten nflict with ciple or the nce; the cl or cannot	the application but eory underlying the claimed invention t be considered to	
* Special of *A* docum consid 'E* earlier filing of 'L* docume	categories of cited documents : "T" later document published atter or priority date and not in concluder to be of particular relevance r document but published on or after the international date "X" document of particular relevance nent which may throw doubts on priority claim(s) or la loried to considered novel involve an inventive step which	er the Inter nflict with ciple or the or cannot en the door	the application but eory underlying the claimed invention t be considered to cument is taken along	3
* Special of *A* docum consid *E* earlier filing of *L* docume which	categories of cited documents : nent defining the general state of the art which is not idered to be of particular relevance r document but published on or after the international date	er the Inten nflict with ciple or the nce; the ci or cannot en the doo nce; the c	the application but eory underlying the claimed invention to be considered to current is taken along claimed invention	
* Special d *A* docum consid "E* earlier filing d ·L* docum which citatio 'O* docum	 categories of cited documents : categories of cited documents : nent defining the general state of the art which is not idered to be of particular relevance r document but published on or after the international date r document but published on or after the international date rent which may throw doubts on priority claim(s) or no rother special reason (as specified) r document is combined with the considered to involve an oral disclosure, use, exhibition or 	er the Internflict with ciple or the or cannot en the do nce; the c nce; the c olve an inv one or mo	the application but eory underlying the elaimed invention to be considered to cournent is taken alone slaimed invention ventive step when the ore other such docu-	
* Special d *A docum consid 'E' earlier filing d 'L' docum which citatio 'O' docum other	 categories of cited documents : categories of cited to understand the princ invention categories of particular relevance cannot be considered novel involve an inventive step which is cited to establish the publication date of another on or other special reason (as specified) r means r document is combined with or ments, such combination beigned with the particular relevance 	er the Internflict with ciple or the or cannot en the do nce; the c nce; the c olve an inv one or mo	the application but eory underlying the elaimed invention to be considered to cournent is taken alone slaimed invention ventive step when the ore other such docu-	
* Special of *A* docum consid 'E* earlier filing 0 'L' docum which citatio 'O' docum other 'P' docum	 categories of cited documents : categories of cited document : categories of cited document : categories of cited to establish the publication date of another on or other special reason (as specified) categories of cited to invect document is combined with or ments, such combination being the combination is combined with the methy is categories of the categories of th	er the Internifict with ciple or the or cannot en the do nce; the c pive an inv one or mo ing obviou	the application but eory underlying the claimed invention the considered to current is taken alone claimed invention ventive step when the ore other such docu- us to a person skilled	
* Special of *A* docum consid *E* earlier filing of *L* docum which citatio *O* docum other *P* docum later ti	 categories of cited documents : categori	er the Internet inter	the application but eory underlying the claimed invention the considered to current is taken alone claimed invention ventive step when the ore other such docu- us to a person skilled family	
* Special of A* docum consid "E* earlier filing of "L* docum which citatio O* docum other "P* docum later ti	 categories of cited documents : categories of particular relevance cannot be of particular relevance cannot be considered novel involve an inventive step who involve an invent is combined with o ments, such combination bein in the art. *& document member of the same step who involve an invent is combined with o ments, such combination bein in the art. 	er the Internet inter	the application but eory underlying the claimed invention the considered to current is taken alone claimed invention ventive step when the ore other such docu- us to a person skilled family	
* Special of A* docum consid "E* earlier filing of "L* docum which citatio O* docum other "P* docum later the Date of the	 categories of cited documents : categories of particular relevance categories of particular relevance cannot but published on or after the international date categories of particular relevance cannot be considered novel involve ate particular relevance cannot be considered to involve an inventive step when the considered to involve ate involve is combined with or ments, such combination beiling date but than the priority date claimed categories of cited document is combined with cate. cannot be considered to involve an inventive step when the art. cannot be considered to involve an inventive step when the art. cannot be considered to involve an inventive step when the priority date claimed cannot be considered to involve an inventive step when the art. cannot be considered to involve an inventive step when the art. cannot be considered to involve an inventive step when the priority date claimed cannot be considered to involve an inventive step when the art. cannot be considered to involve an inventive step when the art. cannot be considered to involve an inventive step when the art. cannot be considered to involve an inventive step when the art. considered to involve an inventive step when the art. considered to involve an inventive step w	er the Internet inter	the application but eory underlying the claimed invention the considered to current is taken alone claimed invention ventive step when the ore other such docu- us to a person skilled family	
* Special of *A* docum consid *E* earlier filing of *L* docum which citatio *O* docum other *P* docum later the Date of the	 categories of cited documents : categories of particular relevance cannot be of particular relevance cannot be considered novel involve an inventive step who involve an invent is combined with o ments, such combination bein in the art. *& document member of the same step who involve an invent is combined with o ments, such combination bein in the art. 	er the Internet inter	the application but eory underlying the claimed invention the considered to current is taken alone claimed invention ventive step when the ore other such docu- us to a person skilled family	
* Special of *A' docum consid 'E' earlier filing of 'L' docum which citatio O' docum later ti Date of the 1	categories of cited documents : ** nent defining the general state of the art which is not idered to be of particular relevance ** r document but published on or after the international date ** nent which may throw doubts on priority claim(s) or his cited to establish the publication date of another on or other special reason (as specified) ** nent which may throw doubts on priority claim(s) or rmeant which may throw doubts on priority claim(s) or nent referring to an oral disclosure, use, exhibition or rmeans ** nent published prior to the international filing date but than the priority date claimed ** document of particular relevance cannot be considered to invod to inventive step who inventive step who document is combined with or meants such combination bein in the art. ** document of particular relevance cannot be considered to invod using the international filing date but than the priority date claimed *8 document member of the sam *8 document member of the sam 18 September 2007 27/11/2007 I mailing address of the ISA/ Authorized officer	er the Internet inter	the application but eory underlying the claimed invention the considered to current is taken alone claimed invention ventive step when the ore other such docu- us to a person skilled family	
* Special of *A' docum consid 'E' earlier filing of 'L' docum which citatio 'O' docum later ti Date of the 1	categories of cited documents : "T" later document published atter or priority date and not in concited to be of particular relevance r document but published on or after the international date "T" later document published atter or priority date and not in concited to understand the principy date of particular relevance r document but published on or after the international date "T" later document published atter or priority date and not in concited to understand the principy date of particular relevance r document but published on or after the international date "X" document of particular relevance cannot be considered novel of involve an inventive step which is combined with or remeans on or other special reason (as specified) "Y" document of particular relevance cannot be considered to invention or remeans nent published prior to the international filing date but than the priority date claimed "&" document member of the same cannot be considered to invention 18 September 2007 27/11/2007 I mailing address of the ISA/ European Patent Office, P.E. 5818 Patentlaan 2	er the Internet inter	the application but eory underlying the claimed invention the considered to current is taken alone claimed invention ventive step when the ore other such docu- us to a person skilled family	
* Special of *A' docum consid 'E' earlier filing of 'L' docum which citatio 'O' docum later ti Date of the 1	categories of cited documents : ** nent defining the general state of the art which is not idered to be of particular relevance ** r document but published on or after the international date ** nent which may throw doubts on priority claim(s) or his cited to establish the publication date of another on or other special reason (as specified) ** nent which may throw doubts on priority claim(s) or rmeant which may throw doubts on priority claim(s) or nent referring to an oral disclosure, use, exhibition or rmeans ** nent published prior to the international filing date but than the priority date claimed ** document of particular relevance cannot be considered to invod to inventive step who inventive step who document is combined with or meants such combination bein in the art. ** document of particular relevance cannot be considered to invod using the international filing date but than the priority date claimed *8 document member of the sam *8 document member of the sam 18 September 2007 27/11/2007 I mailing address of the ISA/ Authorized officer	er the Internflict with ciple or the ciple or the core cannot eren the doo nce; the c ove an inv one or mo ing obviou ne patent f	the application but eory underlying the considered to considered to current is taken alone claimed invention ventive step when the claimed invention ventive step when the step when the step when the step when the step when the step when the state alone ventive step when the state alone ventive step when the state alone ventive step when the state alone vention to state alone vention the vention to state alone vention to state alone	

Box No.11 Observations where certain plains were found unsearchable (Continuation of item 2 of first sheet) This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: 1. Image: Image	INTERNATIONAL SEARCH REPORT	International application No. PCT/EP2007/006027
This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: 1. X Claims Nos: because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210 2. Claims Nos: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international application that do not comply with the prescribed requirements to such an extent that no meaningful international application that do not comply with the prescribed requirements to such an extent that no meaningful international application that do not comply with the prescribed requirements to such an extent that no meaningful international application is accordance with the second and third sentences of Rule 6.4(a). Box No. III Observations where unity of invention is tacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet 1. As all required additional search fees were timely paid by the applicant, this international search report covers alleearchable additional fees. 2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report;		
 Claims Nos:: because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210 Claims Nos:: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claims Nos:: because they are dependent claims and are not drafted in accordance with the second and third sentances of Rule 6.4(a). Claims Nos:: because they are dependent claims and are not drafted in accordance with the second and third sentances of Rule 6.4(a). Deservations where unity of invention is tacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers 	Box No. II Observations where certain claims were found unsearchable (Continuat	tion of item 2 of first sheet)
because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210 Claims Nos:: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claims Nos:: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Eox No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable As only some of the required additional search fees were timely paid by the applicant, this international search report covers allsearchable	This international search report has not been established in respect of certain claims under	Article 17(2)(a) for the following reasons:
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet 1. As all required additional search fees were timely paid by the applicant, this International search report covers allsearchable claims. 2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers	because they relate to subject matter not required to be searched by this Authority	y, namely:
3. Claims Nos:: because they are dependent claims and are not drafted in accordance with the second and third sentances of Rule 6.4(a). Box No. III Observations where unity of invention is tacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet 1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers	see FURTHER INFORMATION sheet PCT/ISA/210	
 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box No. II Observations where unity of invention is tacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet 1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. 2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional rees. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers 	because they relate to parts of the international application that do not comply with	h the prescribed requirements to such
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet 1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable 2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers		
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet 1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable 2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers		
 This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers 		cond and third sentences of Rule 6.4(a).
 see additional sheet As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers 	Box No. III Observations where unity of invention is lacking (Continuation of item 3	3 of first sheet)
 As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers 	This International Searching Authority found multiple inventions in this international applicat	tion, as follows:
 As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers 		
 claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers 	see additional sheet	
 claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers 		
 claims. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers 		
 additional fees. 3. As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers 		ational search report covers allsearchable
		ees, this Authority did not invite payment of
		cant, this international search reportcovers
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:		
1-30 (only partially)	1-30 (only partially)	
Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.	payment of a protest fee.	
The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.		
No protest accompanied the payment of additional search fees.	No protest accompanied the payment of additional set	arch fees.

Form PCT/IS	A/210 (cont	inuation of	first sheet	(2)) (April 20	005)

International Application No. PCT/EP2007 /006027

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210	·····		
Continuation of Box II.1		· · · · · · · · · · · · · · · · · · ·	
Although claims 25-26 are directed to of the human/animal body, the search has been card the alleged effects of the compound/composition. Although claims 27-28 are directed to practised on the human/animal body, the search has based on the alleged effects of the compound/compo	ried out ar o a diagnos s been carr	nd based on tic method	
			ł

International Application No. PCT/EP2007 /006027

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210 This International Searching Authority found multiple (groups of) inventions in this international application, as follows: 1. claims: 1-30 (only partially) A peptide consisting of SEQ ID NO. 4, or a variant thereof, the nucleic acid encoding it and the uses thereof. 2. claims: 1-30 (only partially) A peptide consisting of SEQ ID NO. 1, or a variant thereof, the nucleic acid encoding it and the uses thereof. 3. claims: 1-30 (only partially) A peptide consisting of SEQ ID NO. 2, or a variant thereof, the nucleic acid encoding it and the uses thereof. 4. claims: 1-30 (only partially) A peptide consisting of SEQ ID NO. 7, or a variant thereof, the nucleic acid encoding it and the uses thereof. 5. claims: 1-30 (only partially) A peptide consisting of SEQ ID NO. 5, or a variant thereof, the nucleic acid encoding it and the uses thereof. 6. claims: 1-30 (only partially) A peptide consisting of SEQ ID NO. 6, or a variant thereof, the nucleic acid encoding it and the uses thereof. 7. claims: 1-30 (only partially) A peptide consisting of SEQ ID NO. 3, or a variant thereof, the nucleic acid encoding it and the uses thereof.

INTERNATIONAL SEARCH REPORT				International application No		
				PCT/EP2007/006027		
Patent document cited in search rep	t ort	Publication date		Patent family member(s)	/	Publication date
WO 20050325	82 A2	14-04-2005	CA EP JP	253236 164850 200750072	59 A1 D0 A2 26 T	14-04-2005 26-04-2006 18-01-2007